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ABSTRACT
Breast cancer is the leading cause of cancer mortality in women in the Western 
world. Its growth and development is directly governed by endogenous 
steroids and growth factors. Endocrine therapy is the most effective form of 
treatment for a proportion of breast cancer patients. Work from several 
laboratories has shown that breast cancer cells metastasise via a pathway that 
involves the plasminogen activator system and metalloproteinases. Thus, the 
plasminogen activator system, which consists of urokinase (uPA), its inhibitor 
(PAI-1) and receptor (uPAR), is central to the process of invasion and 
metastasis. Given their important role, it is hardly surprising that these three 
proteins have been used as biological markers of patient prognosis. uPA and 
PAI-1 has been significantly implicated as markers of aggressive breast 
cancer. 1
The first step of invasion involves the conversion of plasminogen into plasmin 
by uPA. uPA is localised on the cell surface (bound to its receptor uPAR) and 
is principally regulated by two inhibitors, plasminogen activators type-1 and 
type-2 (PAI-1 and PAI-2). Possessing a wide substrate specificity, plasmin in 
turn activates a variety of enzymes which degrade different components of the 
extracellular matrix such as laminin, fibronectin, collagenase(s), proteoglycans 
etc.
The present study was conducted to further understand the effect(s) of 
different growth factors and steroid hormones on the proliferation and invasive 
potential of two well characterised human breast cancer cell lines, MCF-7 
(hormone sensitive) and MDA-MB-231 (hormone insensitive). Furthermore, 
extracellular matrix (EHS) was used to determine the effect, if any, that
«
support substrate might have on the levels of plasminogen activators and 
growth rate. Plasminogen activators were quantified both at the mRNA and
"1
xxiii y
protein levels, using RT-PCR and ELISA, respectively. uPA activity was 
determined by chromogenic assay and the invasive properties of the two cell 
lines were determined using the Boy den invasion chamber.
In the initial phase, proliferation of each cell line on both substrata, plastic and 
EHS, was studied after treatment with growth factors (TGFa, TGF(3 and 
EGF), steroid hormones (E2 and Pg) and anti-oestrogen, tamoxifen. Different 
amounts of each growth factor and hormone were used and cell numbers were 
obtained after 24, 48 and 72 hours. These studies showed that growth of MCF- 
7 cells was stimulated significantly by exogenous TG Fa and EGF, on both 
EHS and plastic with cells being more sensitive to growth factors on EHS. 
Proliferation of MDA cells was only slightly increased by the same growth 
factors on either substrate. By contrast, TGF|3 inhibited the growth of MDA 
cells, on both surfaces. However, the concentrations required for inhibition on 
the two substrata were enormously different. E2, Pg, and TAM (an anti­
oestrogen) also stimulated the growth of MCF-7 cells on both plastic and 
EHS.
For quantification of uPA, uPAR and PAI-1, a combination of Western 
blotting and ELISA, using specific monoclonal antibodies, was employed to 
monitor the relative amounts of these proteins after treating the cell lines with 
growth factors and hormones. These studies showed that the MDA cell line 
expressed uPA and PAI-1 proteins whereas uPA was hardly detectable in the 
MCF-7 cell line. Moreover, qualitative RT-PCR analysis clearly showed that 
uPAR and PAI-1 transcripts were present in both MDA and MCF-7 cells. 
Flowever, uPA mRNA could not be detected in MCF-7.
EGF and TGFa induced an increase in uPA, PAI-I and uPAR mRNA levels in 
MDA cells. In MCF-7 cells, both factors induced an increase in uPAR and 
PAI-1 transcripts. Corresponding changes in invasive potential were measured 
after growth factor treatment.
XXIV
TGFp increased plasminogen activator components both at the transcriptional 
and the translational levels in MDA cells. It caused an increase in both cell 
secreted and cell associated uPA and PAI-1 proteins, the amounts of which 
varied depending on the substratum. The percentage increase in cell secreted 
and cell associated proteins was higher on EHS than on plastic. Amounts of 
secreted uPA and PAI-1 were higher than cell associated levels. TGFp 
stimulated the secreted form of PAI-1 by about 420% (Fig 33A) as compared 
to 349% (Fig 29A) for uPA on EHS. On the same substratum, PAI-1 and uPA 
levels in cell extracts were 170% (Fig 35A) and 151% (Fig 31 A), 
respectively. Interestingly, cell associated PAI-1 and uPA levels on plastic 
were only 30% and 23%, respectively. With the passage of time, however, the 
antigen levels fluctuated in response to certain growth factors, and their 
response to different doses also varied with time and substratum. TGFp 
increased the amounts of uPA enzyme activity in MDA cells. In vitro invasion 
of MDA and MCF-7 cell lines were also enhanced by TGFp.
The TGFp induced increase in invasion by MDA cells was reduced to the 
value of control in the presence of a neutralising anti-uPA antibody, whereas 
MCF-7 cell invasion, in the presence of same antibody, remained above the 
level of control. Fetal calf serum on the other hand, inhibited the In vitro 
invasion of both cell lines in a dose dependent manner. Addition of 
plasminogen to the FCS medium also could not revert the inhibitory affect of 
FCS on invasion of matrigel. Increased uPA and PAI-1 and uPAR mRNA and 
protein expression correlated with increased invasion.
E2 significantly increased cell secreted and cell associated PAI-1 protein 
levels in MCF-7 cells whereas tamoxifen induced an increase in cell 
associated antigen only. E2 also increased the invasion of the same cell line by 
about 50% while TAM caused a decrease in invasion. In the MDA cell line 
TAM did not change the level of invasion. Thus tamoxifen is seen to be
XXV
positively anti-oestrogen in relation to invasion, rather than a weak agonist as 
it is in relation to proliferation.
In conclusion, these results clearly show that various growth factors and/or 
hormones not only have an effect on the proliferative properties of cell lines 
but they also change the relative amounts of uPA, PAI-1 and uPAR and that 
these changes can be reflected in invasive activity. The ECM contributes to 
the overall response of these cells.
t
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CHAPTER 1 
INTRODUCTION
I
In tro d u ctio n  2
1.1 Overview
In Westernised societies, breast cancer is the leading cause of cancer-related 
death among women aged 30-70 years (Blackwood & Weber, 1996) It is 
estimated that approximately 8-10% of all women in the United States and 
Western Europe suffer from this disease at some point in their lifetime (Clarke 
et a l ,  1992 ; Li et a l ,  1994; Schmitt et ai, 1997a). In the UK alone, 25,000 
new cases are diagnosed every year and 15,000 die of the disease every year. 
Furthermore, its incidence is increasing world-wide, for example in the UK, 
the incidence is rising at about 1-1.5% per year but this is coupled with falling 
mortality (Lochter & Bissell, 1995; Sainsbury, 1997). 5 year survival for 
breast cancer is 68% (Campaign, 1996). Breast cancer can not only occur 
sporadically but can also be inherited. The incidence of sporadic breast cancer, 
however, is much higher than genetically inherited disease(Cavenee & White, 
1995; Wooster & Straton, 1995). It is estimated that about 3-10% of all the 
patients suffering from breast cancer are genetically susceptible to the disease 
(Stratton & Wooster, 1996; Wooster & Straton, 1995). 60% of patients die 
because of metastasis.
In the US, breast cancer incidence is four to seven times higher than it is in 
China or Japan. Moreover, studies have shown that the incidence of the 
disease increases in Chinese, Japanese or Phillipino women upon migration to 
the United States and eventually approaches that among US white women. 
Similarly, Asian women born in the West have a breast cancer risk 60% higher 
than those born in the East.
Among white and black Americans, there are dramatic differences in not only 
the incidence of breast cancer but also in survival and mortality rates. 
Incidence rates in white women are 20% higher than in black women but the 
mortality rate, as estimated in 1990, was lower in white women (27.4) and
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higher (31.7) in black women per 100,000, respectively (Marchant, 1994). 
Similarly, black Americans have a higher mortality rate from prostate cancer. 
In the USA, the black population have an incidence rate for prostate cancer 
that is 30 times more than that for Japanese men. However, the mortality rate 
is only two times higher than that of Japanese immigrants living in USA (see 
review by (Verde et al., 1984) The increasing incidence of breast cancer in the 
United States and immigrant populations have led to the speculation and/or 
suggestion that the differences are due more to environmental risk factors 
rather than genetic factors. National Cancer Institute (NCI), reported to the 
White House that an estimated 2 million women will succumb to breast cancer 
between 1990 and the year 2,000, 460,000 of whom will die of the disease 
(Marchant, 1994). Recent data from the NCI, for the period 1989-1992, show 
that in the USA there was an overall 4.7% reduction in mortality. This 
reduction was mainly confined to the white population (5.5% reduction) as 
mortality amongst the black population was still on the increase (2.6%) 
(Sainsbury, 1997). The incidence of breast cancer is similar among all the 
Western countries such as the United States and Western Europe. It is very 
likely therefore that certain common factors, such as diet or life style may 
influence the rate of breast cancer.
Over the years, a tremendous amount of effort has gone into trying to 
understand breast cancer. Unfortunately, due to complexity of the disease, 
there is little evidence that significant progress has been made, since the 
introduction of anti-oestrogens, in improving overall survival. Although there 
are various endocrine and cytotoxic therapies which have been used to treat 
the disease, it is disturbing to note that the incidence of breast cancer has been 
on the rise (Cufer, 1995; Hankey, 1992; Parkin & Nectoux, 1991). Many 
factors have been associated with breast cancer but there has not been any 
explanation for its continuous increase in western societies as compared to the 
Asian societies (Stephens, 1997). Most oncologists, in spite of some
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spectacular success in the tumour suppressor genes, feel that there has been 
almost no progress in the therapy of solid tumours including breast cancer 
(Bissell & Werb, 1995) in the last 30 years. If the present trend continues it is 
predicted that there will be more than one million sufferers of the disease by 
the turn of the century. In order to combat this disease it is imperative that a 
clearer understanding of the biology of tumours at both the cellular and 
molecular level is achieved. Breast cancer is a problem of differentiation, and 
in order to understand the problems associated with breast, it is necessary to
1.2 Aetiology of Breast Cancer
understand the normal differentiated breast. Clearly, this knowledge in turn 
can be used to invent innovative therapies to prevent breast cancer growth and 
progression.
Several factors appears to play important roles in triggering the disease (Boyle 
and Leake, 1988) and in the aetiology of breast cancer (Kuller, 1995), 
including family history, early menarche, late menopause, age at first 
conception, use of oestrogen containing oral contraceptives, nulliparity, late 
pregnancy and the lack of breast feeding and endogenous and exogenous 
reproductive hormones (Tavassoli, 1997; Vessey, 1997). External factors such 
as ionizing radiation, exposure to chemicals, and excessive consumption of 
alcohol have also been thought to play a role in causing breast cancer. Alcohol 
consumption may have a carcinogenic effect by altering hepatic metabolism 
and interference with clearance, or by products of ethanol metabolism in the 
circulation (Stampfer et al., 1993). Other controversial and putative risk 
factors include cigarette smoking, x-rays and high fat diets. The effects of 
cigarette smoking on breast and or other cancers have been extensively studied 
but the conclusions are still vague e.g. the inverse relationship between 
smoking and endometrial cancer could not be corroborated nor there has been
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a significant relationship between smoking and colorectal or breast cancer 
(Nordlund et a l,  1997). Others have suggested an association of smoking with 
breast cancer depending on the receptor status of the tumour. Morabia and 
associates have shown that smoking is related to both oestrogen receptor 
positive (ER+) and oestrogen receptor negative (ER") tumours but the strength 
of the association is greater for ER- tumours among post menopausal women 
(Morabia et a l,  1998). A study by a Russian group has also suggested some 
environmental factors (smoking) play a great role in the modification of breast 
cancer risk. They have suggested that these factors change the endogenous 
hormonal and metabolic parameters that modify the autocriiie-paracrine 
relationship in the tumour tissue and of the hormone sensitivity of the latter 
(Khanson et a i,  1998). However, studies have shown no practical importance 
between cigarette smoking and breast cancer risk (Braga et ciL, 1996). 
Recently tobacco use has been shown to be the most preventable cause of 
cancer (Yu et al., 1997). Due to the huge discrepancy in the field, cigarette 
smoking cannot totally be eliminated as a risk factor in breast cancer. A high 
fat diet has been associated with a decreased excretion of oestrogen in the 
faeces. On the other hand, high fibre diet increased the secretion of oestrogens 
in faeces and therefore, lower blood oestrogen levels and decreased breast 
cancer risk (Rose, 1990). A vegetarian diet high in lignin's and isoflavonoids 
appears to reduce the risk of breast cancer (Stephens, 1997). The mechanism 
of action of these factors is not known but could involve prolonged hormonal 
stimulation of cellular proliferation, DNA damage, disregulation of growth 
factors, and cell-cycle associated genes in the breast (Service, 1998).
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1.3 Prognostic Factors in Breast Cancer
Reliable prognostic markers are required for predicting the risk of developing 
breast cancer. It is also used to divide the patient groups into low versus high 
risk of recurrence and identification of appropriate treatments (Leinster, 1998).
1.4 Role of Steroid Hormones in Breast Carcinogenesis
Prognostic markers may reflect growth potential e.g. Ki-67, p53, and bcl-2, or 
invasive potential, e.g. uPA, tPA, PAI-1 and uPAR (Barendsz-Janson et al., f
1998). Tumour cell invasion and metastasis depends on the content of 
fibrinolytic parameters i.e. the proteolytic enzymes in the tumour. Extensive 
research has suggested the association of elevated levels of uPA and PAI-1 
and metastasis in breast cancer (Grondahl-Hansen et al., 1997b; Janieke et al.,
1993; Pedersen et al., 1997; Schmitt et al., 1990; Schmitt et al., 1997b;
Sumiyoshi et al., 1991). A similar correlation has been reported in cervical 
cancer (Kobayashi et ai, 1994), pulmonary adenocarcinoma (Pedersen et a i, |
1994b), squamous and large cell lung carcinoma (Pedersen et ai, 1994a) and 
in colon carcinoma (Gandolfo et al., 1996). Cathepsin D (a lysosomal aspartic 
protease) has also been associated with a poor prognosis in breast cancer.
Relapse rate for patients with high cathepsin D and PAI-1 is high (Kute et al.,
1998). tPA on the other hand, is an index of longer survival and therefore a 
good prognostic factor in breast tumours (Grebenshikov et a l ,  1997). The 
authors have also described uPA and PAI-1 as markers of poor prognosis in 
node negative breast cancer patients.
The natural oestrogen 17-(3-estradiol (E2) has been known to influence f4
proliferation and neoplastic transformation of mammary epithelium. An early 
intermediate event in carcinogenesis is the aberrant proliferation which is
«
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7associated with an altered estradiol metabolism (Telang et al., 1997b; Zhu &
■"'iConney, 1998). Telang and co-workers have implicated an altered cellular E2 
metabolism as an endocrine biomarker in the modulation of human mammary 
carcinogenesis (Telang et aL, 1997a). Female sex hormones, oestrogens and 4
progestérones, have long been known as potential stimulators of cell 
proliferation and thus as promotors of breast cancer. Since cells which harbour 
cancer causing mutations proliferate rapidly after growth stimulation by 
steroid hormones they promote carcinogenesis (Service, 1998). A positive
4correlation of breast cancer risk and high concentrations of endogenous r.
estradiol has been strongly suggested, in post menopausal women (Thomas et 
a i,  1997).
Early surgical observations by Beatson (1896) established the basis for our 
understanding that ovarian endocrine influences are of primary importance in |
growth control of some breast cancer (Beatson, 1896). Epidemiological
evidence in women indicates that the length of exposure of the mammary 4
■'iglands to oestrogen and progestogenic stimuli is directly proportional to breast 
cancer risk (Kuller, 1995). Women who have their first pregnancy after age 35 
have a higher risk of breast cancer than those who remained nulliparous. H
Prolonged exposure to endogenous oestrogens as a result of early menarche, 
late menopause and late age at first full term pregnancy increase the time 
window for the initiation of breast cancer (Kelsey & Whittemore, 1994). The |
increased levels of oestrogens and progesterone and other hormones, at late
4age (35+) pregnancy, will result in increased breast cancer growth, if their are 
transformed cells present because of their increased mitotic activity. Obesity 4
also appears to increase the risk of developing breast cancer, perhaps as a y
result of increasing peripheral aromatisation of circulating androgens to 
oestrogen (Boyle & Leake, 1988; Kuller, 1995). Oral contraceptives 
(containing both oestrogen and progesterone) do not appear to be a major risk A
1.4.1 Oestrogen and Progesterone Receptors
'ji
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factor but this is currently controversial (Malone et al., 1993). Hankinson has 
suggested an increased risk of breast cancer with longer duration of the use of 
contraceptives (Hankinson & Stampfer, 1997). Oestrogen stimulation is more 
clearly implicated as an aetiologic agent in vaginal adenocarcinoma, 
endometrial carcinoma and ovarian cancer. Recent evidence of involvement of 
oestrogen metabolites (which can bind to DNA and remove two bases, adenine 
and guanine, and thereby triggering damage) have been implicated in breast 
cancer by different groups, and this has further signified the link of oestrogen
to breast cancer (Service, 1998).
The mechanism of interaction of oestrogens and progestins requires E2, acting 
through its receptor (ER) to induce the expression of PR. Both of these 
hormones work in harmony to regulate other genes, such as those for growth 
factors and cell cycle associated genes.
%
Oestrogen and progesterone receptors are members of the steroid/ thyroid 
receptor super family. ER modulates gene expression in an oestrogen- 
dependent manner and thus functions as a transcription factor (Yamamoto,
1985). These specific, high affinity, low capacity binding sites are essential for 
the cells to respond to hormonal stimulation. Oestrogen receptor undergoes 
transformation after binding to its ligand, (oestrogen), ER then dimerizes and 
complexes with additional proteins to form the complete ER. Recent work has 
shown mutated forms of ER in breast cancer. The presence of ER in normal 
mature human breast tissues has been reported. 6-7% epithelial cells in normal 
breast are ER positive while 29% are PR positive. The level of ER varies 
according to different phases e.g. in menstrual cycle and during cell cycles. i:
Progesterone receptors levels are at their highest and oestrogen receptor at
■y
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their lowest, in the luteal phase of the menstrual cycle, when the epithelial 
mitoses are at their peak suggesting the pivotal role of progesterone in breast 
epithelial cells in mitosis (Clarke et al., 1992).
However, it has been shown that in ER negative cell lines there is no 
transcription of the gene due to extensive méthylation of 5'-promoter of the 
gene. The knowledge that oestrogen action promotes the synthesis of PR 
improves the predictive value of steroid receptor status. Clinical studies have
It is clear that oestrogens can act both directly and indirectly on normal 
mammary tissue to induce events that are closely associated with carcinogenic 
potential. The ability of E2 to stimulate the proliferation of some ER-positive 
breast tumour cells both In vivo and In vitro clearly implicates oestrogens as 
regulators of tumour growth, subsequent to carcinogenesis (Clarke et al.,
1992). Thus it is possible that oestrogens function as carcinogens, tumour 
promoters and as regulators of tumour growth (Thijssen & Blankenstein,
1994).
The presence of ER in a proportion of breast tumours may indicate that these 
tumours arise from ER positive epithelial cells. Since breast cancer is often 
characterised by hormonal control of Its growth, measurements of ER levels in 
the tumour are used to predict patients’ prognosis (Leake, 1997). About 60% 
of human breast cancers are ER positive (have an ER content above a 
minimum clinical cut-off value) and from these only 2/3 respond to endocrine 
therapy. Approximately 1/3 of breast cancers are hormonally responsive at the 
time they become metastatic. 5-10% of ER negative breast cancers by the 
biochemical assay respond to endocrine therapy (Dickson et al., 1989). The 
mechanism for loss of ER expression in malignant progression of breast 
cancer is unknown and may only be a minor phenomenon since about 80% of
ER+ breast cancers, at first presentation, remain ER positive for the majority 
of their subsequent history (Crawford et al., 1987; Robertson, 1996).
.1
' 4 M
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shown that 70% of ER+/PR+ breast cancers respond to hormone therapy. Not 
all the ER positive breast cancers respond to endocrine treatment and it may 
be because of non-functional ER in ER+ cells. Some measure of ER 
functionality much improves the clinical value of ER determination (Leake et 
al., 1981). However, discrepancies among the predicted values and levels of 
receptors may also be due to different laboratory errors, differential 
metabolism of tamoxifen, mutated ER that can modulate regulate gene 
expression in the absence of ligand or ability of defective or phosphorylated 
ER to bind ligand but not regulate gene expression. ER- and PR- negative 
breast cancers differ from their receptor-positive counterparts. ER- negative 
tumours are often highly proliferative and invasive In vivo and In vitro, and 
have altered expression of certain growth factors such as EGF and TGFa etc. 
Growth factor production in ER-negative cells can be constitutive, 
uncontrolled and non-oestrogen regulated (Dickson et al., 1989).
It has been shown that protein kinase-C (PKC) remarkably increased the 
invasiveness of ER positive (MCF-7 and ZR-75) cell lines, after modulation of 
PKC activity with tetradecanoyl-phorbol-acetate (TPA), whereas it decreased 
the invasiveness of ER negative (MDA-MB-231 and MDA-MB-435) cell lines 
(Platet et al., 1998). Oestrogen also down regulates ER mRNA by inhibition 
of ER gene transcription (Dickson et al., 1989). It has also been shown that 
ER-negative and drug resistant breast cancers express elevated levels of PKC
as compared to ER- positive breast cancer. Future investigation into 
modulation of ER function could have an impact both on diagnosis and 
therapy of breast cancer.
Ï
J
1.5.1 Epidermal Growth Factor (EGF)
' Ï ,; 
' 1
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1.5 Growth Factors : Overview
Growth factors are specialised polypeptides that co-ordinate and regulate
cellular activity. These growth factors are normally secreted at only basal
levels to maintain homeostasis, but the levels vary according to the hormonal
. .environment and age of the individual. Growth factor levels increase in
:4-response to injury, carcinogens and in the presence of neoplastic cells. They 
are responsible for rapid cell division in embryogenesis, cancer and early 
wound healing. Growth factors are also mediators by which oestrogens and
■
progesterone stimulate both normal and neoplastic mammary tissue.
It is now known that growth factors are the mediators of several of the actions 
of steroid hormones. Oestrogens stimulate the production of endogenous 
growth factors in mammary gland, which can function in autocrine, paracrine 
and juxtacrine manner (Duffy, 1992). The EGF family is a very important 
group in the development of the mammary gland and in the pathogenesis of 
breast cancer.
The EGF family is comprised of EGF, TGFa, heparin binding EGF-like 
growth factor (Whiltelock et al., 1991), amphiregulin (Albini et a i,  1991) and 
betacellulin (Khokha et al., 1989). These peptides are potent mitogens that 
interact with the EGF receptor, a structural homologue of the c-erbB oncogene 
family.
Native EGF is a 53 amino acid long polypeptide (6kDa) which is derived from
a much longer precursor containing nine other copies of EGF- like units. EGF 
was first identified from mouse sub maxillary gland that causes eyelid opening 
of a new born animal (Murphy et a l,  1989), and later from human urine and
I
t
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thus designated as urogastrone (Uria et a l,  1994). EGF is synthesised as a 
much larger transmembrane glycosylated, biologically active precursor of 
128kDa. Precursor molecules have an N-terminal extracellular domain, a 
single transmembrane domain of 25 amino acids and a C-terminal domain of 
150 amino acids, as predicted from the cDNA sequence. Mature EGF spans 
the cell membrane. The function of the other 8 units of EGF remains to be 
elucidated. Immunological studies have suggested that amino acids represent 
the receptor binding domain and are also responsible for signal transduction, 
while amino acids 35-53 stabilise the ligand receptor interactions.
Epidermal Growth Factor Receptor (EGFR)
The EGFR is a 170kDa transmembrane glycoprotein and is expressed in most 
normal epithelial tissues. It is expressed or overexpressed in many human 
epithelial malignancies, including lung, breast, head and neck, and bladder 
cancers. EGFR has intrinsic tyrosine kinase activity. It is composed of three 
domains: an extracellular domain that binds receptor specific ligands, a 
lipophilic transmembrane segment and intracellular tyrosine kinase domain 
that initiates a signal cascade from the cytoplasm to the nucleus. Signal 
transduction through EGFR occurs upon ligand binding followed by 
dim erization o f the receptor, activation of tyrosine kinase, 
autophosphorylation of the receptor and phosphorylation of other substrates.
4 .
EGFR structure, functions, mechanism of action and its role in carcinogenesis 
have been extensively reviewed by (Liotta et a l ,  1991; Lochter & Bissell,
1995). Autophosphorylation processes are thought to result in internalisation 
and down regulation of the receptor after ligand binding (Sappino et al,
1989). Whether the receptor is recycled or degraded is yet unknown though 
there is probably an element of both. EGFR is expressed in 30-40% of human
progression. In this respect, sex steroids play an important role in the
:
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breast cancer. Expression of EGFR is an indicator of poor prognosis 
(Nicholson et al., 1990). EGF dependent transformation of rodent fibroblasts 
due to overexpression of EGFR again implicate its role in the process of 
cellular transformation. Patients with EGFR positive tumours have shorter 
disease free intervals and lower overall survival than EGFR negative patients. 
The presence of EGFR can be correlated with the histological grade of 
tumours, the involvement of lymph nodes, the number of métastasés, and 
poor prognosis for the patient. EGFR is detected in invasive ductal 
carcinomas, but not in lobular or colloid carcinoma (Klijn et al., 1992). An 
uncontrolled autocrine loop of TGFa/EGFR results in a rapidly growing 
tumour as in squamous carcinoma of the head and neck, in which EGFR is 
frequently overexpressed. Although overexpression of EGFR is often present 
in epithelial carcinomas and is an indicator of poor prognosis, its role in 
tumour initiation, growth and progression needs to be better defined.
*
The proto-oncogene c-erbB2 is a related EGFR system. It is a 185kDa tyrosine 
kinase receptor and is homologous to EGFR. 20-30% of invasive breast 
carcinomas express c-erbB2. There is an inverse correlation between the 
expression of c-erbB2 and survival particularly in lymph node negative cases 
(Paget, 1889). erbB2 positive tumours also have minimal response to 
endocrine therapy and a poor response to chemotherapy regimens such as 
CMF.
EGF and Breast Cancer
Breast and other endocrine glands like ovaries, endometrium and prostate are •Î
4
e  
;
under the hormonal modulation for normal growth and also for tumour
"■ 'I
1.5.2 Transforming Growth Factor a (TGFa)
tumours and from the culture media of virus-transformed cells. It has been 
demonstrated in a variety of retrovirally transformed cells, human tumours and 
normal embryonic cells (Guidice & Saleh, 1995)
.;.y
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regulation of locally acting growth factors such as the EGF family (Martinez- 
Lacaci & Dickson, 1996) &Î:
EGF has been detected in a variety of breast cancer cell lines (Johnson et al.,
1993) and human breast tumours (Albini et al., 1986). EGF is mitogenic for 
several breast cancer cells. Low levels of EGFR are associated with growth 
response to EGF whereas cell lines with higher EGFR are growth inhibited by 
EGF. This observation is clinically very important (Kirby, 1965; Zetter et al.,
1990) because ER-/EGFR positive tumours are associated with metastasis and .4
shorter survival time whereas ER+/EGFR negative tumour types are better 
differentiated and is good prognosis. EGF promotes anchorage dependent 
growth of human mammary epithelial cells (Sato & Rifkin, 1989).
Interestingly TGFa mRNA levels are also higher in hormone responsive 
endometrial cells (Murphy, 1994) and prostate cancer thus suggesting 4
hormonal stimulation of an autocrine loop in hormone responsive cell lines.
EGF mRNA levels can further be increased by progestins in T47-D breast 
cancer cells (Dei-Rosso et al., 1990). This shows a possible hormonal 
regulation of EGF. EGF is probably the principal milk derived growth factor 
and appears to be an important regulator of growth and differentiation of the 
mouse mammary gland (Yagel et al., 1989) especially during pregnancy, 
lactation, and spontaneous formation of mammary tumours.
TGFa and TGF(3, have the ability to bring transformation and anchorage 4
independence to normal cells. TGFa was first isolated from human solid
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demonstrated that this induction is mediated through ER by using anti- 
oestrogens. The mitogenic effect of E2 is mediated by TGFa in ER positive 
human breast cancer cells (Flaumenhaft et al., 1992; Testa & Quigley, 1990) 
Availability of purified antibodies has made it easy to find the expression of 
any factor. Experiments using in situ hybridisation analysis have detected 
TG Fa mRNA during the proliferative stage and during human pregnancy.
TG Fa is a 47-50 amino acid peptide with a molecular weight of 6kDa. It has 3 
disulphide bonds between six cysteine residues (Graham & Lala, 1991).
Human TGFa is derived from a large membrane bound precursor protein of 
160 amino acids that is biologically active. The N-terminal sequence consists 
of a 23 amino acid signal peptide, 74-75 amino acids constitute the mature 
growth factor domain followed by 39 amino acids at the C-terminus. This 
latter sequence is a cysteine rich part of the growth factor and remains in the
cytoplasm. Pro-TGFa is juxtacrine in function (Lala & Graham, 1990). 4
"7Human TGFa shares 42% homology with human EGF while it is thought to |
r-
have 27% amino acid sequence homology with murine EGF. Three 
dimensional studies have revealed that its tertiary structure resembles that of 
EGF and is able to bind to EGF receptor with the same affinity. |
: : i
TGFa and Breast Cancer
TGFa has the same biological effects as EGF in cultured human and mouse 
mammary cell lines and mouse mammary explants (Yagel et al., 1989). A 
number of studies have clearly shown that TGFa is present in both primary 
and metastatic human breast cancers. TGFa is expressed in mammary 4
epithelial cells and breast cancer cells and is regulated by oestrogens. 
Physiological concentration of E2 is sufficient to induce TG Fa mRNA 
transcription and protein translation (Flaumenhaft et al., 1992). It has been
.1
'îV.:MS:
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' V :Similar studies have indicated that breast cancer cells synthesised the growth
'v-factor. (Irving & Lala, 1995) have demonstrated that 31% of primary tumours |
and 50% of metastastic tumours analysed were positive for TGFa. Further, 
during mouse mammary gland studies, immunohistochemistry has revealed
4:TGFa expression in the basal epithelia, proliferative and bud cap cells. v
5
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1.5.3 Transforming Growth Factor P (TGFP) I
TGFp was first studied in the 1970s in association with mammalian and avian 
retroviruses that could induce sarcomas in animals. It was found that retrovirus 
could transform normal fibroblasts by certain substances later called Sarcoma 4
Growth Factor (SGF). It had been observed that SGF from transformed cells 
was composed of TGFa and TGFp, operating in tandem. (Duffy et a l,  1988)
t
The chromosomal locations of the human TGFp genes are 19ql3 for TGFp-1, f
lq41 and 14q24 for TGFp-2 and 3, respectively. The corresponding mRNAs y
range from 2.5kb (TGFp-1) to 6.5kb (one of the TGFP-2 transcripts). It is 
indicative of a differential regulation of these three isoforms that they have 
distinguishing promoter sequences.
Mature TGFP is a 25kDa polypeptide that belongs to a much larger 
superfamily of sequence related molecules in the inhibin family. This family 
of multifunctional regulatory peptides is involved in a range of processes 
including regulation of growth, development, and differentiation. The 3 
mammalian isoforms TG Fpl, P2, and P3 are all homodimers. As the most
predominant member of its family, TGFp lis found essentially in all 
mammalian tissues, with the highest concentrations being found in platelets 
and bone. Each of the members consist of two peptide chains of 112 amino
acids and nine cysteine residues with a molecular weight of 25kDa. The
■f
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25kDa form represents the C-terminal end of a precursor molecule. TGpp-1 is 
encoded as a 390 amino acid precursor while TGFP-2 as a 412 amino acid 
precursor. All three precursors have N-terminal signal peptides of 20-23 
hydrophobic amino acids (for reviews see Sainsbury, 1997; Knabbe & 
Zugmaier 1994; Benson & Codetta, 1995).
inactive molecule.
Biological Functions of TGFP
TGFp is a multifunctional growth factor. It plays a central role in most 
processes of intercellular communication, including differential regulation of
Latency in TGFp is conferred by dimerization of N-terminal part of associated 
proteins which folds itself around TGFpi (called latency associated peptide 
p 1-LAP). An additional component called latent TGF (LTBP) is also found in 
the latent complex released from blood platelets. The function associated to 
LTBP is to target TGF to extracellular matrices (Heidtmann et al, 1989).
TGFp isoforms have been identified in normal tissues of both developing and 
adult organisms, as well as neoplastic tissue (Patthy, 1985; Wolf et a l, 1993a)
Most cells, normal or transformed, release TGpp as a latent, biologically
TGFp can be activated in vitro by acidic pH (Kobayashi et a l ,  1990; Schmitt 
et al., 1989). However in vivo mechanisms of activation require proteases such 
as plasmin and cathepsin D (Goretzki et ah, 1992). Latent TGFP has a longer 
plasma half life thus providing stability to the molecule to act at a distant site 
from its origin (Gunzler et a l,  1982a). It has been shown that the half life of 
recombinant TGFp is about 90 minutes in vivo. The active form of TGFp has a 
very short half life and is removed from the circulation by the liver (in 2-3 
minutes) (Gunzler et al, 1982a).
I
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the extracellular matrix, angiogenesis and immunosuppression. In general it is 
inhibitory to a range of epithelial and endothelial cells, human kératinocytes, 
hepatocytes and human carcinoma cell lines but stimulatory to mesenchymal 
cells (Schwann cells. Osteoblasts, Chondrocytes, W138 human fetal lung 
fibroblast). TGpp regulates the expression of a wide variety of genes and 
proteins, including several nuclear proteins involved in cell growth control. 
TGFp regulates c-jun and c-fos. There is inhibition of keratinocyte DNA 
synthesis by down regulation of c-myc by TGFp. However, mouse NIFI3T3 
cells are stimulated by TGFp by the induction of c-myc, thus having a more 
direct mitogenic effect. Picomolar quantities of TGpp can regulate 
proliferation. TGFP regulates cyclin D function and Retinoblastoma (Rb) 
protein phosphorylation. TGFp stimulates the anchorage independent growth 
of human and rat fibroblasts. For example, NRK-49 fibroblasts are stimulated 
by TGFp but inhibited when transformed by Kirsten sarcoma virus thus 
showing the bifunctional nature of TGFp. TGFpi has a role in wound healing 
processes indicated by its high content in blood platelets (Lyons et ciL, 1990). 
It is believed that many cancers may arise due to dysfunction of TGFp 
regulation. Solid tumours require vascularization to gain a clinically detectable
size. TGFp stimulate the production of stromal components like fibronectin, 
proteoglycan and tenascin, their overexpression favouring stroma formation 
and thus angiogenesis. Increased expression of TGFp allows the tumour to 
escape from immunological response. The overexpression of TGFP2 is likely 
to be responsible for the immune deficiency in patients with Glioblastoma.
Thrombospondin, a stromal element, promotes angiogenesis and tumour 
invasion. These effects may be due to its ability to activate latent TGFp 1.
'
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TGFp and Breast Cancer
Growth factors exert their functions by autocrine or paracrine loops. Over 
activity of any of these loops results in excessive proliferation, a characteristic 
of the preneoplastic state or tumour progression.
In the field of cancer, dysfunction of TGFp has been implicated. It has a 
growth inhibitory effect on the progression of cancers derived from epithelial 
origin like breast cancer. Exogenous TGFp inhibits the growth of breast 
cancer cell lines indicating its principal inhibitory autocrine loop. Breast 
cancer cells resistant to anti-oestrogens are still growth inhibited by TGFP in 
vitro (Gunzler et al., 1982b). The anti-oestrogen, tamoxifen, can also inhibit 
the growth of the hormone insensitive (anti-oestrogen insensitive) cell line 
MDA-MB-231 when co-cultured with ER positive (MCF-7) cells in a system 
permitting interchange of conditioned media. This is due to enhancement of 
TGFp secretion by the MCF-7 cells. This could explain how endocrine 
insensitive cells respond to endocrine therapy, since tumours are often 
heterogenous in ER content. In vivo studies have also confirmed the induction 
of TGFp by tamoxifen in ER positive cells by antagonising the stimulatory 
effect of oestrogen and so tamoxifen may inhibit ER negative cells. In vivo 
studies, using immunohistochemistry on tissue from a group of breast cancer 
patients following tamoxifen therapy, further confirmed the elevation of TGFp 
in both ER positive and ER negative cells (Schmitt et al, 1997a). :|
Other growth inhibitors such as retinoic acid are of interest. These are 
naturally occurring derivatives of vitamin A (retinol) and exert a key role in 
maintenance of epithelial homeostasis through regulation of cellular 
proliferation and differentiation. Retinoic acid induces the secretion of TGFp-
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1 and TGpp-2 depending upon the cell types (reviewed in Benson & Colletta, 
1995; Knabbe & Zugmaier, 1994)).
Induction of TGpp is not only confined to breast tissue/cells. Up regulation of 
TGFp has been observed in the peri tumoral fibroblasts in vivo, suggesting 
involvement of paracrine loop between stromal and epithelial cells (Schmitt et 
al., 1997a). Experimental evidence has suggested that overexpression is 
associated with enhanced metastatic potential of rat prostate cancer cell lines. 
Withdrawal of androgen leads to enhanced expression of TGpp-2 in the 
androgen responsive human prostate cancer cell line LNCaP (Blasi, 1988). 
TGFP-2 has been suggested as a marker of the hormonally regulated growth 
state of tumour tissue. A more aggressive stage of tumour is said to be 
accompanied by the loss of the inhibitory function of TGFp in vivo.
Mechanism of Action of TGFP
The mechanism of action of TGFp is not fully understood. A complex pattern 
of cross-reactive ligands and cell surface receptors has been described (Blasi et 
al., 1987). Three major transmembrane receptors are known to bind TGFps 
(Heidtmann et al., 1989). These are type I (53kDa), type II (70-80kDa) and 
type III (250kDa) receptors. These were found by cross linking studies of 
iodinated TGFp with ceil surface proteins of human breast cancer cells. TGFp 
interacts with two types of membrane receptors, which functionally cooperate 
to generate an intracellular signal (Janicke et al., 1990). These two types i.e. 
type 1 and type 2 contain a serine-threonine kinase domain and are thought to 
mediate the growth inhibitory action of TGFp. (Derynck, 1994; Duffy et al., 
1990; Pennica et al., 1983). The three types of TGFp receptors have been 
cloned. Growth inhibitory functions of TGFp remain to be elucidated but it 
has been shown that growth inhibition by TGFP is linked to suppression of the
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retinoblastoma protein (pRB) phosphorylation (Grondahl-Hansen et al., 1991). 
However, inactivation of retinoblastoma gene alone does not lead to the loss 
of TGF(3 receptors or of response to TGFp in breast cancer cell lines (Skriver 
et aL, 1984)
1.5.4 Insulin like Growth Factor (IGF)
?Insulin like growth factors were discovered as the somatomedins in 1957 but i
were purified and sequenced in the mid 1970s. Insulin like growth factor 7
:î(IGF) is named due to its close homology to pro-insulin. The IGF family |
consists of two ligands IGFI and IGFII with their respective receptors IGFRI
and IGFRII and some six different binding proteins IGFBP are described. f
I ' -IGFI and IGFII are single chain molecules of 70 and 67 amino acids 
respectively with high affinities for their respective membrane bound T
receptors. The single chain 7.5kDa IGFI and IGFII are produced in many body 7
: *■tissues, specially in liver, and are under the control of hormonal regulation. ,
IGFI is known to have a role in bone elongation in an endocrine manner under ))
GH control, while IGFII is thought to be involved in fetal development. IRecently, their role in development, growth and transformation has been ;S
'a.described. I
IGFRI is a heterotetrameric protein consisting of two alpha and two beta f
chains. Like insulin receptor, it has intrinsic tyrosine kinase activity. It has 
been observed that ligand binding causes autophosphorylation of the receptor 
and this transduces the signal of the ligand. The receptor binds, both ligands v
IGFI and IGFII, with equal affinity. On the other hand, IGFRII is a single 
chain molecule with affinity for only IGFII. Unlike IGFRI, IGRFII has no 7
tyrosine kinase activity and therefore the signalling mechanism is obscure. 7
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IGFs and Breast Cancer
IGF increases the rate of proliferation of some breast cancer cells (Ossowski & 
Reich, 1983) (Ossowski, 1988). Kullen et al have described that IGFII mRNA 
is expressed in T47-D cells and that both T47-D and MCF-7 cells are growth 
stimulated by both IGFI and IGFII In vitro (Wei et a i ,  1996) IGF may 
stimulate mitogenesis by reducing the levels of active TGFp. 50% of breast 
carcinomas appear to have IGFII mRNA while it is present in all normal 
breast tissues.
The levels of IGFI and IGFII appear to be low in epithelial cells but their 
confirmed presence in the stromal components of a number of breast tumours ■ „ ■
have suggested a potential paracrine role for IGFs, whose level can be 
modulated by the anti-oestrogen, tamoxifen (Vassalli et aL, 1985; Xing &
Rabbani, 1996). It is believed that stromal secretion of IGFI can be induced by 
platelet derived growth factor present in breast epithelial cells with stromal 
cells possessing PDGF receptors. IGFI mRNA is absent in primary breast 
tumours but is present in normal breast. Stromal cells are rich sources of IGFs 
which may serve as positive paracrine growth factors. The functions of IGFs 
in breast cancer are not only controlled by levels of ligands and receptors but 
also by the presence of IGF binding proteins. These extracellular binding 
proteins may either stimulate or inhibit IGF action and they may determine 
both activity and bioavailability of these growth factors (Yee et ai, 1991).
Breast cancer cell lines secrete significant levels of IGF binding proteins and
:::ï
their addition to the culture media has been shown to inhibit cancer cell 
,growth.
Breast cancer patients have higher plasma IGFI levels than their normal 
counterparts (Felsenfeld et aL, 1996) and 25% reduction in IGFI has been 
observed in patients treated with tamoxifen. The levels of IGF binding
;
1
:
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proteins are also subject to modulation by oestrogens and possibly by anti- 
oestrogens (Lonning et aL, 1992).
1.6 Tumour Development and Metastasis
■^:i
Breast carcinomas are mixtures of genetically and phenotypically distinct 
cells, despite having arisen from a single cell. Genetic disposition, either by
:external (UV-irradiation or chemical carcinogens) or internal stimuli 
(hormones or growth factors) leads to transformation in a ceil. One of the 
earliest detectable changes in transformed cells is a several fold increase of 
genomic instability compared with normal cells (Tisty, 1997). Both these 
properties, genetic instability and tumour heterogeneity determine the ability 
of the cells to metastasise (Welch & Wei, 1998). Transformation is the initial 
stage of a tumour development. Proliferation of the transformed cell is 
followed by formation of a primary tumour. The cells in the primary tumour 
are confined within its place and therefore cancer is localised. Primary 
tumours can be treated surgically, so patients rarely die of carcinoma in situ. It 
is the undetected spread of tumour cells throughout the body, which is life 
threatening. This establishment of tumour at a site distant from the primary 
site, is metastasis. The term "metastasis" was first described by a French 
physician, Joseph Claude Recamier, in his 1829 treatise Recherches du 
Cancer. He was the first to show that cancer cells can form distant tumours in 
the body through the circulatory system. He observed the growth of a tumour 
in the brain of a patient with breast cancer. He also noted that the veins in the 
same site were invaded by tumour cells. A clearer understanding of the 
mechanisms underlying invasion and metastasis is required.
I
i
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Steps Involved in Metastasis
This process of invasion and metastasis requires a series of sequential steps 
(Liotta & Stetler-Stevenson, 1991) begining with dissociation of the cells from 
primary mass, to move through a basement membrane surrounding the 
tumour, making its way through the interstitial connective tissue (extracellular 
matrix) and then through another basement membrane into the bloodstream. 
After escaping the immunosurveillance in circulatory system, the cells have to 
cross all the barriers of basement membranes and extracellular matrix (ECM)
on reaching the suitable destination, but in a reverse order. The tumour cell in
lilthe new environment establishes the micro metastasis and only grow in size in 
the presence of ample supply of blood vascular system. Tumours 1 -2mm in 
diameter can receive all the nutrients by diffusion but for further growth it 
needs to develop its own blood supply (Folkman, 1990).
:,;ï
r
■ ■’7;:
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Fig. 1 Tumour associated proteases are involved in the degradation o f stroma and basement membrane, which  
leads to tumour invasion. The m etalloproteinases include coHagenasc. strom clysins, cathepsins and 
gelati liases.
This figure is modified fromSchmitt et al 1990
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1.7 Metastatic Spread: Where, Why?
INormally, tumour cells are carried away through the blood and/or lymphatic 
circulation until a favourable environment is found. One might anticipate that 
malignant cells would metastasise to an organ of the same somatic origin. This 
is not the case. However, metastasis is not random but displays a selective 
pattern e.g. cancers of the breast and large bowel exhibit different metastatic 
foci, despite both originating in epithelial cells (Picford & Birnie, 1992). One 
may speculate, on the basis of the lymphatic system and the blood flow, that 
60% of the metastasis from the primary tumour may deposit in the lung, liver
and bone marrow. The frequency with which metastasis occurs in lung and
liver may be because the metastasising cell passes through the heart before it
finds the resting place. Because the heart pumps all the blood through the lung
capillaries before sending it to other parts of the body, lungs therefore, are the
most common metastatic site, for many cancers. Liver is the favoured site of
metastasis from colon cancer because of the direct drainage of the venous
blood from the large intestine, into the liver (Liotta, 1992). Sometimes, the
metastatic foci are different from that mentioned and the only explanation
applicable may be the hypothesis proposed by (Paget, 1889). The consensus of
"seed and soil" theory was proposed by him after his studies on breast cancer.
.He referred to the circulating tumour cells as "seed" and the favourable 
environment that is provided by the organs for the cells to metastasise, as the ;
"soil". It appears that hormones and growth factors provide greater affinity for 
the circulating tumour cells and therefore induce them to move out of the 
bloodstream and into cells/tissues which have the appropriate balance of the 
desired endocrine and paracrine functions (Liotta, 1992).
It has been observed that not all cells, that have survived mechanical
turbulence and escaped the host immune system, can grow in an organ. Only 
as few as one in 10000 tumour cells leaving the primary mass can initiate a
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new tumour at a distant site. Once in the new environment tumour cells 
proliferate. Cell proliferation is eontrolled by growth factors (Zetter et aL,
1990). Another important factor for a tumour cell to grow and establish A
metastasis beyond about 3mm in diameter, must establish its own blood
supply i.e. angiogenesis is essential (Picford & Birnie, 1992). |
1.8 Extracellular Matrix and Epithelial Cells Interactions
*Cells are dependent on their interaction with the substratum for proper growth
and differentiation. For instance, it has been shown that whereas cells grown 
on plastic respond poorly to lactogenic hormones, those grown on collagen 
gels, or EHS, induce the gene expression of milk producing genes in response 
to lactogenic hormones. Protein secretion is also dependent on substratum and |
has been shown to be enhanced generally in cultures on floating gels.
Epithelial differentiation can be induced and maintained on and within a 7
variety of matrices derived from ECM components. Both normal and
neoplastic mouse mammary epithelium displayed some morphogenesis and 7Li.
also high growth rate when grown on and within collagen gels. These as well
as other results clearly underscore the role that a substratum plays on the |
proper biological functioning of a normal or a malignant cell.
Although surgeons and oncologists can treat cancers that are in their early 
stages, very rarely are they able to save patients whose tumours have 
metastasised to other parts of their body. Tumour cell invasion across the
basement membrane (BM) and tumour associated angiogenesis are considered 
to be the key steps of metastasis (Figure 1). Although it is a complicated
process that requires the co-ordinated action of numerous proteins to degrade' 
the BM, understanding how metastasis occurs is of obvious importance. Thus, 
in order to study the in vitro invasive potential of a certain cancer cell line and 7
■i;I
.. . .  .     . _   _
■■■ ■
!
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how different hormones and growth factors affect it, it was important to use a 
substratum that contained different membrane proteins and was therefore more '
physiological than plastic. Matrigel, which is an extract of Engelbreth-Holm- 
Swarm (EHS) tumour basement membrane (BM), is a substratum which has 
been widely used since 1986 (Albini et aL, 1986) for such invasion studies.
Matrigel is comprised largely of laminin, type IV collagen, heparan sulphate 
proteoglycan, fibronectin and entactin. Recently, however, trace amounts of 
plasminogen have also been found in Matrigel (Farina et aL, 1996). In its 
reconstituted form it has been used extensively as a BM barrier to tumour cell 
invasion and to study the effect that the BM has on vasculargenesis In vitro.
Several laboratories have noted the importance of the major proteins in 
Matrigel on cellular growth and differentiation. Specifically, it has been found 
that all five proteins in Matrigel are required for proper growth and 
maintenance of different cell lines. In one study it was found that proper 
alveolar morphogenesis and mammary-specific functional differentiation 
required the presence of Matrigel. Growth of these cells on individual 
components of the ECM, however, was not associated with proper alveolar 
formation and differentiation. Another study showed that the growth and 
differentiation of the mammary epithelium ceils is dependent on the 
substratum. In this case protein synthesis and secretion by mouse epithelial 
cells on floating collagen gels and EHS-matrix were compared and it was 
found that protein synthesis was consistently higher in cells that were attached 
to EFIS matrix. Similarly, cells associated with the EHS matrix also had higher 
rates of growth and protein secretion into the culture medium than those which 
were grown on plastic. The much greater rates of growth suggest that the 
matrigel may facilitate both two and three dimensional interaction of epithelial 
cells
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1.9 Proteases In Invasion and Metastasis
In a comprehensive study (Li et aL, 1994) showed the influence of a 
reconstituted basement membrane and its various components on casein gene 
expression and subsequent secretion in mouse mammary epithelial cells. 
Consistent with previous reports the results show that when these cells were 
plated on plastic they immediately stopped synthesising and secreting most 
milk proteins even in the presence of lactogenic hormones. More importantly, 
cells cultured on type- 1 collagen gels were found to have increased amounts of 
p-casein mRNA and protein in addition to other milk proteins. On Matrigel, 
most of the cells produced high amounts of the p-casein. Interestingly, they 
found that while individual components of the basal lamina such as type IV 
collagen, and fibronectin had no effect on morphology and p-casein mRNA 
levels, both laminin and heparan sulfate proteoglycan caused an increase in p- 
casein mRNA levels. A dramatic difference in the morphology of mammary 
epithelial cells was seen when they were plated on plastic and matrigel. 
Whereas no changes were evident on plastic, on EHS the same cells formed 
ducts, ductules, and lumina which resembled secretory alveoli. Taken together 
these results clearly show the important role of substratum on cellular 
metabolism.
Cells in the body are scaffolded in a basement membrane which is responsible
for the regulation of many cellular functions. The components of basement
membrane consists of type IV collagen, laminin, heparan sulphate and
proteoglycan and the destruction of these components correlates with invasion
and metastasis (Liotta & Stetler-Stevenson, 1991; Tryggvason, 1989). This
step requires the coordinated expression of destructive enzymes and their
inhibitors. Several lines of evidence show that particular proteases are
.responsible for the breakdown of basement membranes (involved in
-y'
Matrix Metalloproteases
and chymotrypsin (Duffy, 1992), or by organomercuriaLs (Woessner, 1991).
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compartmentalisation and many cellular functions) and subsequently the
extracellular matrix. All the evidence points to a common set of enzymes and
their inhibitors that are involved in many forms of cancer. These enzymes
_consists of 4 main classes namely; serine proteases, matrix metalloproteases, 
cysteine proteases and aspartyl proteases which allow tumour cells to escape 
from its primary site and to intra and extravasate the basement membrane.
The key enzymes appears to be plasminogen activators (Mignatti & Rifkin,
1993). While the uPA/plasminogen system is undoubtedly very important in 
the spread of metastasis, the other proteases i.e. metalloproteases (Bassat et 
aL, 1990; Matrisian, 1990; Woessner, 1991) such as the stromclysins (Bassat 
et aL, 1990) and cathepsins (Duffy et aL, 1991; Foucre et al., 1991; Moscatelli 
& Rifldn, 1988; Rochefort et aL, 1990; Rochefort et al., 1996) have also been 
implicated to play roles in the dissemination of tumour cells.
■■■■I
Matrix metalloproteases are an important group of zinc enzymes responsible 
for degradation of extracellular components, including interstitial collagens, 
basement membrane collagen (type IV), fibronectin, laminin and various 
proteoglycans (Moscatelli & Rifkin, 1988) in normal embryogenesis and 
tissue remodelling, as well as in disease processes such as arthritis, cancer, and 
osteoporosis.
The chief characteristics of matrix metalloproteases (MMPs) are no different
from other proteases involved in normal and cancer situations in that these 
proteases are secreted in zymogen form. The inactivity is because of a highly 
conserved sequence of nine amino acids. This sequence contains a reactive
cysteine residue. The zymogen can be activated by other enzymes, plasmin
Tissue Inhibitors of Matrix Metalloproteases (TIMPs)
Control of extracellular proteolysis is critical to the normal, healthy organism. 
Just as there is a family of metalloproteases, there is also a family of TIMPs. 
Different forms of these inhibitors are described e.g. TIMP-1, -2 and -3. 
Several groups have shown that TIMP-1 and TIMP-2 can inhibit the process 
of tumour cell invasion (Parish, 1994). TIMP-1 is a glycoprotein with a 
molecular mass of 28kDa and it inhibits invasion and metastasis in animal
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The question arises as to how these metalloproteases are activated In vivol 
Since organomercurials or trypsin are not present in the tissues it is expected 
that plasminogen enters from the blood and that the local tissue can produce 
plasminogen activator (PA) forms plasmin by PA and in turn MMPs are 
activated either directly or indirectly by plasmin. This again emphasises the 
role of PAs in invasion. The activity of these enzymes is inhibited by tissue 
inhibitors of matrix metalloproteases (TIMPs) (Matrisian, 1990).
Several members of the MMPs family have been linked to cancer cell biology. 
Liotta et al. (1992) have found that in general, augmented levels of 
metalloproteases in tumours correlated with the development of invasion and 
métastasés in cancer of the human breast, colon, stomach, thyroid, lung and
liver. These include Type IV collagenase or gelatinase (known as MMP-2) 
which is found in a wide variety of tumours including mammary 
adenocarcinoma cells where the degree of its expression is correlated to
metastatic potential (Nakajima et al., 1987). Type IV collagenase is expressed 
in human skin and colon cancers (Tryggvason et al., 1993) at the invading 
front and in bladder carcinoma. Type I collagenase (MMP-1), also showed 
elevated expression in mammary carcinoma cell lines (Whiltelock et al.,
1991).
I'
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models. This has been observed by transfecting anti sense TIMP-1 RNA in 3T3 
cells (Khokha et ciL, 1989). TIMP-2 is non-glycosylated and inhibits invasion 
of ECM (Albini et al., 1991). It has been shown that TIMP-3 is expressed in 
human breast tumours (Uria et al., 1994). TIMP forms a 1:1 stoichiometric 
complex with MMP-1 and MMP-3. The enzyme binds reversibly and can be 
dissociated by acid treatment or EDTA (Murphy et al., 1989).
Cathepsins
Cathepsin D is the most studied protease of the group cathepsins. It is secreted 
as a 52kDa precursor form. It is a lysosomal aspartic protease whose 
expression is regulated by oestrogens and certain growth factors in breast 
cancer cells. Normal breast tissue contains little cathepsin D while its content 
is higher in cancer tissues (Duffy et al., 1991). A number of studies have
k
Stromelysins 4i',a"
Stromelysins are also MMP family members involved in tumour biology.
They are broad spectrum proteases which can cleave ECM components. There 
are different forms of stromelysins i.e. stromelysin-1 ,-2 and -3. In addition to 
others, the metalloprotease stromelysin 3 is often found in breast cancer and is 
rarely present in benign tumours of the breast. The prognostic value of 
stromelysin 3 in invasive breast cancer however has not been established. 
However the correlation with other known prognostic factors, point out that it 
may play an important role. Stromelysins-1 and -2 are present in elevated 
levels in most invasive breast carcinomas (Wolf et al., 1993b).
shown that high levels of cathepsin D offer a bad prognosis, reduced overall
. :survival and early metastatic spread (Foucre et al., 1991). Its involvement in
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metastasis is controversial. On one hand no correlation was found between 
cathepsin D and invasiveness (Johnson et al., 1993), while others have shown 
a link between elevated levels of tumour cathepsin D and poor prognosis in 
either node-negative or node positive patients. The influence of other 
cathepsins, such as cathepsins B, H, and L, on the prognosis of breast cancer 
patients is under study.
Plasminogen Activators
There are two independent structural genes that code for plasminogen
; i ■ - :activators. These are molecularly, functionally and immunologically distinct 
(Pennica et al., 1983) but have about 40% homology on the basis of their 
amino acid sequences (Pennica et al., 1983; Verde et al., 1984). They are 
called urokinase type (uPA) and tissue type (tPA) plasminogen activators.
They are termed after their original identification in urine and tissue extracts, 
respectively (Dano et al., 1985). The molecular weights of uPA and tPA are 
50kDa and VOkDa, respectively (Laiho & Oja, 1989). tPA has a role in 
fibrinolysis, whereas uPA is involved in tissue remodelling, development and 
also in cancer invasion and metastasis (Mignatti & Rifkin, 1993) .
I
.'Î,
1.10 Plasminogen Activator System
Plasminogen activation system has been shown to play a pivotal role in 
tumour cell invasion (Dano et a l ,  1985) Plaminogen activators mediate the 
conversion of inactive plasminogen, by limited proteolysis, to active plasmin, 
which has a broad substrate specificity (Robins et al. 1967).
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1.10.1 Plasminogen
Plasminogen is an inactive proenzyme consisting of a single polypeptide chain 
with a molecular weight of 92,000. It exists in two forms; the Glu- 
plasminogen and the Lys-plasminogen. Both these variants differ slightly due 
to the differences in the glycosylation. The Glu-plasminogen has glutamic acid 
and Lys-plasminogen has lysine at the N-terminus. The molecular weight of 
Lys-plasminogen is approximately 8kDa lower than Glu-plasminogen (Dano 
et a l,  1985).
predominantly appears to be located extravascularly (Grondahl-Hansen et a l ,
1991).
Plasminogen regulation
Glu-plasminogen is converted into its active Glu-plasmin form by cleavage of 
a single polypeptide bond (Arg 560-Val 561) that is catalysed by the 
plasminogen activator (PA). The active two chain Glu-plasmin is held together 
by disulphide bonds. The formation of Lys-plasminogen from Glu- 
palsniinogen is catalysed by plasmin by the cleavage of another peptide bond 
(Lys76-Lys77). Plasminogen is widely available in the body, having a 
circulating concentration of approximately 2 mM and a half-life of 2.2 days 
(Saksela, 1985). Numerous studies have shown that plasm inogen
Plasminogen activation is regulated at several stages. Firstly, the activation of 
inactive plasminogen to active plasmin. Secondly, plasmin can be inhibited by 
its inhibitors e.g. a 2-antiplasmin. Thirdly, binding of plasminogen and/or 
plasmin to its receptor is required, close to the uPA receptor on the cell 
surface. Fourthly, there is regulation of the activators of plasminogen, i.e. uPA 
and other molecules like plasmin that activate plasminogen.
. J
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1.10.2 Plasmin
Plasmin, is generated by a single proteolytic cleavage at 
plasminogen activators. Plasmin has an important role in physiological 
fibrinolysis and is also ascribed other important roles in several physiological 
and pathological circumstances characterised by tissue remodelling and cell 
motility. Amongst the two types of plasminogen activators, uPA has a specific 
substrate, plasminogen. Plasmin can, either directly or through its ability to 
activate some prometalloproteases (e.g. procollagenase type IV), degrade 
components of the tumour stroma such as fibrin, fibronectin, proteoglycans 
and laminin (Blasi et a l,  1987; Duffy, 1992; Ellis et aL, 1991; Janicke et a l,  
1990; Schmitt et aL, 1992). In addition, plasmin affects various growth factor 
systems, e.g. activation of latent TGFfI (Lyons et al., 1990) and dissociation of 
IGF from its binding protein (Campbell et al., 1992).
Plasmin is a trypsin-like protease with a molecular weight of approximately 
25kDa. It is a two chain polypeptide held together by disulphide bonds. Like 
other serine proteases such as trypsin, chymotrypsin and pancreatic elastase, it 
has a relatively broad substrate specificity and hydrolyses proteins and 
polypeptides at lysine and arginine residues.
Regulation o f Plasmin Activity
Plasmin is inhibited by several protease inhibitors occurring in plasma but the 
most important are a2-antiplasmin and a2-macroglobulin. The latter seems to 
be involved only when there is a depletion of the fast reacting a 2-antiplasmin. 
Plasmin activity can be controlled at several levels but most important steps 
include 1) Availability of plasminogen activator 2) Levels of plasminogen 
activator inhibitor.
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1.11 Components of Plasminogen Activation System
Two well documented activators of plasminogen are urokinase type of 
Plasminogen Activator (uPA) and tissue type Plasminogen Activator (tPA).
1.11.1 Urokinase Type of Plasminogen Activator (uPA)
uPA is a very well characterised 50kDa protein which is glycosylated at 
Asn302. uPA is secreted as an inactive single-chain protein (pro-uPA) with no 
intrinsic enzymatic activity. Pro-uPA is activated by a variety of proteases 
including plasmin, cathepsins B/L, Kalliki'ein, trypsin-like enzymes, and nerve 
growth factor-Y, leading to the enzymatically active high molecular weight two 
chain form, HMW-uPA. Pro-uPA is cleaved at a peptide bond lysine (158)- 
isoleucine (159), by these proteases (Blasi et a i,  1987). uPA is a multidomain 
protein (Gunzler et al., 1982a) whose N-terminal A-chain (20kDa) and the C- 
terminal B-chain (34kDa) are linked by a single disulphide bond (Verde et al., 
1984; Dano et ah, 1985).
Over years many forms of uPA have been identified. The precursor protein 
called high-molecular weight (HMW)-uPA is 411 amino acids in length («52 
kDa) and is secreted from normal fibroblasts, trophoblast cells of the placenta 
and kidney tubules etc, as well as from tumour cells and is then subsequently 
activated extracellularly (Saksela, 1985; Schmitt et a l,  1992). The HMW-uPA 
is further converted into an enzymatically active LMW-uPA which is 276 
amino acids («34 kDa) and an inactive form called ami n o - ter mi nal - fi agment 
(ATT) which is 135 amino acids in length («16 kDa). Subsequently, ATF is 
converted into a 49 amino acid polypeptide termed growth factor like domain, 
GFD («6 kDa) and 86 amino acid ICidngle domain (Gunzler et al., 1982a; 
Gunzler et al., 1982b). The GFD domain has a sequence homology to EGF
...j
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(Patthy, 1985) and is involved in the binding of uPA to its receptor, uPAR 
(Appella et a i ,  1987) (see Fig 2). The Kringle domain binds to heparin-related 
cell surface entities (Brunner et a l ,  1994; Schmitt et al., 1995). Many 
hormones and cytokines control the expression of uPA in a cell specific way 
(Laiho & Oja, 1989).
Conversion of the inactive form of uPA to active uPA requires its interaction 
with its cognate receptor (uPAR). Pro-uPA, active uPA and the amino 
terminal 135 residue region of uPA (ATF) bind to cell surface receptor uPAR 
with high affinity with a Kd ranging from 0.05-3 nM, while low molecular 
weight uPA does not bind to uPAR (Blasi, 1988). The mechanism of pro-uPA 
activation is not fully elucidated. Once active, uPA activates plasminogen into 
its active form plasmin which in turn activates other proteases to breakdown 
and/or remodel the extracellular matrix (ECM).
The conversion of plasminogen into plasmin by uPA is controlled by two 
inhibitors, termed PAI-1 and PAI-2, which can rapidly inactivate 
enzymatically active uPA by binding to uPA when present alone or when 
bound to its receptor, uPAR (Fig 2) (Schmitt et al, 1992; Schmitt et a l,  1995). 
These two inhibitors belong to the serpin family but are the product of 
different genes.
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Figure 2. Structure of plasminogen activator components.
(A) The domain structure of pro-u-PA and plasminogen. SPD, serine proteinase 
domain; K, kringle: G, growth factor domain. Closed arrows indicate the position 
of the cleavage sites at the conversion of the inactive, 1-chain zymogen forms pro- 
u-PA and plasminogen to the active, 2-chain proteinase u-PA and plasmin. Open 
arrow shows the position of the cleavage site at conversion of u-PA to low-m.w. u- 
PA. Inter-domain disulfide bridges also are indicated.
(B) Domain structure of u-PAR. Numbering of domains is given. A bound u-PA 
molecule is indicated, as well as the reported interactions of u-PAR with VN and 
Bi-and B^-integrins.
(C) Simple schematic diagram of plasminogen activator system.
The figures, A and B, are adapted from Andreasen et a i ,  1997.
Although uPA is predominantly responsible for the conversion of 
enzymatically inactive plasminogen (Kobayashi et al, 1990), it can also break 
down a variety of lysine and arginine esters and amides as well as other low 
molecular weight substrates. Specifically, uPA hydrolyses the arginine-valine 
bond in plasminogen and this reaction has been shown to be inhibited by 
various compounds including heavy metals such as Zn.
1
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uPA and Carcinoma
The urokinase type plasminogen activator (uPA), is widely distributed in body
V...
fluids and tissues but is more abundant in urine (Laiho & Oja, 1989). Several
V
cell lines have now also been found to be rich sources of uPA. For instance, 
mouse sarcoma virus infected 3T3 cells are an exceptionally rich source of 
uPA. A strong correlation has been found between uPA secretion and tumour 
formation and metastasis in nude mice using carcinogens or chemical agents 
(Sisskin et a l ,  1980). High levels of uPA were found in malignant epithelial 
cells of human breast and colon cancer as well as in lewis lung carcinoma 
(Duffy et a l,  1990; Grondahl-Hansen et al, 1991; Janicke et a l,  1990; Skriver 
et a l,  1984). uPA and other components of the plasminogen activation system 
have been demonstrated in adeno-, squamous cell-, and large cell lung 
carcinoma cell lines (Dosne et a l ,  1991; Heidtmann et a l,  1989; Pappot &
Brunner, 1995). It has been demonstrated that tissues of primary cancer and/or 
metastasis of the breast, ovary, prostate, cervix uteri, bladder, lung, and of the 
gastrointestinal tract contain high amounts of uPA compared to control tissues 
(Dano et a l,  1985; Schmitt et a l,  1990).
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1.11.2 Tissue Type Plasminogen Activator (tPA)
tPA structurally resembles uPA. It has been found in blood and normal tissues. 
tPA has been mostly associated with fibrinolytic function, while uPA has been 
associated with the regulation of extracellular proteolysis. tPA is secreted as 
an inactive polypeptide and is converted into its active two chain form by 
digestion with plasmin. Native tPA is a single polypeptide chain with a 70kDa 
molecular weight. The two chains, A and B, are linked together by disulphide 
bonds. Similar to uPA, tPA A-chain contains a region of sequence homology 
with EGF and is responsible for the fibrin binding property (Pennica et al., 
1983).
1.11.3 Urokinase-Type Plasminogen Activator Receptor (uPAR)
uPAR, also known as CD87, was first described by (Vassalli et a l, 1985) on 
human monocytes and on the promyelocytic leukemia cell line U937. uPAR is 
expressed in peripheral blood monocytes, granulocytes and T-lymphocytes 
(Blasi et al., 1986; Stoppelli et al, 1985).
Human uPAR, encoded by a gene on chromosome 19, is a 313 amino acid, 
highly glycosylated, long single polypeptide. The molecular weight is reduced 
to 35kDa after deglycosylation (Behrendt et al., 1991). uPAR essentially 
contains three homologous domains of 90 amino acids (Behrendt et al., 1991; 
Roldan et al., 1990). The polypeptide, once synthesised is processed at the C- 
terminus. uPAR is attached to the plasma membrane covalently via an anchor 
known as GPI (glycosyl-phosphatidyl inositol) (Ploug et al., 1991). It 
possesses five potential attachment sites for N-linked carbohydrate and has an 
unusually high content of cysteine. The glycosylated forms of the protein 
range in size from 45-60 kDa (Ploug et a l ,  1991; Behrendt et a l, 1991) and 
this apparent variation in the molecular weights may be due to the extent of N- 
linked glycosylation.
;
à
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1.12 Regulation of Plasminogen Activators
The two important parameters of uPAR for binding to uPA are ( 1) the 
conformation of uPAR (Chucholowski et a l,  1992) and (2) glycosylation 
(Ploug et ah, 1991). Both of them are important from a regulatory point of 
view, since the unfolded, chemically reduced form of uPAR does not block 
the binding of pro/HMW uPA to cell surface anchored uPAR (i.e., it does not 
compete). Secondly, a mutant uPAR has decreased affinity for uPA in 
comparison to wild type uPAR (Schmitt et al., 1995). Any alteration in the 
five sites of glycosylation of uPAR results in an inactive uPAR. The authors 
have shown that recombinant uPAR missing the GPI-anchor, blocks uPA 
binding to native uPAR.
High affinity uPA-uPAR binding sites have been described on the surface of 
several cultured tumour cells and in membranes of human breast carcinoma 
(Dano et a l ,  1994). The complex, consisting of cell bound uPAR, uPA, and 
PAI-1 is readily internalised by normal and tumour cells. Recently it has been 
shown that a multiligand a -2  macroglobulin receptor/low density lipoprotein 
receptor (CD 91) is involved in the binding and endocytosis of the 
uPAR/uPA/PAIl complex .
Regulation of extracellular proteolysis appears to be the result of the concerted 
action involving various types of malignant cells and host cells. It is assumed 
that tumour cells and host cells do interact in a co-operative manner e.g. uPA 
may be produced by adjacent fibroblast like cells or tumour cells and may 
bind to uPAR, expressed at the invasive foci of the cancer cells or host cells
.(Stoppelli et a l ,  1986). PAI-1, present in endothelial cells may bind the 
uPA/uPAR complex. Several experiments have shown that the inhibition of 
nPA leads to the inhibition of invasion thus showing the important role of uPA
1.12.1 Regulation of Plasminogen Activator Synthesis
In trod u ction  4 2
in cancer invasion. These studies have been performed with in vitro system 
measuring the penetration and degradation of a human amniotic membrane 
(Mignatti et aL, 1986) and extracellular membrane (Cajot et al., 1990; Hollas 
et al., 1991; Kobayashi et a l ,  1992). The results in this thesis also show the 
inhibition of invasion in breast cancer cells, in a Boy den chamber, by using 
antibodies against uPA. The same results have been demonstrated in 
experiments with prostate cancer cells by other members in our laboratory.
Extensive studies on inhibition of invasion have been performed by Ossowski 
and CO workers. They have found that inhibition of uPA by anti catalytic 
antibodies inhibits invasion and metastasis of human cancer cells transplanted I
on the chorioallantoic membrane of chicken embryos (Ossowski & Reich,.
1983; Ossowski, 1988). uPA is selectively expressed at invasive foci in some 
experimental and human cancers.
I
The activation of plasminogen, under physiological conditions requires uPA at 
the cell surface and the presence of uPAR. uPA has high affinity for its 
receptor, uPAR and the dissociation rate is low (Vassalli et a l, 1985). The 
receptor bound uPA provides focused proteolysis and therefore, can be taken 
as a regulatory target. The receptor bound uPA is not internalised in the 
absence of PAI-1 (Cubellis et a l ,  1990), which binds to uPA/uPAR complex 
(Conese & Blasi, 1995a) and initiates internalisation and then subsequent 
degradation of uPA by lysosomal enzymes.
The synthesis of each of these components is regulated by a variety of 
hormones, growth factors and cytokines (Andreasen et a l ,  1990; Dano et a l ,  
1985). The pattern of regulation varies among different cell types. If, for 
example, a certain growth factor induces uPA synthesis in one cell type, it
,7
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may inhibit it in another and leave it unchanged in most cell types. However, 
it has been shown that the interaction of growth factor and plasminogen 
activator is bi-directional, in that growth factors regulate plasminogen 
activation and are regulated by plasminogen activators. For example, EGF 
stimulated uPA produetion in brain astrocytes while IGF stimulated only tPA 
and PDGF had no effect on PA activities in astrocytes (Tranque et al., 1994). 
Changes induced by TGF|3 in the PA system differ depending on the cell 
types. TGFp upregulates uPA in MCF-7 cells (Albo et al., i 997) and induces 
both uPA and PAI-1 in MDA-MB-231 cells (Arnoletti et al., 1995; Farina et 
al., 1998) and in the human adenocarcinoma cell line A549 (Keski-Oja et al.,
1988). It has been shown by Graham (1997) that TGFp, as low as O.lng/ml 
increases PAI-1 by 63%, in human trophoblast cells. While Lund et al., (1987) 
demonstrated that uPA and tPA are decreased by TGFp in embryonic 
fibroblasts. On the other hand, growth faetors including IGF (Campbell et al.,
1992) and TGFP (Lyons et ah, 1990) are regulated by the plasminogen 
system. For example, PAI-1 is known to induce TGFp in certain cells. Cell 
surface bound plasminogen activates latent growth factors such as TGFp, 
insulin and interleukins (Schmitt et al, 1995).
Hormones like oestrogens, progesterone and prolactin are also involved in the 
regulation of the plasminogen activation system (M-y-Lopez & Ossowski, 
1987). E2 has been shown to induce tPA in MCF-7 cells (Ryan et al., 1984). 
However, it down regulates uPA in S30 cells (a transfectant stably ER- 
expressing cell line) (Long & Rose, 1996). Ossowski et al., (1979) has 
suggested a very distinct difference in the response of plasminogen activator 
synthesis to hormonal modulation between normal and neoplastic cells. The 
bi-directional regulation and also the differential regulation of plasminogen 
activation varies among different cell lines under different circumstances. 
This, therefore, provides a versatile system for regulation of cell surface 
plasminogen activation that allows regulatory factors to turn on plasminogen
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activation on one ceil type but not on others. Such a system may form the 
basis for a strict regulation of plasminogen activation during non malignant 
physiological processes such as trophoblast invasion, wound healing and 
prostate involution, while defects in this regulatory system may lead to the 
apparently uncontrolled plasminogen activation and result in invasive cancer.
Plasminogen activation can be controlled at several levels. Pro-uPA is 
converted more efficiently when bound to its receptor than when present in 
soluble form. The activation is 20 times higher (Ellis et a i ,  1989). In addition 
to other enzymes, plasmin appears to be the main enzyme involved in the 
activation of inactive uPA. Plasmin also has cell surface receptors and 
therefore presents an efficient mechanism of uPA activation. The mechanism 
of the initiation itself, however, has not been clarified. The overall efficiency 
of plasminogen activation due to receptor bound plasmin is because receptor 
bound plasmin,(which has low affinity and high dissociation rate towards its 
receptor) has some degree of protection from its inhibitors, alpha-2 
antiplasmin (Ellis et al., 1990) and other serum inhibitors.
I,3
1
PAI-1 induced internalisation and degradation of receptor bound uPA, 
signifies another level of regulation (Conese & Blasi, 1995b). It has been 
shown in a number of studies that the localisation of the components may 
itself regulate the proteolytic processes, e.g. in HT1080 fibrosarcoma cells
.;3.
PAI-1 and uPA do not co-localise; uPA is found at the cell-cell or cell-
substratum sites whereas PAI-1 has been found in the extracellular matrix. 
Cell migration brings the receptor bound uPA and PAI-1 in contact and 
therefore cell migration may be thought to regulate surface proteolysis.
If internalisation and degradation of receptor bound uPA by PAI- i go through 
an endocytotic step, then migrating cells have the ability to carry out a 
complete plasminogen activation sequence, starting with the synthesis and
■i:;
secretion of inactive pro-uPA, followed by binding to uPAR, activation,
-7
■ ' 1
uPAR binds both active and inactive pro-uPA with high affinity (Kd 10"^-]0- 
M) (Ellis et al., 1991). uPAR is bound to cell surface by a GPI anchor 
(Ploug et al., 1991) and can be released by its specific enzyme phospholipase 
C (Blasi et a l ,  1990). This suggests still another type of regulatory 
mechanism. Concomitant binding of pro-uPA and plasminogen to cell surface 
suggests the enhancement of plasmin formation.
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production of surface plasmin, inhibition by PAI-1 and internalisation and 
degradation of the receptor bound uPA/PAI-1 complex.
Another type of regulation however, may also be possible. Enzymatic activity 
is not necessary for binding to uPAR (Schmitt et a l ,  1992). The amino 
terminal fragment, with no enzymatic activity can bind to uPAR. The 
occupation of the receptor with an inactive uPA (ATF) results in the decrease 
of its actual as well as surface bound activity.
1.12.2 Regulation of Plasminogen Activators by Growth Factors and 
Steroid Hormones
Growth factors including TGFa, TGFp and EGF (Arnoletti et a l ,  1995; 
Tranque et a l,  1994) and hormones (Mira-y-Lopez et al., 1983) are not only 
able to promote cell proliferation but can also modulate urokinase expression 
in various tumour cells.
Furthermore, a mitogenic effect of urokinase itself was found in certain human 
tumour cell lines e.g. prostate cell lines derived from hyperplasia or carcinoma 
(Kichheimer et a l ,  1987) and the human ovarian cancer cell line OV-MZ-6 
(Wilhem et a l ,  1994). A positive correlation was shown by Vecchio et al. 
(1993) between uPA concentration and rate of proliferation. They have 
assessed proliferation by immunostaining with monoclonal Ab K167. uPA can
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also activate latent growth factors directly or through a plasmin mediated 
mechanism and thus contribute to the proliferative activity.
EGF increased the secretion and activity of uPA in the MDA-MB 231 breast 
cancer cell line, and this finding was correlated with increased expression of 
uPA mRNA (M-y-Lopez & Ossowski, 1987). EGF increases the plasminogen 
activator activity in both intracellular and extracellular levels in HeLa cells 
and also in other cell lines such as cultured human foreskin fibroblasts and the 
rat kidney cell line NRK-536-3-1. Since TGFa induces its affects via the same 
receptor as EGF it has been observed that TGFa also stimulates the activity of 
plasminogen activators.
With the exception of glucocorticoids which suppress uPA activity in a variety 
of cultured cells and tissues (like primary cultures of involuting murine 
mammary glands and explants of rat mammary tumours), steroid hormones 
generally increase plasminogen activator activity. Oestrogens, for instance, 
increase plasminogen activator activity in both primary culture and in the 
MCF-7 cell line (Pourreau-Schneider et al., 1989). They also increase the PA 
activity in mammary tumours induced by chemicals and promote the prolactin 
stimulation of uPA activity. Progesterone blocks prolactin stimulation of uPA 
activity. Similarly, anabolic steroids and androgens increase the plasminogen 
activator activity in different cell lines.
uPA activity is increased by EH, LHRH and HCG in granulosa cells of 
preovulatory follicles of rat ovaries. It should also be noted that polypeptide 
hormones and cAMP have been reported to cause parallel changes in 
intracellular and extracellular levels of uPA by affecting de novo synthesis of 
uPA by a mechanism dependent on mRNA synthesis.
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1.12.3 Regulation, interaction and functions of uPAR
Critical balance of the protease uPA, the inhibitor PAI-1 and cell surface 
receptor uPAR, are the prerequisites of the efficient tumour cell invasiveness, 
focal proteolysis and metastasis (Liu et ciL, 1995). For instance, 
overexpression of not only uPA and PAI-1 (Schmitt et aL, 1997b) but also 
uPAR in breast cancer cells resulted in increased invasion and metastasis 
(Xing & Rabbani, 1996). In addition to PAI-1, uPAR is another major binding 
protein to the vitronectin rich extracellular matrix (Kanse et a i ,  1996). uPAR 
even may influence cell adhesion and direct migration of adherent cells by 
regulating integrin functions of the cells (Felsenfeld et aL, 1996; Wei et aL, 
1996).
It had been shown earlier that uPAR does not internalise uPA (Vassalli et aL, 
1985). However, uPAR is responsible for mediating internalisation of 
uPA/PAI complexes (Cubellis et aL, 1990; Olson et aL, 1992). Both uPA and 
pro-uPA binds with the same affinity to uPAR with a Kd of 0.1-2 nM (Appella 
et aL, 1987). In uPA, the receptor binding site is located in the amino terminal 
fragment (ATF) of the growth factor domain (GFD). LMW uPA that lacks 
GFD does not bind to uPAR (Schmitt et aL, 1995). The ligand (uPA) binding 
domain in uPAR is located within the first 90 amino acids, of the N-terminus 
(Behrendt et aL, 1991). uPAR is specific for uPA and does not bind tPA, 
plasminogen or EGF (Blasi et aL, 1986). Ossowski showed that mere 
production of high levels of uPA in the absence of uPAR will not provide a 
tumour cell with maximal invasive potential (Ossowski, 1988). Vecchio and 
colleagues strongly support the idea that uPAR plays a central role in invasive 
phenotypes in breast cancer patients and therefore suggests its potential use as 
a prognostic marker in such patients (Vecchio et aL, 1993). 3
• V.V
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1.13 Plasminogen Activator Inhibitors (PAI)
I"
There are several classes of protease inhibitors in the plasma but the
1994). The distinct protease inhibitors specific for plasminogen activators are
their reactive centre (Hill & Hastie, 1987).
predominant class of inhibitors is referred as SERPINS (serine protease 
inhibitors), including PAI-1, PAI-2 and PN-1. The serpin family is diverse.
This class includes inhibitors of the serine proteases involved in physiological 
and pathophysiological processes.
3
The main function of these inhibitors is to negatively regulate proteolytic
'Sevents associated with numerous biochemical pathways (Potempa et aL,
endothelial type PAI (PAI-1) (Kruithof et aL, 1987), the placental type PAI A
.7(PAI-2) and protease nexin (PN-I). These are different in immunological and
'.Ï-.physiological characteristics (Springer & Kluft, 1987) but all have arginine in |
1.13,1 Plasminogen Activator Inhibitor Type-1 (PAI-1)
'KPAI-1, mainly produced by endothelial cells (Springer & Kluft, 1987), is
present in high concentration in plasma. PAI-1 is also produced by a number 
of other cell types including platelets (Erickson et aL, 1984), normal rat 
kidney cells (NRK) (Ryan et aL, 1996) and different tumour cells (Andreasen 'IIet aL, 1990). The expression of PAI-1 is differentially regulated in different a'
human cancer cell lines by inhibitors of protein synthesis (Lund, 1996).
II.PAI-1 is a secreted protein. Amino acid sequencing and cDNA nucleotide 
sequencing have revealed the structure of human PAI-1 as a 381 amino acid 
long, single chain glycoprotein, with a signal peptide of 21-23 amino acids.
PAI-1 has a 50kDa molecular weight (Andreasen et aL, 1986). The authors 
have shown that PAI-1 has arginine in its reactive centre towards the carboxy-
Molecules that affect the synthesis and secretion of PAs, also affect PA- 
inhibitors. For example, the secretion of PAI-1 is stimulated by TGFpl treated
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terminus of the protein. Human PAI-1 efficiently inhibits tPA and uPA but not 
pro-uPA (Andreasen et aL, 1990) and is present across all components of the 
tumour. PAI-1 reacts with thrombin, albeit slowly, until some cofactor like 
heparin is added to the system.
PAI-1 is secreted as an active protease inhibitor but is spontaneously 
converted into its inactive form. The half life of active PAI-1 is about 2 hours 
in culture medium (Levin & Santell, 1987). The inactivation may be because 
of conformational changes that hide the reactive centre of the protein (Springer 
& Kluft, 1987). The inactive stable form is termed latent. The latent form is 
stable because the inhibitory activity can be restored by dénaturation or 
renaturation (Hekman & Loskutoff, 1985). Recently, Mottonen and associates 
have shown the crystal structure of the latent form. The authors have shown 
that vitronectin (Vitronectin is serum spreading protein or S protein and is a 
75kDa adhesive glycoprotein found in plasma and in connective tissues-it 
binds strongly to glass and plastic surfaces and promotes the spreading of a 
variety of cell types on cultures dishes) maintains the active conformation of 
PAI-1, once it is bound to this ECM protein, and can inhibit uPA mediated 
proteolysis (Mottonen et aL, 1992). PAI-1 is heterogenously distributed in the 
tumour. This was shown by immunocytochemical studies. Fukao and 
associates, using an immunohis toe hemic al technique, have shown that PAI-1 
is mostly present in the carcinoma itself and not in the normal mucosa in 
stomach and colorectal tissues (Fukao et aL, 1991). Whereas Cajot and others 
have shown even distribution of PAI-1 in ECM and also its localisation not 
only in microgranular and fibrillar material but also as lining of the cell 
membrane, plasma membrane protrusions and surface pits (Cajot et al., 1990).
J
1.13.2 Plasminogen Activator Inhibitor Type-2 (PAI-2)
1.13.3 Protease Nexin-1 (PN-1)
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cells, whereas uPA and tPA are decreased (Lund et al., 1987). PAI-1 is 
decreased by gonadotrophins in granulosa cells (Ny e ta i ,  1985).
PAL2 is produced mainly by placenta and macrophages (Kruithof et al.,
1987). PAI-2 is a 60kDa glycosylated protein with 393 amino acids. PAI-2, 
also belongs to the SERPIN family. It binds uPA specifically but less 
efficiently than PAI-1 (Conese & Blasi, 1995a). PAI-1 and PAI-2 are 
immunologically different, their genes are located on different chromosomes 
and are expressed differentially in individual cell types.
PAI-2 was first purified from placenta extracts but is also released by tumour 
cells and phagocytic cells. Higher concentrations of PAI-2 have been observed 
in the plasma of pregnant women during the 3rd trimester of pregnancy 
suggesting a role of PAI-2 in the control of plasminogen activation by uPA 
during parturition (Springer & Kluft, 1987). The clearance of PA and 
inhibitory activity takes place primarily in the liver (Emeis, 1985).
■;3'
A third PA inhibitor is protease-nexin-1 (PN-1). It is a 43kDa protein and is 
present in human fibroblasts and placental cells (Baker et a l,  1980) and in
murine kidney (Moll et al., 1996). In contrast to the PA-specific inhibitors,
PN-1 also inhibits plasmin , thrombin , and other trypsin like serine proteases
.
(Scott et a l,  1985).
I
..I
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It has been shown recently by Conese and his colleagues that PN -1 binds uPA 
and this complex follows the same pattern of internalisation and degradation 
as uPA-PAI-1 complexes. (Conese et al., 1994). Both complexes involves Œ2- 
MR, in addition to uPAR (Hertz et al., 1992). Therefore its role in the control 
of uPA mediated plasminogen activation cannot be ruled out. PN -1 has an 
important function in reproduction as indicated by its presence in the mouse 
seminal vesicle (Vassalli et al., 1993) and human placenta (White et al,
1993).
1.14 Regulation of PAI-1 and PAI-2
Both PAI-1 and PAI-2 react rapidly and specifically with both tPA and uPA 
but not with pro-uPA (Kruithof et al., 1987). PA-inhibitors form stable 
covalent complexes with uPA and tPA in equimolar ratios (1:1) (Kobayashi et 
al., 1994). The complex formation between uPA and its inhibitor is formed 
between the reactive sites of the respective proteins. It has been shown by 
many authors that receptor bound uPA is available for efficient inhibition by 
PAIs (Cubellis et al., 1989; Ellis etal., 1990; Pyke el al., 1991).
1.14.1 Regulation of PAI-1 and PAI-2 in Cell Cultures
The inhibitors of plasminogen activators are modulated in a similar fashion to 
the plasminogen activators themselves. The effects of TGFp on cell 
proliferation and urokinase plasminogen activator system have been studied 
extensively on both normal and cancer cells and tissues. TGFP is known to 
regulate the PA system both at the transcription and translational levels. ' 
Bourhis and colleagues have shown recently that TGFpl and sodium butyrate 
differentially modulate components of the PA system, e.g. TGFp inhibited
I:
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proliferation and uPA activity but increased PAI-1 levels in normal human 
breast epithelial cells (HBECs) whereas, an increased uPA activity and PAI-1 
antigen levels were observed in response to TGFp in MDA-MB-231 cells 
(Bourhis et a l ,  1998). Sodium butyrate showed no effect on PAI-1 levels. A 
close correlation of PAI-1 and TGFP mRNA levels has been associated with 
perturbance in PA/PAI-1 balance thereby resulting in glomerulosclerosis 
(Moll et a l,  1995). PAI-1 gene expression is regulated by both serum and the 
nature of the substratum. This has been observed in normal rat kidney cells 
(NRK) by Ryan et al. They have shown an increase in PAI-1 expression by 
serum both, in agarose suspension, and in monolayer cultures (Ryan et al., 
1996). TGFp induces increased PAI-1 activity and antigen in medium 
conditioned by the different cell lines e.g. human lung fibroblast cell lines WI-
38 and Hel 229, in HT 1080 and in the human epidermoid ceil line A431 etc.
Autocrine activity of growth factors may be involved in the regulation of the 
PA system e.g. basic fibroblast growth factor (bFGF) is known to induce PAI- 
1 mRNA in bovine endothelial cells (Pepper et al., 1992). EGF does not only 
increase PAI-1 protein level but also increased the mRNA levels in prostate 
cancer cell lines. This has been shown recently by a work in our laboratory. 
Insulin also induced PAI-1 levels.
I -A time dependent increase in the components of plasminogen activators was
observed by Lund and colleagues, after treating mouse skin with phorbol 
esters, such as phorbol 12-myristate 13-acetate (PMA), which are tumour 
promoters and activators of protein kinase C. PAI-1 mRNA could be detected 
after 24 hours of PMA treatment (Lund et al, 1996). PMA also increased PAI- 
2 protein in U937 cells due to an increase in PAI-2 mRNA and gene 
transcription rate (lOuithof et al., 1987).
■G%
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1.15 Relation of Tumour Invasion and Metastasis to Normal 
Processes
Tumour invasion and metastasis are the major causes of treatment failure for |
cancer patients. Métastasés do not occur randomly and/or accidentally but it is 
an active process of tumour invasion, which involves a complex phenomenon 
of responses by both cancerous and normal cells.
The complex series of host-tumour interactions involves invasion of the :|
healthy tissues, by penetrating the ECM at multiple steps in the metastatic 
cascade by cyclic repetition of 3 biochemical steps: 1) Tumour cell attached to 
the basement membrane or ECM. 2) Breakdown of the basement membrane or 
ECM by the proteolytic enzymes. 3) Increased motility of the tumour cells to 
the distant sites with the help of the tumour associated proteases.
uPA is the key enzyme required for the invasiveness of cells, both in cancer
;|and inflammation and for the normal physiological processes including |
mammary gland involution (Duffy, 1987), embryogenesis, tissue remodelling, 
wound healing (Del-Rosso et al., 1990), angiogenesis (Sato & Rifkin, 1989), 
trophoblast implantation (Saksela, 1985) and gametogenesis (Sappino et al.,
1989).
The biochemical and molecular biological steps in physiologically invasive 
processes and cancer cell invasion and metastasis are qualitatively identical, 
e.g. during both mammary gland involution and cancer invasion, basement 
membranes are destroyed. Both require uPA dependent proteolysis for plasmin 
generation and thereby activation of a cascade of events leading to the 
degradation of extracellular matrix. Thus, if proteases i.e. plasminogen 
activator/plasmin system play a role in normal destructive processes they may i)
also be involved in pathological destructive processes such as cancer invasion
Î
(Duffy, 1987). |4-
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Proteolysis in normal tissue occurs for only a limited duration and is strictly
' regulated at many levels, e.g. trophoblast cells, like malignant tumour cells, 
are highly invasive which is necessary for implantation and penetration of the 
maternal endometrial stroma and blood vessels. However, the invasion of 
uterus is under strict control, in contrast to tumour cells.
In malignant neoplasms the imbalance of proteolysis favours unchecked
invasion and metastasis. The difference between normal and cancer invasion is A::■■
that proteolysis in tumour cells couples with motility of cells to the places and
Iat times which is inappropriate for normal cells (Liotta ei al., 1991). More 
importantly, there is a very large difference in the amounts of uPA synthesis, 
its inhibitor and receptor that are secreted. A large number of studies have 
demonstrated the increased levels of uPA, PAI-1 and uPAR in cancer invasion 
and metastasis. High levels of uPA in cancer made it a significant prognostic
indicator in many of the cancers e.g. breast, colon, ovary, prostate, 
oesophagus, and lung etc. uPA is a marker of poor prognosis. Extensive 
studies on trophoblast implantation have been performed to compare the 
invasive trophoblast and tumour cell. The intrinsic invasiveness was 
determined (Kirby, 1965) by using mouse blastocyst and showed that In vivo 
invasion was greater in non-pregnant uteri than pregnant uteri. Mignatti et al.., 
(1986) also demonstrated the in vitro invasiveness of the trophoblast using the 
human trophoblast cultures in in vitro invasion assays. These and other studies 
showed that trophoblast invasion is under strict control which limits its 
invasion beyond certain required point. Some early studies by (Kirby, 1965; 
Mignatti et al., 1986; Yagel et a l ,  1989) have shown that invasion during 
pregnancy is controlled by decidual tissues of the uterus, to limit implantation. 
It was later demonstrated by Graham, (1991 and 1992) that decidua derived 
factors play a role in the in vivo control of trophoblast invasion.
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One of the molecules thought to regulate the trophoblast invasion is TGpp 
(Lala & Graham, 1990). It has been shown that TGFp limits implantation by 
inducing differentiation of the human cytotrophoblast cells into non invasive 
syncytiotrophoblasts (Graham & Lala, 1992). The exact mechanism of TGFP 
action in not clear but it is known that TGFP induces the expression of TIMPs 
(Laiho & Oja, 1989) and also PAI-1 (Lund et al, 1987). Furthermore, 
Graham, (1991 and 1992) confirmed that the trophoblast invasiveness is 
increased by using antibodies against TGFp. It may be because the presence of 
this antibody decreases the level of TIMP, at both protein and message levels. 
TGpp also up regulates integrin expression and reduces the migratory ability 
of the invasive trophoblast. This was confirmed by using antibodies against 
integrins where stimulated migration was observed (Irving & Lala, 1995).
The interesting feature of the regulatory pathway is the activation of latent 
TGFp by plasmin (Flaumenhaft et ciL, 1992). uPA activates plasminogen into 
plasmin, which then activates latent TGFP in the extracellular matrix. TGFP 
increases the inhibitor levels and therefore, in the presence of increased 
inhibitor expression, the invasion process is terminated (Strickland & 
Richards, 1992). Thus proteases that are normally involved in tumour invasion 
are also responsible for trophoblast implantation (Testa & Quigley, 1990). 
Proteases are found at highest levels in the invasive front, where degradation 
of the normal tissue occurs, both during normal and invasive processes. If 
TGFp controls the trophoblast invasion, it has the potential to be used as an
inhibitor of cancer invasion and metastasis, since metastasis is the cause of 
mortality.
V ."
1"I
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1.16 Plasminogen Activator Components as Prognostic 
Markers in Cancers?
The importance of plasminogen activator components, uPA and PAI-1, and 
recently uPAR, has been strongly suggested in the process of invasion and 
metastasis. Their involvement in cancer metastasis has been proved by results 
from experimental model systems with animal tumour m etastasis. 
Furthermore, results from the studies on many human cancers have shown that 
high levels of uPA, PAI-1 and uPAR predict poor patient prognosis.
Considerable evidence indicates that uPA is a strong and independent 
prognostic marker in breast cancer (Duffy et ciL, 1996; Duffy et al., 1990;
Ferno et al., 1996; Flildenbrand et al., 1998; Holst-Hansen et al., 1996;
Janicke et a i,  1991; Janicke et al., 1993; Schmitt et al., 1997a; Schmitt et al.,
1990). Clinical studies have suggested that expression of the uPA system 
directly influences malignant behaviour. For example, Foekens and associates 
have shown that the level of uPA in tumour cytosols have been correlated with 
metastatic disease and shortened survival among breast cancer patients 
(Foekens et al., 1992). Further studies on the major subgroups of patients with ■Ibreast cancer (ER+, Positive axillary nodes, women younger or older than 50 f
years of age) have shown that uPA was an indicator of prognosis in all sub- 1,groups. In all sub-grouping in node negative breast cancer patients, uPA has 
been suggested to be a more significant prognostic marker than tumour size or Ioestrogen receptor status (Duffy et al., 1998; Duffy et al., 1994). High uPA |
antigen levels were shown to be a stronger prognostic marker than uPA 
activity in breast cancer (Reilly et al., 1991). It has been demonstrated by
ïij
Janicke and colleagues that uPA is 12 times higher in cancer tissues extracts
•j;than in the extracts of normal breast tissue. The same group has further shown 
that patients whose tumours have levels of uPA as high as 3.49 ng/mg protein 
had a statistically significant high relapse rate and shorter life expectancy
"k;
..
Not only uPA but elevated levels of PAI-1 has.been associated with poor 
prognosis of patients in many cancer types. A plethora of data has shown that
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(Janicke et a i ,  1991). Many groups have shown that established markers of 
poor progression in breast cancer (lymph node involvement and negative 
hormone receptor status etc) were associated with higher uPA content. The 
impact of uPA on prognosis is even stronger than hormone receptor and lymph 
node status (relative risk 21.1> 5.8> 3.0), respectively (Schmitt et al., 1990). 
There is a significant correlation between uPA and PAI-1 and tumour 
associated angiogenesis (Hildenbrand et al., 1995a; Hildenbrand et al., 
1995b).
uPA has been suggested as a marker of metastasis in colorectal cancer 
(Mulcahy et al., 1994). High uPA antigen levels were correlated with poor 
overall survival in patients with colorectal cancer (Schmitt et al., 1992). 
Elevated uPA levels were found to be associated with poor prognosis in 
gastric cancer and therefore has been suggested as a new prognostic factor in
gastric cancer predicting shorter survival in clinically important subgroups of 
patients. They have further shown that uPA levels in tumour tissue extracts 
significantly correlated with vascular invasion (Cho et al., 1997; Nekarda et 
al., 1994). A 4-fold elevated uPA content, in addition to increase in other 
fibrinolytic components, was observed in metastatic ovarian cancer. These 
elevated levels at the site of métastasés may contribute to the aggressive 
potential of cancer cells. Therefore uPA can be used as a prognostic marker in
'selecting more aggressive cancer (Schmalfeldt et al., 1995). Furthermore, high 
iiPA levels, as measured by immimohistochemistry have been reported to be 
associated with poor prognosis in pulmonary adenocarcinoma (Oka et al.,
1991). The adenocarcinomas constitute about one fourth of all lung cancers.
The prognostic value of uPA has also been determined in other types of lung 
carcinomas (Pedersen ef a/., 1994a).
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PAI-1 is an independent and significant prognostic marker in breast and other 
cancer types. PAI-1 was found to be an independent prognostic variable 
predicting short overall survival with a relative risk of 2.27 in node positive 
cancer patients (Grondahl-Hansen et al., 1997b). In another study Grondahl- 
Hansen and associates have shown that PAI-1 is a much stronger prognostic 
factor than uPA and uPAR in breast carcinoma (Grondahl-Hansen breast et 
al., 1997a). Janicke and associates have found an increased risk of relapse and 
death in patients with PAI-1 levels greater than 2.18 ng/mg protein and uPA 
levels >2.97 ng/mg protein (Janicke et a l,  1993). The same group have found 
that in node negative patients, PAI-1 follows the impact of uPA. In a time 
dependent risk profile of prognostic markers Schmitt and associates have 
shown that the prognostic significance of uPA and oestrogen receptor status 
has been decreased whereas PAI-1 prognostic impact is increased with time 
and become similar in prognostic strength to the lymph node status (Schmitt et 
al., 1997b). Elevated amounts of PAI-1 in patients with primary tumour has a 
significant correlation with high relapse rate (Schmitt et al.. 1992). This high 
risk of relapse in breast cancer patients with high PAI-1 antigen is 
confounding and contradictory to what one would expect given the 
biochemical role of PAI-1, which has been known to serve as a local 
attenuator of uPA mediated proteolysis (Bacharach et al.. 1992). Cajot and 
associates in their early studies on the role of PAEl in the degradation of the 
extracellular matrix by fibrosarcoma and colon carcinoma cells have shown 
that PAI-1 inhibited the breakdown of the extracellular matrix whereas, 
monoclonal antibodies to PAI-1 increased the degradation of the matrix (Cajot 
et al., 1990). This clearly implies that PAI-1 acts as an inhibitor of uPA 
mediated proteolysis but the enormous amount of data regarding elevated 
levels of PAI-1 and poor prognosis indicate that PAI-1 protects the tumour 
from autoproteolysis and thereby helps in reimplantation of tumour cells at a 
site distant from its primary site (Schmitt et al.. 1992). It has recently been
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shown that PAI-1 may promote tumour progression, by (a) promoting the 
intra- or perivascular tumour cell development, or (b) by either disrupting 
uPAR-integrin complex or by interfering with integrins, or both, and thereby 
causing tumour cell migration (Chapman, 1997). Kanse and colleagues have 
also observed that PAI-1 can modulate the uPAR binding to vitronectin, again 
enabling tumour cells to migrate (Kanse et al., 1996). PAI-1 may also 
conserve tumour tissue integrity and its involvement in promoting cancer 
progression and metastasis formation.
A significantly higher level of PAI-1 (5.08 ng/mg) was found in the higher 
stages (G2/G3) as compared to PAI-1 level (2 .19ng/mg) in lower (G1 ) stage of 
the endometrial carcinoma (Kohler et al., 1997) but longer observation time 
has been proposed by the authors to use uPA and PAI-1 as prognostic markers. 
It has been shown recently in clinical studies of various lung cancer cells that 
PAI-1 expression in tumour tissues is an adverse prognostic feature. In assays 
for invasiveness, a cell line with no PAI-1 antigen and expressing only uPA 
and uPAR displayed no invasive capability despite levels of secreted uPA 
more than 20-fold higher than other cell lines. So, they concluded that both 
uPA and PAI-1 are necessary for optimum invasiveness of lung cancer cells 
(Liu et al., 1995). In another study on gastric cancer, it has been demonstrated 
that PAI-1 showed a significant correlation with advanced lymph node 
involvement which was associated with decreased survival. The relative risks 
of failure were 2.9 and 5.0-fold for PAI-1 and lymph node involvement, 
respectively.
It has been shown that, unlike PAI-1, low levels of PAI-2 had a worse 
prognosis in breast cancer patients than those with elevated levels and 
therefore high levels of PAI-2 has been suggested as a marker of good 
prognosis in breast cancer (Duggan et al., 1997; Foekens et al., 1995). PAI-2 
mRNA was found in cancer cells. Low levels of PAI-2 in breast cancer is
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correlated with shorter disease-free survival in post menopausal women and 
women without lymph node involvement (Bouchet et a l,  1994).
uPAR has recently been implicated as a possible prognostic marker in breast 
cancer as well as other types of cancer. The potential prognostic value of 
uPAR in breast cancer tissues was determined by ELISA and significant 
correlations were found between the levels of uPAR relative to the uPA and 
PALI levels (Ronne et al., 1995). In another study, a significant correlation 
between elevated levels of uPAR and poor prognosis has been demonstrated in 
breast cancer (Grondahl-Hansen et a l ,  1995). This group has shown that when 
the clinically relevant subgroups were analysed separately, the prognostic 
value of uPAR was particularly strong in node-positive post menopausal 
women with considerable shorter overall survival. The multivariate analysis 
including other established factors such as uPA, PAL 1 and ER status, however 
showed that PALI was the only independent variable for both relapse free and 
overall survival.
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AIMS AND OBJECTIVES
The plasminogen-plasmin system represents a complex cascade of proteolytic 
enzymes which, together with other enzyme systems such as collagenases and 
other metalloproteases, is involved in the degradation of extracellular matrix 
(Blasi et a l ,  1987; Dano et a l ,  1985; Liotta & Stetler-Stevenson, 1991; 
Mignatti & Rifkin, 1993). Urokinase type of plasminogen activator (uPA) is 
the key enzyme in this system in that it activates plasminogen into a broad 
trypsin like substrate, plasmin. Proteolytic activity of uPA is potentiated and 
localised by binding to its receptor on cell surface (Chucholowski et a l,  1992; 
Ellis & Dano, 1991; Schmitt et a l,  1997b). The net uPA activity is determined 
not only by the amount of enzyme but also by the specific inhibitor, such as 
plasminogen activator inhibitor type 1 (PAI-1).
Breast cancer cell proliferation, invasion and metastasis is under the control of 
multiple factors including steroid hormones and growth factors (Ossowski et 
a l ,  1979; Springer & Kluft, 1987). However less is known about the exact 
role of hormones and growth factors in modulating the invasiveness and 
progression of metastasis of breast cancer. Many studies showed earlier the 
morphological changes of cells grown on different substrata, e.g. plastic, 
collagen, fibrinogen etc., but it was only recently that EHS was used to study 
the morphological changes of the cells. There were no data available, at least 
for breast cancer cell lines, to determine the effect of EHS on the regulation of 
cellular function.
In the light of the foregoing, the aim of the study was to :
Examine the effects of several hormones and anti-hormones including 
oestrogen, progesterone and tamoxifen, together with different growth factors 
like TGFpl, EGF and TGFa on the components of the uPA system in relation 
to invasive potential.
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Spe cific questions were;
1) Were there any significant differences between the regulation of secretion 
of members of the urokinase family when cells were grown on either plastic or 
EHS (Extracellular matrix),
2) To what extent was modification of uPA secretion reflected in change in 
invasive potential?
3) Was the regulation of these potential metastatic enzymes at transcriptional 
and/or translational levels?
4) Did oestrogen alter sensitivity of the cells to exogenous factors?
5) How did PAI-1 levels relate to uPA levels relative to invasive potential?
I-
CHAPTER 2 
MATERIALS AND METHODS
i  i '  '  W,  " L  - V i d- . . r f l  '  ' «,
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2.1 Materials
2.1.1 Tissue Culture Plastic Ware:
Costar Co
U.S.A
Gibco/BRL 
Paisley, UK 
Medicell International
London, UK 
Nunc
InterMed, U.K. 
Whatman Ltd. 
Maidstone, U.K. 
Nalgene
Filters (0.22 jtim)
Falcon tissue culture flasks (25, 75,150cin^) 
24 well plates
96 well Tissue culture plates 
96 well ELISA plates 
Trans well chambers 
Tissue culture pipettes 
Chamber Slides
Dialysis Membrane
Cryotubes
80 cm2 tissue culture flasks 
Whatman 3 MM Paper 
Whatman 0.2 niM nitrocellulose paper 
0.2 p.m Bottle top filters
2.1.2, Tissue Culture Medium:
Gibco/BRL RPMI-1640 medium with 25mM Paisley, UK 
HEPES
Foetal bovine serum
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Sigma
Poole, Dorset, U.K.
2,1.3 General Reagents: 
Chemical Compounds:
BDH, MERCK Ltd
Glasgow, U.K.
Fisher Scientific
Loughborough, U.K
Glutamine (200 mM)
Penicillin (10 000 lU/ml)/Streptomycin (10 
ng/ml)
Sodium bicarbonate (7.5 %)
Trypsin (0.25 % w/v) 
Phenol-red free RPMÏ-1640
p-Mercaptoethanol I
Charcoal (Norit Gsx)
HEPES ■3
Methanol 3
SDS (Sodium dodecyl sulphate) f
Tween 20 %
DMSO 1
Glycerol '■i■;3
Sodium acetate i
Sodium carbonate ?;
Sodium chloride 7■:iSodium hydrogen carbonate
Triton X-100
EDTA I
Calcium chloride .,'1' !:
Potassium chloride 1 '
Magnesium chloride ■1:ï
'4
. ....................
Boehringer
Lewes, E. Sussex, U.K.
Biochemical Reagents:
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Glycine 
Sulphuric acid 
Hydrochloric acid 
Acetic acid 
Tris HCl
T
American Diagnostica
Alpha Laboratories 
Bio-rad Laboratories Ltd 
Hertfordshire, U.K.
BRL
Paisley, Scotland 
Calbiochem 
Cambridge, U.K.
Dako 
ICN International
UK
Qudratech
Surrey, UK 
R&D System
Sigma
Poole, Dorset, U.K.
Mouse anti-uPA ab (Clone No # 394) 
Mouse anti-PAL 1 ab (Clone No # 3785) 
Bradford dye reagent
Pre-stained molecular weight markers
Pansorbin
uPA
OPD tablets 
Plasminogen (human)
S-2251, H-D-VaLLeu-Lys-pNA.2HCL 
(Chromogenic substrate for plasmin) 
EGF (Recombinant human)
TGFBl (Purified from human platelets)
17-p Oestradiol
Progesterone
MTT
Plasminogen
BSA
I
:S
t:
A
3'Yt
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Tamoxifen 
Dithiothreitol 
Dextran 
TEMED
Trypan Blue (0.4 % w/v)
HRP conjugated anti-rabbit IgG 
DNA (calf thymus) type XV
Hoechst 33258 
Ribonuclease A
Ayr Scotland
2.1.4 Mlolecular Biology Reagents:
Pharmacia Biotech First strand cDNA synthesis kit
Gift from Dr. Anneke Geurts
: ; i ï
Nijmegen, Netherland Sheep anti-chicken IgG
ÎChicken anti-uPA IgG ,e
Chicken anti-PAI-1 IgG 
Chicken anti-tPA IgG 
Rabbit anti-uPA IgG 
Rabbit anti-PAI-1 IgG 
Rabbit anti-tPA IgG 
uPA standard (Grunenthal)
PAI-1 standard (Peter Andreasen) 
tPA standard (Actilyse)
Gift from Dr. Collin Wilde EHS 
Hannah Research Institute, h,11
Herts, U.K.
Sigma
Poole, Dorset, U.K.
Promega
Southampton, U.K.
2.1.5 Equipment:
Progene 
Cambridge, U.K. 
Labsysytems Multiscan
UK
LKB Biocrom ltd
UK
Hitachi-Perkin Elmer
UK
Bio-Rad
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Agarose (high melting temperature) 
DEPC
Ethidium bromide 
Tri-reagent
Deoxyribonucleoside triphosphates 
MgCl2
Phixl74 DNA/Hae III Markers 
Taq buffer 
Taq polymerase
PCR amplification machines
MCC/340 ELISA plate reader
Ultraspectrophotometer 4050
MPF-2A fluorescent spectrophotometer
MRC 600 Confocal illumination unit 
attached to a Nikon Diaphot inverted 
microscope
i
■ ;
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2.2 General and Tissue Culture Solutions 
Phosphate Buffered Saline (PBS), pH 7.2
170 niM NaCl
3.4 mM KCl
10 mM Na2HP04
2 mM KH2PO4
Adjust to pH 7.2 with H2SO4
HE buffer
20 mM HEPES; pH 7.4 
1.5 mM EDTA 
10% glycerol
ETN Buffer
10 mM Tris-HCl; pH 7.0 
10 mM EDTA 
100 mM NaCl
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Hank’s Modified Buffer (pH 7.2)
1.3 inM CaCl2
5.4 niM KCl 
0.5 mM MgCl2 
0.5 mM MgS04 
1.37 mM NaCl
4 mM Na2HC03
0.4 niM Na2HP0 4 .2H2 0 .
Tris Buffer (pH 8.5)
10 mM Tris-HCl 
50 mM NaCl
Glycine Buffer (pH 10.5)
0.1 M glycine 
0.1 M NaCl
Triton X-100 Solution
1% (v/v) Triton X-100 in Tris-buffer
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Versene
125 niM NaCl
2.7 iiiM KCl
6.3 mM Na2liP04
3.2 mM IŒ 2PO4
0.5 mM EDTA
0.0015% (w/v) phenol red
T rypsin-V ersene
40 mis Versene
10 mis 0.25% (w/v) trypsin
Dextran Coated Charcoal
0.5% (w/v) sieved, prewashed charcoal 0.005% (w/v) dextran; suspended in 
HE buffer and stirred continuously for 30 minutes at room temperature.
!
Cell Freezing Medium
90% (v/v) PCS
10% (v/v) dimethyl sulphoxide
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Dialysed Heat-Inactivated Dextran-Coated Charcoal Stripped Fetal Calf 
Serum (DHIDCCFCS)
100 ml of PCS was dialysed against four 1 litre changes of Hank’s modified 
buffer over 48 hours at 4°C. The serum was then heat inactivated by 
incubating at 56^C for 45 minutes. The serum was then cooled and a pellet of 
dextran coated charcoal (derived from 12.5ml of solution. See 2.2.7) was 
added and this mixture was stirred at 4°C for 30 minutes before centrifuging at
10,000 rpm for 30 minutes at 4°C to pellet the charcoal. Subsequently, the 
supernatant was filter sterilised through a 0.2 mm filter.
Experimental Medium (MCF-7 and MDA-MB-231 Cells)
RPMI-1640 with L-glutamate, without phenol red and sodium bicarbonate. 
This was prepared from powdered stock with the addition of 23.8 mM sodium 
bicarbonate and 25 mM HEPES. pH was adjusted to 7.2-7.4
Routine Sub-Culture Medium for MCF-7 and MDA-MB-231 Cells.
RPMP1640 medium supplemented with L-glutamine and 25 mM HEPES; pH 
7.4, 10% fetal calf serum. This was further supplemented if required with T
penicillin (100 units/ml) and streptomycin (50 mg/m l).
4
Solutions for SDS-PAGE Electrophoresis 
Protein Sample Buffer (2X)
60 mM Tris-HCl; pH 6.8
' Î
. -T
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2% (w/v) SDS
10% glycerol
100 niM dithiothretol
0.05% (w/v) bromophenol blue
Electrophoresis Running Buffer
25 mM Tris-HCl; pH 8.3 
192 mM glycine 
0.1% (w/v) SDS
Coomassie Blue Stain
0.25% (w/v) Coomassie Brilliant Blue R-250
40% (v/v) methanol
10% (v/v) glacial acetic acid
Lysis Buffer
1% Triton-XlOO in Tris buffered saline (TBS); pH 8.5
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Solutions and Buffers for ELISA 
Coating Buffer pH 9.6
15 mM Na2C03 
35 mM NaHCOs
Phosphate Buffered Saline (PBS); pH 7.4
Washing Buffer
0.1% Tween-20 in PBS
Dilution Buffer
1% BSA in washing buffer
a
.1
14 mM NaCl
2.7 mM KCl
1.5 mM KH2PO4 
S.lnxM Na2HP04
Blocking Buffer
1% BSA in PBS
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Colour Buffer; pH 5.0
76 mM NaH2P0 4 .H20  
35 mM citric acid
Substrate Solution
4 mg OPD + 10 pi 30% H2O2 in 11 ml colour buffer
Antibodies for ELISA 
Coating Ab
Sheep anti chicken; S02; # 91/99 
Catching Ab
Chicken anti uPA; chrm # 93/100 
Chicken anti PAI-; chrm # 94/101 
Chicken anti tPA; chrm # 95/102 
Tagging Ab
Rabbit anti uPA; chrm # 96/103 
Rabbit anti PAT 1 ; chrm # 97/104 
Rabbit anti tPA; chrm 98/105 
Detecting Ab
Goat anti Rabbit/Peroxidase conjugate;
2.3.1 Cell Lines
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2.3 Cell Culture Methods
3
Two breast cancer cell lines, namely MCF-7 and MDA-MB-231, used for 
these studies were obtained from the European Collection of Animal Cell 
Cultures (Porton Down, Salisbury, UK).
The MCF-7 cell line was derived from a pleural effusion from a 69 year old 
woman. The line has been characterised as being oestrogen receptor positive 
and so is responsive to steroid hormones. It exhibits some of the 
characteristics of differentiated mammary epithelium including oestrogen 
metabolism.
The MDA-MB-231 cell line was also generated from a pleural effusion and is 
oestrogen receptor negative and therefore is not responsive to steroid 
hormones.
2.3.2 Maintenance of Ceil Lines 
Subculture Techniques
All cells were routinely grown in a 37°C incubator with atmospheric air 
enriched with 5% CO2 . Experimental plates and dishes were grown in a 
humid environment to prevent media evaporation. Flasks of various surface
gareas were used depending on the mass of the cells required: 25cnm 
containing 5ml of medium, 75cm^ containing 10 ml of medium and ISOcm  ^
containing 25ml of medium. Fresh culture media were generally renewed 
every 48 hours. All manipulations were performed aseptically within the 
confines of a clean laminar airflow.
plate.
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All the solutions were prewarmed to 37°C prior to use. Cells were passaged 
when the surface area was about 80-90% confluent. The medium was decanted 
aseptically and the cellular monolayer washed twice with approximately 5 mis 
of sterile PBS. Subsequently, 0.05% trypsin, prepared in a Versene solution, 
was added to each flask (1ml for a 25cm^ flask; 3ml for a 75cm^ Flask, and 
5ml for a 150cm^ flask). The flasks were incubated at 37°C for 2-3 minutes, 
then checked under the microscope to make sure that the cells were rounded. 
This was followed by removing most of the trypsin-Versene and the flasks
incubated for a further 2-3 minutes to allow the cells to detach completely. 
Trypsin was neutralised by adding fresh culture medium (2-3 volumes) and 
the cells evenly dispersed by rapid pipetting. This suspension was then 
dispensed into new culture flasks containing appropriate amounts of fresh 
growth medium. For routine subculturing the cells were split in a ratio of 1:3. 
To plate cells for experiments the above procedure was modified slightly as 
follows. The cells were trypsinised and resuspended as described previously 
and counted using a haemocytometer. After making appropriate dilutions to 
obtain the desired cell density the cell suspension was plated on different 
experimental plates. For instance, 2 ml of the required dilution was plated in
6-well plate, 1ml per well for a 24-well plate and 200|.l1 per well for a 96-well
•Ï
2.3.3 Mycoplasma Testing
Cell lines were routinely screened for the presence of contaminating 
mycoplasma because it causes serious intracellular infection which results in
'
aberrant cell growth. In order to screen for this infection, which cannot be 
detected with the naked eye, the cells were fixed and stained with a fluorescent 
dye. This involved growing cells on a sterile coverslip or a glass slide under
i'
I
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standard tissue culture conditions. The cells were allowed to reach 
approximately 50-60% confluence and the medium was aspirated and the cells 
washed with three changes of PBS. The cells were then fixed with freshly 
prepared Carnitov's fixative (75% methanol; 25% glacial acetic acid for 5 
minutes). After air drying, the cells were stained with a lOng/ml solution of 
Hoechst 33258 and left for 15-20 minutes at room temperature. After washing 
the cells thrice with PBS, the cover slips or slides were inverted onto a drop of 
mounting fluid (90% glycerol; 10% PBS). The cells were viewed under a 
fluorescent microscope for visual evidence of any infection. Presence of 
mycoplasma was indicated by the presence of extranuclear DNA which 
stained with the dye. Any contaminated cell line was destroyed and new 
stocks from the negative test date were retrieved from the frozen stock or new 
stocks were ordered from the European Animal Cell Culture Collection.
2.3.4 Cryopreservation of Cell Lines
Frozen stocks of cells were prepared while the cell line was still at the early 
passage number. This meant that all the cells used in experiments were of a 
similar passage number. To keep the stock of same passage number going new 
stocks were grown every few months from the frozen stocks. In order to 
prepare frozen stocks, the cells were grown in 150cm^ flasks in RPMI-1640 
(routine culture medium) supplemented with 10% FCS until they were 
approximately 80-90% confluent. Cells were trypsinised and resuspended as 
described previously, and the cell suspension was transferred to a sterile 
Universal container and centrifuged for 3-4 minutes at 500rpm. The 
supernatant was aspirated and the pellet resuspended in a freshly prepared 
solution of 10% DMSO in FCS. Aliquots of 1ml were then transferred to 
sterile Cryo tubes. These were initially slowly frozen at -70^C in a polystyrene 
box overnight but once frozen were transferred to liquid nitrogen vats.
 1
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2.3.5 Rejuvenation of Frozen Ceils
To rejuvenate cells, the frozen vials were removed from the liquid nitrogen 
and thawed rapidly in a waterbath at 37<^ C. The vials were removed allowing
:'!:4few ice crystals to remain in order to minimise the cytotoxic action of DMSO. 
The vials were sterilised by spraying then with some 70% ethanol and the 
semi-frozen cell suspension was transferred to a Universal container to which 
10ml routine medium had been added. This was centrifuged for 5 minutes at 
500rpm. The supernatant was discarded and the pellet resuspended in 
approximately 10 ml of prewarmed medium. Subsequently, the cells were 
transferred to a new tissue culture flask (25cm^ or 75cm^ ) containing 
medium. The flasks were then incubated in a 37^C incubator. The medium 
was replaced with fresh medium after 24 hours.
2.3.6 Determination of Cell Number and Viability
An aliquot of the cell suspension was mixed with an equal volume of Trypan 
Blue solution (0.4%) and the number and viability of the cells was determined. 
This was achieved by viewing the cells under a light microscope in a 
haemocytometer. The viability of cells was established as the percentage of 
cells that excluded the Trypan Blue dye, thus the proportion of cells whose 
membranes remained intact and appeared white under the microscope (>95 
%). Where determined to be viable the cell number was calculated by using 
the grid on the slide which ensured that the same area was counted for each 
determination.
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2.4 Colorimetric Assays for Quantitation of Cell Number
2.4.1 MTT Assay
Cellular proliferation and viability was determined by MTT (3-(4, 5- 
dimethylthiazoi-2-yl)-2,5“diphenyltetrazoliumbromide) which is a yellow 
water soluble tétrazolium salt which is reduced by the hydrogenase enzymes 
in viable cells into an insoluble purple formazan product. This was dissolved 
in dimethylsulphoxide and the absorbance read at 540nm. The assay was 
carried out by subculturing cells followed by the addition of 50^1 of MTT 
(5mg/ml in PBS) into each well. The plates were wrapped in an aluminium 
foil and incubated for 4 hours at 37^C in a humidified environment. After 
incubation with MTT, the medium was replaced by 200f.il of DMSO in order 
to dissolve the MTT-formazan crystals. Finally 25jutl of glycine buffer was 
added to each well and the absorbance read at 540nm immediately using a 
plate reader. One column was used as a blank .
Ï
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Figure 3 Cell number versus absorbance at 540 nm reading in MTT 
assay.
A range of numbers of cells were plated onto 96 well plates and allowed to 
attach overnight in routine medium. Then the medium was replaced with 
serum free experimental medium containing MTT the concentration of 1 
mg/ml. MTT crystals were then dissolved by adding 200 pi DMSO after 4 h 
incubation. Absorbence was read at 540nm, subsequently adding the glycine 
buffer, in the plate reader. These data are the mean values of three separate 
experiments.
■ f tII:
I
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2 .4 .2  X T T  A ssa y
This assay was used instead of MTT because the XTT was more efficient. It 
involves fewer steps than MTT and did not involve the use of irritating 
chemicals, like DMSO. This colorimetric assay was used to quantitate cell 
proliferation and viability. The assay is based on the hydrolysis of the yellow 
tétrazolium salt XTT (sodium 3’-[l-(phenylaminocarbonyl)-3,4-tetrazolium]~ 
bis(4-methoxy-6-nitro) benzene sulphonic acid hydrate) to form an orange 
formazan product by the action of the dehydrogenases of the viable cells. The 
formazan dye formed is soluble in aqueous solutions and is directly quantified 
using a scanning multiwell spectrophotometer at 540 nm. Cells from a 60-70% 
confluent flask were trypsinised, centrifuged for 5 minutes at lOOOrpm and 
resuspended in the medium. Subsequently, the cells were counted in a 
hemocytometer and 1x10^ cells/ml were used. The cell suspension was plated 
down in 96 well microtitre flat bottomed plates in a final volume of 200pl 
culture medium per well. The first column had growth medium only to be used 
as a blank. Plates were incubated for 24 hours in a humidified incubator at 
37^C. After 24 hours the medium was aspirated from the wells with a sterile 
hypodermic needle attached to a suction pump and replaced with experimental
:medium containing the appropriate growth factors and drugs. The plates were 
then incubated from 24 to 72 hours depending on the aims of the experiment.
After the incubation period, 50fil of XTT prepared according to manufacturer's 
instructions (final XTT concentration 0.3mg/ml) was added to each well. The 
plates were wrapped in aluminium foil and incubated for a further 2-8 hours 
according to the need of the experiment and the absorbance of the samples 
were determined at 540nm.
9 #
(A540), using MTT assay, is shown in (Fig 4).
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2.4.3 Hoechst DNA assay
The assay methodology was modified from that of Leake & Habib (1987), and 
involves the intercalation of Hoechst 33258 with solubilised DNA resulting a 
complex which fluoresces with a maximum emission at 450 nm.
Cells were plated into 24-well plates and incubated overnight at 37°C. 
Following the washing with PBS, medium was replaced with experimental 
medium containing steroids or growth factors. Control wells for steroids 
received experimental medium containing ethanol 0.1% (v/v). After 
appropriate incubation time cell monolayers were harvested and the DNA was 
solubilised using 0.2% SDS in ETN buffer for 30 min at 37^C. 100 pi aliquots
of samples were added into plastic test tubes containing 3ml ETN buffer, 
Hoechst 33258 (lOOng/ml) and RNase (5pg/ml). The mixture was vortexed 
and incubated in the dark for 30 min at room temperature. The fluorescence 
enhancement at 450nm was measured using the fluorescent spectrophotometer 
with an excitation wavelength of 360nm.
■S
DNA standards were prepared from a 100 pg/ml solution of calf thymus DNA 
dissolved in ETN buffer. The standards were used in the range of 0-60pg/ml 
DNA. The concentration of DNA present in the samples was extrapolated
from a calibration curve which is obtained from the standards. A correlation
,between the total cellular DNA count and absorbance reading at 540nm
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Figure 4 Total cellular DNA counting versus absorbance a t 540 nm 
reading in M TT assay.
MTT readings of the increasing number of cells were obtained as described in 
Fig 3. The same number of cells were plated into 24-well plates and left 
overnight for attachment. Cell culture monolayers then were harvested and 
DNA was solubilised using 0.2% SDS in ETN buffer. lOOpl aliquots of 
samples were added into RT-30 tubes containing 3 ml ETN buffer, Hoechst 
33258 (lOOng/ml), RNase (Spg/ml). The mixture was vortexed and incubated 
in the dark for 30 min. at room temperature. The fluorescence enhancement at 
450nm was measured with an excitation wavelength of 360nm. These data are 
the mean values of three separate experiments.
I-.y
I
■Î
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2.4.5 Protein Determination
Protein was routinely measured by the method of Bradford (1976) with bovine 
serum albumin (BSA) as a standard. Standard curve was constructed using 0- 
20 }lg range of bovine serum albumin. The standard and unknown protein 
solutions were made up to a volume of 800 pi with distilled water before the 
addition of 200 pi of Bradford reagent and the tubes were vortexed. 
Absorbance was determined at 595 nm using a LKB Biochrom ultra 
spectrophotometer. Unknown concentrations were determined by plotting the 
standard curve (x axis = mg/ml of protein concentration, y axis = A595) (Fig
5).
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Figure 5. Standard curve for a Bradford protein assay
The samples for the standard curve were prepared as described in section 
2.4.5. Bovine serum albumin concentrations of 0-20pg/ml were used as 
indicated and the absorbance was read at 595nm. The blank without protein 
was used to zero the spectrophotometer. The assays were carried out in 
duplicate. This is a representative experiment which has been carried out at 
least twenty times.
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2.5 SDS-Polyacrylamide Gel Electrophoresis
Separation of proteins by SDS-discontinuous polyacrylam ide gel 
electrophoresis (SDS-PAGE) was essentially as described by (Laemmli, 
1970). Generally the Bio-Rad Mini-Protein II Electrophoresis system was used 
with 0.75 mm spacers and combs. A large and a small plate separated by 
spacers was assembled in the clamp assemblies in the gel casting apparatus as 
directed by Bio-Rad. Depending on the molecular weight of the proteins to be 
analysed, the appropriate separating gel mix (see table 1) was prepared and 
poured in between the glass plates, leaving about a 1.5 cm space at the top for 
the stacking gel. Subsequently, water-saturated butanol ( 1 ml) was poured on 
top of the separating gel before allowing it to polymerise.
______ Table 1: Composition of SDS-PAGE gel mixes
Percent Gel (30 mis)
Solution Components 8 % 10% 12% 15%
dH20 13.9 11.9 9.9 6.9
30% Acrylamide 8.0 10.0 12.0 15.0
1.5 M Tris-HCl; pH 8.8 7.5 7.5 7.5 7.5
10% SDS 0.3 0.3 0.3 0.3
10% Ammonium persulfate 0.3 0.3 0.3 0.3
TEMED 15 ul 15 ul 15 ul 15 ul
L
TEMED 10 ul
the gel. The gel was then removed and either electroblotted onto a
I
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Preparation of 10 ml of a 5% stacking gel (5%) was carried out by mixing the 
following:
dH^O 6.8 ml
30% acrylamide 1.7 ml
1.0 M Tris-HCl; pH 6.8 1.25 ml
10% SDS 0.1 ml
10% Ammonium persulfate 0.1 ml
For both separating and stacking gels, all reagents except ammonium 
persulfate (APS) and TEMED were combined and the monomer solution 
degassed under vacuum for 5 minutes followed by the addition of APS and 
TEMED to initiate polymerisation.
After washing the butanol away with dH20, the stacking gel was poured and 
the comb put into position. The comb was removed, gel assembled into the 
electrophoresis apparatus and the reservoirs filled with protein running buffer 
(0.192 M glycine, 25 mM Tris, and 0.1% SDS). Protein samples were boiled 
in an equal volume of Laemmli sample buffer (containing 0.062 M Tris-HCl; 
pH 6.8, 2% (w/v) SDS, 10% (w/v) sucrose, and 10 mM DTT) for 3 minutes 
before loading onto the gel. Samples and standards (20-30 ml per well) were 
loaded into the wells with a microsyringe (Hamilton). Electrophoresis was
carried out at a constant voltage of 200 Volts using a power supply (Biorad;
;■
Model 200/2.0) until the bromophenol blue tracker dye reached the bottom of "ir
I
M ateria ls and M e th o d s  89
nitrocellulose membrane for Western blotting or directly stained with
Coomassie blue.
2.5,1 Staining and Destaining Gels
Staining was carried for 1 hour at room temperature using 0.1% (w/v) 
Coomassie Brilliant Blue dissolved in 10% (v/v) acetic acid, 40% (v/v) 
methanol. Gels were destained by washing several times with gentle stirring 
between 2-3 hours or overnight in 20% (v/v) methanol, 10% (v/v) acetic acid.
■:v
2.6 Western Blotting and Immunological Detection of Specific 
Proteins by Enhanced Chemiluminescence (ECL)
Following separation by gel electrophoresis, proteins were electrophoretically 
transferred onto Hybond-C nitrocellulose paper (Amersham) in the presence of 
a buffer containing 25mM Tris-HCl; pH 8.3, l92mM glycine, 0.02% (w/v)
SDS and 20% (v/v) methanol as described by Towbin et al. (1979) and 
Batteiger et a l.  ( 1982). This was carried out in a BioRad Trans-Blot ceil either 
at 10mA overnight or at 250mA for 1.5 hours. The nitrocellulose was briefly 
stained with Ponceau S solution which allowed visualisation of transferred 
protein bands. The membrane was washed free of this stain with distilled 
water and subsequently blocked by immersing it for 1-2 hours on a rotatory 
shaker in a solution containing TBS (20mM Tris-HCl; pH 7.2, 15iiiM NaCl,
5% (w/v) non-fat dried milk and 0.2% Tween- 20 (v/v). Excess blocking 
reagent was then washed with TBS, containing 20mM Tris-HCl; pH 7.2,
15mM NaCl and 1% (w/v) non-fat dried milk. Washing was carried out twice 
briefly, once for 15 minutes and then twice for 5 minutes using 200 ml of 
wash buffer each time. The membrane was then incubated for 1-2 hours at
-T
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room temperature or overnight at 4^C  in a 100ml solution containing 20mM 
Tris-HCl; pH 7.2, 1% (w/v) non-fat dried milk, 0.1% (v/v) Tween-20 and the 
appropriate dilution of the primary antibody. The membrane was washed 
again as detailed above and incubated for 2 hours at room temperature with a 
1:1000 dilution of horseradish peroxidase conjugated secondary antibody. 
This was carried out in approximately 10ml of buffer containing 20mM Tris- 
HCl; pH 7.2, 150niM NaCl and 1% (w/v) non-fat dried milk. In order to keep 
the volumes of the antibody solutions as small as possible, incubation was 
sometimes carried out in a sealed bag. Following incubation in secondary 
antibody the membrane was given three, 30 min washes in wash buffer and 
one 30 min wash with a buffer containing 20mM Tris-HCl; pH 7.2 and 
150mM NaCl. The detection steps were carried out in a dark room following 
the protocol outlined in the ECL kit manual. Exposure times were typically 15 
seconds to Imin.
2.7 Enzyme-Linked Immunosorbent Assay (ELISA)
Assay Principle
Four-span ELISA is an enzyme linked immunoassay for the determination of 
human uPA, PALI and tPA in monolayer cultures and tissue extracts. The 
method was developed by Grebenshikov et al... (1997). The assay detects 
latent, active and complexed forms of uPA, PALI and tPA.
Antibodies (Ab)
The four-span ELISA comprised four antibodies and a substrate: sheep anti­
chicken as the coating antibody (1st Ab), chicken anti-analyte as the catching 
antibody (2nd Ab), rabbit anti-analyte as the tagging antibody (3rd Ab) and
2.7.1 Sample Preparation
uPA or PAI-1 Extraction from Human Ceil Lines
2.7.2 Assay Procedure
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goat anti-rabbit conjugated horseradish peroxide (HRP) as the detecting 
antibody (4th Ab).
Cells were grown in 25 cm^ flasks in routine culture medium RPMI-1640,
10% FCS and incubated at 37°C in a humidified incubator for 24 hours. The 
medium was then replaced by experimental medium with or without growth
'factors and steroid hormones and further incubated, for time course studies, 
from 48 and 72 hours. At the end of each time point the medium was collected
and snap frozen until assay at -70^C. The cells were then washed with PBS.
Subsequently, 1ml of 1% Triton X-100 in TBS was added to the cells and
incubated for 2-4 hours at 4°C with constant stirring. The cell suspension was
then centrifuged at 100,000rpm for 60 minutes at 4"C to pellet cell membranes
and other debris. The supernatant was collected and the total protein
quantitated using the (Bradford, 1976) protein assay. The supernatant was
aliquoted into 200 pi portions and stored at -70°C. For immediate use the
,samples were diluted 1:100 for PAI-1, and 1:50 tor uPA tor MDA-MB-231
cell line. MCF-7 cell line was used without further dilution.
■I
The 96-well microtitre plate was coated using 100pi of the coating antibody
(dilution 300-fold) per well and incubated overnight at 4°C. After 24 hours the
'plates were washed for 5 minutes, 4 times in a washing buffer (PBS+ 1%
Tween-20) and were blocked at 37°C for 2 hours with blocking buffer (PBS+
1% Tween-20+ 1% BSA). The plates were again washed with washing buffer
Ï
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as before. Standards were prepared in a range of 0.1-lng/ml in a dilution 
buffer. Where required, samples were diluted and JOOpl of the 
standard/control and samples were added to each well and incubated overnight 
at 4°C. All measurements were performed in duplicate. After washing four 
times with washing buffer, the catching antibody was diluted (600-fold uPA 
and 475-fold PAI-1). lOOpl per well each was added and incubated at room 
temperature for 2 hours. The plates were then washed as before with washing 
buffer to remove any unbound antibody and incubated further with 
biotinylated tagged antibody diluted (300X uPA and 150X PAI-1). 100 pi per 
well and incubated at ambient temperature for 2 hours. The plates were 
washed four times and incubated with the freshly prepared substrate OPD (0- 
phenylenediamine) and H2O2 wrapped in an aluminium foil and incubated in 
the dark for 30 minutes. The enzymatic reaction was stopped by adding 50 pi 
of 1 M H2SO4. Yellow colour was developed and the absorbance read at a 
wavelength of 492 nm in an ELISA plate reader. The background average of 
the blanks was deducted from the standard and sample readings. The standard 
curve was constructed from the standards and the values of the unknown 
samples determined (Fig 6).
The sample values were multiplied by the dilution factor in the assay and 
divided by the protein concentration (mg/ml) of the cell extracts to convert 
ng/ml values of uPA/PAI-1 to ng uPA/PAI-1/ mg protein.
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Figure 6. Standard curve for an ELISA assay
The samples for the standard curve were prepared as described in section 
2.7.1. Pro-uPA concentrations of 0-1.8 ng/ml were used as indicated and the 
absorbance was read at 492 nm (A492). The blank well (without uPA) was 
used to zero the plate reader. The assays were carried out in duplicate. This is 
a representative experiment which has been carried out at least twenty times.
®ï
i:'
Î
.a
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2.8 Enzyme Activity Assay 
Plasminogen Activator Assay
Î
1:1
à
:
The ceils were plated at a density of 5x10^ cells per well in a 6-well plate with
growth medium containing 10% fetal calf serum in it. After a 24 hour T1
incubation time the cultures were washed twice with PBS and incubated for an 1
additional period of 8-10 hours with experimental medium supplemented with
2.5% FCS. This medium was then replaced with control medium or medium ■
supplemented with treatments and the plates incubated for further 48 and 72
"I
hours. At each time point conditioned medium (CM) was collected and the |
cells were lysed with 1ml of 1% Triton X-100 for 2 hours at 4°C. The 
supernatant (SN) was collected after centrifugation at 1000 rpm for 30 Iminutes. Both CM and SN were snap frozen and stored at -70°C until assayed |
for uPA activity. 7i
The activity of the samples was determined using the chromogenic substrate s
' 1,for urokinase pyro-Glu-Gly-Arg-pNA (S-2444, Kabi, Stockholm, Sweeden). 1|
30pl of the standard or sample was incubated with 120 ml of the buffer 
containing 110|ll of lOmM Tris-HCl; pH 7.5. lOpl of 1.5mg/ml of the 
substrate S-2444 and 1.5p.l of plasminogen 10 U/ml. All the incubations were 
performed at 37°C in microtitre plates for 2 hours. The activity was measured 
with a Titertek Multiscan spectrophotometer (Flow Laboratories). Activity 
expressed as the change in the absorbance at 405 nm. Urokinase (UK) activity 
was obtained by comparison with the WHO International standard for UK.
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Figure 7. Standard curve for an uPA enzyme activity assay
The samples for the standard curve were prepared as described in section 2.8. 
Active-uPA concentrations of 0-20|Llg/ml were used as indicated and the 
absorbance was read at 403nm. The blank well (without uPA) was used to 
zero the plate reader. The assays were carried out in duplicate. This is a 
representative experiment which has been carried out at least ten times.
The chromogenic substrate S-2444 was changed to a more specific substrate 
S-2251 (Quadratech ) 5mg/ml for urokinase. Because of the sensitivity of the 
assay the amount of the standard/ sample and the substrate was reduced to 
lOp.1 and 4p,l respectively, while the assay buffer mix was increased from 
120p.l to 190p.l. All the other measurement steps in the assay performed were 
the same as described above II
'- s i
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2.9 Invasion Assays 
Principle of the Assay
An in vitro invasion assay was carried out to quantify the invasive potential of 
tumour cells after different treatments. In this assay filter membranes were 
used to support the artificial basement membrane and to discriminate between 
cells that have traversed from those whieh have not.
2.9.1 Cell Harvest for Invasion Experiments
Cells were harvested from 70-80% confluent culture flasks with 0.02% EDTA, 
counted and resuspended in experimental medium, and seeded in the upper 
chamber onto the lower side of the membrane of Boy den blind-well apparatus 
for 6 to 8 hours at 37°C in 5% CO2 in air (Fig 8).
T ra n s  w e ll U pper corn p a r t  m e n t
C ell s /  C u 11 u re  rn e d i u rn
M atrig e lF i l t e r
,L 0 w  e r  comp  a r t  m e n t
Figure.8 Schematic description of In  vitro invasion assay.
For experimental details see section 2.9.3.
I
I
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2,9.2 Invasion Assay Procedure
The Boy den blind-well chamber invasion assay was performed, as described 
by (Albini et a i, 1986). Trans well chambers (Costar) with 6.5mm diameter, 
8pm pore size polycarbonate filters were pre-coated with matrigel for the 
invasion assays. Each 24-well plate contains 12 removable inserts having the 
carbonate filter and a corresponding lower well. Twelve separate wells without 
inserts could be used for positioning the inserts during experimental 
manipulations. I
Each filter was coated with 80pl of matrigel diluted to a final concentration of 
1 mg/ml in experimental serum free RPMI 1640 medium to form a continuous 
barrier on top of the filter. The filter was left at 37°C for an hour to allow an 
even gel layer to form on the filter. The lower Boyden blind well chamber was 
filled with either 780pl experimental medium or where indicated an 
experimental medium plus 2-5 mg/ml matrigel was used. Filters coated on the 
upper side with matrigel were placed in the chamber and 5 x 10  ^ cells/ml 
resuspended in the experimental medium. lOOpl out of this stock was placed 
on top of the matrigel layer and incubated at 37°C in 5% CO2 in air. After 72 
hours the percentage of invading cells was determined as described below. All 
experiments were performed in duplicate.
2.9.3 Evaluation of Invasion Using the MTT Assay
The viability testing MTT assay was used to measure quantitatively the 
proportion of invasive cells. 200|Ltl experimental medium either alone (control) 
or with treatments were added into the chamber. The cells were incubated for 
three days. After 72h, 5 mg/ml of the vital stain MTT in PBS (filter sterilised)
tf.7
'a '
-
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was added into both upper (100 p.1 of volume) and lower compartments 
(200jli1) and incubated for 3 hours at 37®C. At the end of the incubation period 
medium was gently aspirated from the upper chambers. The upper chambers 
were removed and the filters containing the cells, were transferred to a 24-well 
culture plate. Subsequently, after aspiration of the MTT medium cells which 
had not traversed the filter and remained on the top or in the layer of matrigel 
were removed together with the matrigel with a cotton swab. The cotton swab 
and the remaining filter-containing cells which had traversed to the lower side 
of the filter were plaeed in separate wells of a 24-well culture plate. To release 
the formazan from the cells , 800j.il DMSO was added to each well and the 
plates were gently shaken for 5 minutes. 200fxl glycine buffer was then added 
per well and absorbance at 540nm was read immediately thereafter in a 
spectrophotometer.
Assessment of Invasive Capacity of Ceils
The percentage of cells capable of traversing through the matrigel layer and 
attaching to the lower side of the filter was expressed as a percentage of the 
total number of cells present following the 72 hours incubation period in an 
experimental medium:
I
% Invasion = Number of cells attached to the lower side of the filter (A540) / 
total number of cells, i.e. sum of cells attached to the lower filter side and cells
■
still present in the matrigel (A540) x 100%.
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2.9,4 Evaluation of Invasion by Confoeal Microscopy
Approximately 5x10^ cells/ml were prepared from the stock and lOOpl of this
Fixation of the Cells
2.10 Immunofluorescence
Having been seeded at a cell density of 2x10^ cells per well, cells were plated 
down overnight into 8-well glass slide/tissue culture vessels. Following this 
the wells were aspirated and washed three times with PBS and 300p.l of 
RPMI-1640 with 2.5% DHIDCCFCS +/- growth factors or hormones were
dilution was plated on the bottom of the filter and placed in a humidified 
incubator at 37°C for 4-5 hours in order to attach the cells to the filter. The f
inserts were then inverted upside down and 200pl of the respective drug was
prepared in the experimental medium and added on top of the filter which acts
7
as a chemoattractant. Then, 750pl of the experimental medium was added in i
the well and the plate incubated for 5 days at 37°C in a humidified incubator 
to prevent the medium from evaporation.
The inserts from the wells were removed and washed four times with sterile
'■IPBS (5 minutes per wash). The cells were then fixed with methanol (100% or 
70% ) for 20 minutes at room temperature. After washing lour times with PBS 
the cells were stained with propidium iodide~50pl per insert (5 mg/ml). 1:1000 |
dilution was used to stain the cells for 30 minutes at room temperature in the
dark. After thorough washing with PBS the cells were read under confocai 
microscope (Confocai Bio-Rad illumination unit attached to a Nikon diaphot f
inverted Microscope).
I
I
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then added to the wells. After 48 hours the wells were aspirated and washed ri
twice with PBS.
2.11 RNA Isolation
The cells were fixed by the addition of 200pi acetone:methanol (1:1) at -20°C ri
.’Ïper well for 5 minutes and allowed to air dry. Slides were blocked by -7
li;
incubating with normal goat serum (NGS) (1/5 dilution in TBS buffer) for 15 '.Ï
min. After that, NGS was removed and the wells were treated with primary |
mouse monoclonal antibody (200pl/well) uPA/PAI-l (1:50 in PBS + 1% BSA
) added. The wells were then incubated for 1 hour at room temperature in a ;$
■4humidified chamber. The slides were then washed three times with PBS.
Fluorescent labelled goat antimouse IgG (200jil/well) 1:50 in dilution buffer I
(PBS + 1% BSA) was then added and incubated for one hour as before.
Following incubation the wells were washed three times with PBS and then 
mounted with DPX mountant and immunofluorescence examined using a ri
fluorescent microscope (Leitz). I
■’ V-
Total RNA was isolated using the Ultrasoec-II RNA Isolation System 7
(Biotecx) according to manufacturers' instructions. Essentially, cells were 
pelleted and resuspended in three volumes of lysis buffer (provided in the kit).
This mixture was left on ice for five minutes to allow complete dissociation of 
nucleoprotein complexes. Subsequently, 0.2 volumes of chloroform were 
added and the mixture vortexed vigorously for 15 seconds and left on ice for 5 
minutes. After centrifugation at 14,000 rpms at 4°C for 15 minutes 4/5th 
volume of the aqueous phase was transferred to a fresh tube and to this 0.5 
volume of isopropanol and 0.05 volume RNATack Resin was added and the v
mixture was vortexed for 30 seconds. The tube was then centrifuged for 1
minute and the supernatant was discarded. The pellet was washed twice with 1 7
1
Î
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ml 75% ethanol by vortexing and spinning for about 30 seconds. The pellet 
was dried in vacuo. To elute RNA 0.1 volume of DEPC treated water was 
added to the dried pellet and the mixture vortexed for 30 seconds and 
centrifuged for 1 minute. The supernatant containing total RNA was collected 
and stored at -70°C.
I
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2.11,1 Reverse Transcriptase-Polymerase Chain Reaction
For the synthesis of cDNA, lOpg of total RNA was used and 50ng of the 
appropriate reverse oligonucleotide (for oligonucleotide sequences see below) 
annealed in a 19.25pl reaction consisting of AMV reaction buffer for 30 
minutes at 42°C. This was followed by the addition of 0.5pi of 20mM dNTPs 
and 0.25pl (5 units) of avian myeloblastosis virus (AMV)-reverse transcriptase 
(Boehringer Mannheim) and the reaction was incubated for 30 minutes at 
42^'C.
From the 20pl, 5pi were used in a polymerase chain reaction (lOOpl total 
volume) which contained 500ng of each of the oligonucleotides, 0.2mM
using the following program: 94°C 4 minutes (one cycle); 94°C 2 minutes,
uPA: 5' - AGAATTCACCACCATCGAGA - 3' (Forward)
5' - ATCAGCTTCACAACAGTCAT - 3' (Reverse)
PAI-1 5' - ATGGGATTCAAGATTGATGA - 3' (Forward)
5' - TCAGTATAGTTGAACTTGTT - 3' (Reverse)
dNTPs, lOpl lOX reaction buffer and 0.25pl (lU) Taq DNA polymerase 
(Boehringer Mannheim). PCR was carried out on a Perkin Elmer thermocycler
55°C 1 minute, and 72°C 1 minute (30 cycles); 72°C 5 minutes (one cycle).
DNA sequence of the respective pairs of oligonucleotides for the amplification
-of uPA, uPAR, PAI-1 and actin cDNAs were as following:
uPAR
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5' - TTACCTCGAATGCATTTCCT - 3' (Forward)
5' - TTGCACAGCCTCTTACCATA - 3’ (Reverse)
P-Actin 5' - TTGAAGGTAGTTTCGTGGAT - 3' (Forward)
5' - GAAAATCTGGCACCACACCTT - 3' (Reverse)
DNA Cloning
In order to unequivocally establish the identity of the obtained PCR products 
with the four different sets of primers the four fragments were cloned into the 
vector pGEM-T Easy (Promega). This was carried out by ligating each of the 
fragments and 50 ng of the vector in a 10 pi reaction as follows:
-.1
!I
Ipl PCR Fragment (-100 ng)
Ipl pGEM-T Easy(50 ng)
Ipl lOx Ligase Buffer
6pl dH20
Ipl T4 DNA Ligase (Boehringer Mannheim; 5 units)
.9.a
The reaction was incubated at 15°C overnight. For bacterial transformation, 
lOOpl of CaCl2 competent E. coli strain XL 1-Blue (Stratagene) was added to 
the ligation reaction and the mixture left in ice-water for 20 minutes. 
Subsequently, the tube was transferred to a 42°C waterbath for 2 minutes (in
. .  .
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order to induce heat shock) prior to plating the whole reaction mixture on a 
prewarmed LB/ampicillin plate. Plates were left over night in a 37°C 
incubator.
In order to characterise the clones, bacterial colonies from the plates were 
picked and grown in 3 mis of liquid culture in the presence of ampicillin.
1
Plasmid DNA from the turbid cultures was isolated by the alkaline lysis 
method using the Qiagen miniprep kit. Recombinant clones were identified by
'
digesting approximately 500ng of plasmid DNA with the restriction
■endonuclease EcoRI and electrophoresing the products on a 1.2% agarose gel 
prepared and run in Tris-acetate EDTA buffer (TAE)
I
DNA Sequencing
Recombinant plasmids were sequenced with Sequenase (USB) using the T7 
primer. Five micrograms of plasmid DNA was denatured at room temperature 
for 5 minutes in a 20pl reaction containing 200mM NaOH. Subsequently, 4pi 
of lOM ammonium acetate together with lOOpl ice-cold 95% ethanol was 
added and the mixture left on ice for 10 minutes. The precipitate was 
harvested by centrifugation at 14,000 rpm for 10 minutes and the supernatant 
discarded. The pellet was washed with 0.5 ml of 75% ethanol and then dried in 
vacuo. Annealing of the primer to the template, labelling and termination 
reactions were carried out according to the manufacturer's instructions. The 
reactions were heat denatured prior to loading on a 6% sequencing gel. Once 
the bromophenol blue dye had run off, the gel was fixed for 10 minutes in a 1 
litre solution containing 10% methanol and 10% glacial acetic acid prior to 
drying. The dried gel was then exposed to autoradiographic film (Fuji) and 
developed after 12-15 hours.
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2.12 Statistical Analysis
Data from individual experiments are expressed as the mean ± standard 
deviation (SD) and data pooled from at least two experiments, each performed 
in duplicate. To test for differences between groups, the student's t-test was 
used, with p< 0.001 considered as statistically very significant. The student t- 
test was performed using Macintosh computer programme "instat".
f
CHAPTER 3 
RESULTS
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Regulation of The Growth of MCF-7 and MDA-MB-231 Cell Lines
Background
The ultimate focus of this work was to study the invasive potential of two cell
lines, MDA-MB-231 and MCF-7, the former hormone insensitive and the I
latter oestrogen sensitive, in response to various growth factors and steroid
7hormones. As a first step therefore, it was imperative to observe how these 7
growth factors and hormones effected the proliferative behaviour of the two f
cell lines. The growth factors and hormones used in this study were, EOF, |
TGFa, TGFp, progesterone, tamoxifen and oestrogen. These were each used
■■7
at five different concentrations with each of the two cell lines. Subsequently, €
the effects of these exogenously added compounds were monitored by 
counting cells after 24, 48 and 72 hours. Charcoal stripped serum was used for 
these studies to estimate the effects of (most) serum growth factors.
The roles of the growth factors EGF, TGFa, and TGFp in breast cancer In 
vitro invasion remains controversial. The following experiments addressed 
this question.
The growth and function of epithelia in tissue culture are significantly 
influenced by the nature of substratum. To our knowledge this is the first 
comparison of the rate of proliferation on plastic with that on a matrigel from 
mouse sarcoma, which is a complex mixture of extracellular proteins 
including type-IV collagen, laminin, fibronectin and glycosaminoglycans. |
4
-t:
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3.1 PROLIFERATION
4:1
3.1.1 Transforming Growth Factor a  (TGFa)
I4.TGFa, a stimulatory growth factor that mediates its effect via the epidermal 
growth factor receptor (EGFR), was tested on cell growth for both MDA-MB- 
231 and MCF-7 cells. Different concentrations of TGFa were used in this 7
study, ranging from 0.1-10 ng/ml. This dose range was selected since previous 
experiments in our laboratory had shown that this range covered both subtle 
and maximum growth stimulation. To ascertain the optimum mitogenic 
concentrations the j j^^-pT/XTT assay was employed. It was found that exposure |
of low doses (i.e. 0.1 ng/ml) of TG Fa, resulted in a slight reduction of 
proliferation after 24, 48 and 72 hours for the MDA cell line on EHS (Fig 9). %
EHS is a matrigel derived from Engelbreth-Holm-Swarm murine tumour.
Treatment with higher doses of TGFa resulted in a gradual increase in 
proliferation. Stimulation of growth became significant (p< 0.01) at 3.0 ng/ml 
TGFa after 24 hours in comparison to the control. The MDA cell line grown 
on plastic showed a similar behaviour to that which was observed when these 7
cells were grown on EHS in that an initial decrease in growth with lower 
concentrations of TGFa was observed (Fig 10). This decrease was consistent 
with time period. However, a gradual increase in proliferation, with increasing 
dose was observed. The maximum increase observed was about 20% with the 
highest dose (10 ng/ml).
The effect of TGFa on the growth of the MCF-7 cells grown on EHS and 
plastic were also studied. With MCF-7 cells, TGFa augmented the growth rate 
in a concentration and time dependent manner on EHS. Maximum growth
(50%) was observed at TGFa 1 ng/ml (Fig 11). Maximum stimulation of 75 % 
at 3 ng/ml was observed after 72 hours on plastic (Fig 12).
(i:'.:4i
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Conclusions
Figures 9 (EHS) and 10 (plastic) show dose response curves for MDA-MB- 
231 cells in response to TGFa. MDA growth was stimulated by TGFa with 
maximum stimulation at 3ng/ml on EHS and lOng/ml on plastic. Lower dose 
inhibited the growth at 0.1 ng/ml on both EHS and plastic.
Figures 11 (EHS) and 12 (plastic) show dose response for MCF-7 cells in 
réponse to TGFa. The growth of MCF-7 cells was stimulated by TGFa with 
maximum stimulation at lower doses on EHS and higher doses on plastic.
This shows that growth responses of both cell lines in response to TGFa. 
were only slightly altered by nature of the substratum.
I
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Figure 9 Cell proliferation under varying stimulation of TGFa on EHS
in MDA-MB-231 cells.
MDA cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% FDDDCS only (control) or supplemented with doses of TGFa (0.1, 0.3,
1.0, 3.0 and 10 ng/ml). After 24, 48 and 72 hours proliferation was evaluated 
by MTT as described in "materials and methods" section 2.4.1. Results are 
expressed in percent of control value. *p < 0.001 and *p < 0.05. The 
experiments were performed in triplicate 8-96 wells. Results are mean ± SD.
Figure 10 Cell proliferation under varying stimulation of TGFa on 
plastic in MDA-MB-231 cells.
MDA cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% FDDDCS only (control) or supplemented with doses of TGFa (0.1, 0.3,
1.0, 3.0 and 10 ng/ml). After 24, 48 and 72 hours proliferation was evaluated 
by MTT as described in "materials and methods" section 2.4.1. Results are 
expressed in percent of control value. *p < 0.001 and •p  < 0.05. The 
experiments were performed in triplicate 8-96 wells. Results are mean ± SD.
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Figure 11 Cell proliferation under varying stimulation of TGFa on EHS
ill MCF-7 cells.
MCF-7 cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of TGFa (0.1, 
0.3, 1.0, 3.0 and 10 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. Data 
is expressed as a percentage of the control of untreated cells. *p < 0.001 and 
•p < 0.05. The experiments were performed in triplicate 8-96 wells. Results 
are mean ± SD.
Figure 12 Cell proliferation under varying stimulation of TGFa on 
plastic in MCF-7 cells.
MCF-7 cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of TGFa (0.1, 
0.3, 1.0, 3.0 and 10 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. Data 
is expressed as a percentage of the control of untreated cells, '-’^ p < 0.001 and 
•p < 0.05. The experiments were performed in triplicate 8-96 wells. Results 
are mean + SD.
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3.1.2 Epidermal Growth Factor (EGF)
Next, treatment of the MDA and MCF-7 cell lines with varying amounts of 
EGF was studied on either plastic or EHS.
The effect of EGF on MDA cells, on EHS was found to be slightly inhibitory 
after 48 and 72 hours, when exposed to 0.63 ng/ml which lead to a 10% 
decrease in growth rate (Fig 13), This agrees with the growth inhibition seen 
with low doses of TG Fa and the stimulation is sustained in that higher 
amounts of EGF overcame this inhibition and induced gradual increase of 
growth. Analysis of cells after 24 hours showed a slight increase in growth 
rate which continued with the increasing concentrations. The MDA cell line 
on plastic (fig 14), showed a different behaviour. A gradual increase in the 
growth rate was observed with increasing concentrations of EGF, to about 
15% (Fig 9). A further increase in the concentration of EGF resulted in a sharp 
decrease in growth rate. However stimulation with EGF on plastic was short­
lived and fell after 48h or 72h.
When grown on EHS, MCF-7 cells showed a time dependent increase in their 
growth rate, which was quite dramatic after 72h with 0.63 ng/ml reaching a 
maximum of 58% above control (Fig 15). A gradual increase in proliferation 
was observed with increasing concentrations after 24 and 48 hours. On plastic, 
MCF-7 cells exposed to 0.63 and 1.89 ng/ml of EGF showed a gradual 
increase in proliferation at all time points reaching maximum (100%) after 48h 
(Fig 16). Higher concentrations of EGF subsequently decreased proliferation.
P ro lifera tio n  resu lts 115
Conclusions
Figures 13 (EHS) and 14 (plastic) show the dose response curve for MDA 
cells to EGF. On EHS, high doses of EGF induced slight growth stimulation at 
all time points, whereas, on plastic, any effect of higher dose was inhibitory.
Figures 15 (EHS) and 16 (plastic) show the dose response curve for MCF-7 
cells. On both substrata EGF showed growth stimulation but the difference 
was that, on EHS, a dose-related increased growth was observed whilst that on 
plastic was bell-shaped.
The overall results shows that the growth response to EGF, likeTGFa, was 
slightly altered by the nature of the substratum.
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Figure 13 Cell proliferation under varying stimulation of EGF on EHS
in MDA-MB-231 cells.
MDA cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of EGF (0.63,
1.89, 6.3, 18.9 and 63 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4,1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
Figure 14 Cell proliferation under varying stimulation of EGF on plastic 
in MDA-MB-231 cells.
MDA cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of EGF (0.63,
1.89, 6.3, 18.9 and 63 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
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Figure 15 Cell proliferation under varying stimulation of EGF on EHS
in MCF-7 cells.
MDA cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of EGF (0.63,
1.89, 6.3, 18.9 and 63 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
Figure 16 Ceil proliferation under varying stimulation of EGF on plastic 
in MCF-7 cells.
MCF-7 cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of EGF (0.63,
1.89, 6.3, 18.9 and 63 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
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3.1.3 Transforming Growth Factor (3 (TGF|3)
It was important to find the effect of TGFp (a growth factor known for its 
diverse functions under normal and malignant conditions) on the growth 
response of the two cell lines on both plastic and EHS. A time course 
experiment was performed with varying concentrations of TGFp 0.01-1.0 
ng/ml. MDA cells grown on EHS (Fig 17) showed an inhibition which varied 
with time and concentrations. In the presence of the lowest concentration 
(0.01 ng/ml) inhibition reached about 20% after 24 and 48 hours. The observed 
effect approaches a bell-shaped curve because the inhibitory effects were 
decreased with increased doses. When cells were exposed to 1 ng/ml, only 5% A
inhibition was observed after 48 hours. The same dose after 72 hours did not 
show any inhibitory effect. When grown on plastic, the MDA cell line showed 
the concentration dependent inhibition over the time (Fig 18). The most 
pronounced decrease in growth rate (about 25%) was observed after 24 hours
■a-:-
in the presence of 1 ng/ml. It is not known whether use of higher doses of 
TGFp would have led to another bell-shaped curve. Careful monitoring of the 
cells showed that the inhibitory effects were lost after 48 and 72 hours with 
O.I ng/ml as compared to control values though the significance of this is not 
clear. The higher concentrations 0.3-1.0 ng/ml remained inhibitory.
I
In contrast, MCF-7 cells, on EHS, (Fig 19) showed a time and concentration 
dependent small increase in the growth rate in response to TGFp. The 
maximum increase of only 15% in proliferation was observed in the presence 
of 0.3 ng/ml, after 24 hours. The later time points showed an inhibitory effect 
on plastic of TGFp on MCF-7 cells at lower concentrations. MCF-7 cells, on |
plastic, surprisingly showed a time dependent increase in proliferation with 
even the lowest concentration of 0.01 ng/ml. This increase rose to about 2 fold 
after 24 hours (Fig 20). When cells were exposed to higher concentration of 7
....
Conclusions
i
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Ing/ml, there was a reduction in the growth rate but it remained 50% above 
control. After 48 and 72 hours the growth rate dropped.
Figures 17 (EHS) and 18 (plastic) show the dose response curve for MDA 
cells in response to TGpp. MDA cells were growth inhibited by TGpp with
I
maximum inhibition at O.Olng/ml on EHS. The higher doses showed little 
inhibition on EHS but significantly inhibited growth on plastic.
Figures 19 (EHS) and 20 (plastic) show the dose response curve of MCF-7 
cells in response to TGpp. MCP-7 cells initially showed a growth stimulation 
(at 24h) but there was a little inhibition on EHS at the lowest doses of TGPp at 
later time points. Whereas growth stimulation was observed with all doses on 
plastic. I
The effects of TGpp on MDA cells reflected those of TGPa in that effects 
were seen at lower doses on EHS compared with those cells grown on plastic.
On EHS, the inhibition curve approached the expected bell shape. However 
the stimulatory effect of TGpp on MCP-7 cells, especially over 24h on plastic,
■iwas most unexpected and although completely reproducible in these studies,
■‘r
contrasts with previous observations in the literature.
J
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Figure 17 Cell proliferation under varying stimulation of TGFp on EHS
in MDA-MB-231 cells.
MDA cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of TGFp (0.01, 
0.03, 0.1, 0.3 and 1 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
Figure 18 Cell proliferation under varying stimulation of TGFP on 
plastic in MDA-lVIB-231 cells.
MDA cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of TGpp (0.01, 
0.03, 0.1, 0.3 and 1 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
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Figure 19 Cell proliferation under varying stimulation of TGFp on EHS
in MCF-7 cells.
MCF cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of TGFP (0.01, 
0.03, 0.1, 0.3 and 1 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
Figure 20 Cell proliferation under varying stimulation of TGFP on 
plastic in MCF-7 cells.
MCF cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of TGFP (0.01, 
0.03, 0.1, 0.3 and 1 ng/ml). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
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3.1.4 Estradiol (E2)
It has been shown previously that E2 stimulates the growth of ER+ cell lines 
on plastic (Dickson et al., 1990). In order to compare its effect on the growth 
rate of the MCF-7 cell line on plastic and matrigel (EHS), experiments were 
carried out under identical experimental conditions. Concentrations of E2 
from 10"^^ to 10~^M, were used. As expected, E2 increased the rate of 
proliferation with increased doses. On EHS (Fig 21), E2 appeared to stimulate 
the growth in a similar fashion to that on plastic though the absolute level of 
stimulation was less than that observed on plastic (Fig 22). The increase in 
growth rate was concentration dependent with a significant increase in growth 
(23%) being observed with 10'^^ M estradiol on both substrata. Higher doses 
(10“8 M and greater) reduced the growth rate on both EHS and plastic. The 
overall effect of E2 on the rate of proliferation was stimulatory.
Conclusions
Figures 21 (EHS) and 22 (plastic) show the dose response curve for MCF-7 
cells. MCF-7 cells were growth stimulated by E2 with maximum stimulation 
at 10”^^-10"^M concentrations on both EFIS and plastic, though the magnitude 
of stimulation on plastic was about 3 times that on EHS.
Thus the nature of the substratum had no effect on the type of response to 
oestradiol but the extent of growth stimulation was much greater on plastic 
than EHS.
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Figure 21 Cell proliferation under varying stimulation of estradiol (E2)
on EHS in MCF-7 cells.
MCF cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DFflDCCFCS only (control) or supplemented with doses of E2 (I0“ 2^  ^ IQ- 
10, lO'O, 10"^  and 10"^ M). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and •p < 0.05. 
The experiments were perfonned in triplicate 8-96 wells. Results aie mean ± 
SD.
Figure 22 Cell proliferation under varying stimulation of estradiol (E2) 
plastic in MCF-7 cells.
MCF cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of E2 (lO'l^, 10" 
16, 10"9, 10"8 and 10"^ M). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
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3.1.5 Progesterone (Pg)
Progesterone mediates its effect through its receptor, PgR. Like E2, it is also 
known to stimulate the growth of hormone responsive breast cancer cell lines 
when cultured on plastic substratum. In this study, the effects on MCF-7 cell 
line were studied in response to varying amounts of Pg on either EHS or 
plastic.
When grown on EHS, the MCF-7 cells showed a time dependent increase in 
their growth The most dramatic stimulation was observed after 72 hours 
(34%) at 10“  ^2 M concentration, as compared to the control values (Fig 23). 
When higher amounts were used a gradual decrease in growth rate was 
observed at all time points.
On plastic, MCF-7 cells showed a gradual increase in proliferation after 24, 48 
and 72 hours. The most dramatic increase by about 100% was observed after 
48 hours (Fig 24). Increasing the concentration of Pg to 10"  ^ M or higher 
caused a slight decrease in proliferation. Thus no major differences were 
observed between the growth response curves to progesterone when MCF-7 
cells were grown on plastic or EHS.
Conclusions
Figures 23 (EHS) and 24 (plastic) show the dose response curve of MCF-7 
cells in response to progesterone. The growth réponse of MCF-7 cells towards 
progesterone was similar on EHS and plastic in that both were growth 
stimulated at lower doses and the magnitude of stimulation observed on EHS 
was less than that on plastic.
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Figure 23 Cell proliferation under varying stimulation of progesterone
(Pg) on EHS in MCF-7 cells.
MCF ceils (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of Pg (10"^^, 10" 
10  ^ 10~9, iQ-S and 10"6 M). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
Figure 24 Cell proliferation under varying stimulation of progesterone 
(Pg) plastic in MCF-7 cells.
MCF cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of Pg (10"^^, 10' 
10"^, 10"  ^ and 10“^  M). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and •p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
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3.1.6 Tamoxifen (TAM)
The "antiestrogen" tamoxifen is known to be a weak oestrogen agonist for 
breast epithelial cells though it will act as an antagonist in the presence of 
estradiol. The effect of TAM on MCF-7 was analyzed on both EHS and 
plastic. Different doses of TAM ranged from 10'^^-10"(^M.
On EHS, MCF-7 cells when exposed to 10"^M tamoxifen showed an increase 
of about 60% after 72 hours as compared to the control values (Fig 25). 
Overall, TAM stimulated the growth rate in a concentration dependent 
manner. On plastic, MCF-7 showed a similar concentration dependent 
increase in proliferation (Fig 26). A significant increase was observed after 24 
hours (30%) and reached a peak around 48 hours at all doses tested. A 
maximum increase of 72% was observed when exposed to 10"^M.
Conclusions
Figures 25 (EHS) and 26 (plastic) show the dose response of MCF-7 cells to 
tamoxifen. As observed with estradiol and progesterone, tamoxifen stimulated 
the growth of MCF-7 cells. A similar dose response curve on both substrata 
was observed, though the difference in maximum stimulation between the two 
surfaces was much less marked with tamoxifen.
The growth studies in vitro may somehow correspond to in vivo like situation 
but caution may be taken in In vitro studies with growth factors since changes 
in their environment may affect their behaviour.
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Figure 25 Cell proliferation under varying stimulation of tamoxifen
(TAM) on EHS in MCF-7 cells.
MCF cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of TAM (10"^^, 
10‘*0, 10”^ , 10"^ and 10"^ M). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and *p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
Figure 26 Cell proliferation under varying stimulation of tamoxifen 
(TAM) on plastic in MCF-7 cells.
MCF cells (2000 per well) were plated in 96 well plates. After overnight 
incubation, the routine medium was replaced with experimental medium with 
1% DHIDCCFCS only (control) or supplemented with doses of TAM (10"*2, 
lOdO, 10"^, 10"^ and 10"^ M). After 24, 48 and 72 hours proliferation was 
evaluated by MTT as described in "materials and methods" section 2.4.1. 
Results are expressed in percent of control value. *p < 0.001 and »p < 0.05. 
The experiments were performed in triplicate 8-96 wells. Results are mean ± 
SD.
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3.1.7 Discussion
Effect of Growth Factors on the Growth of MCF-7 and MDA-MB-231 
Breast Cancer Cell Lines
Breast cancer cell proliferation and differentiation are associated directly or 
indirectly with several growth factor families including the epidermal growth 
factor family (EOF), the fibroblast growth factor (FGF) family, insulin like 
growth factors (IGF) and transforming growth factors (3, TGF|3. The present 
study was undertaken to determine the effect of different doses of TGFa, EGF 
and TGFp on cell growth in hormone dependent and hormone insensitive 
epithelial cell system using both EHS and plastic.
TGFa, like EGF, is mitogenic for normal and malignant breast epithelial cells. 
The growth of MDA-MB-231 cells on EHS, slightly inhibited by TGFa at low 
doses. MDA cells were, otherwise, gently stimulated by higher doses of 
TGFa, irrespective of substratum. In this study TGFa was found to have a 
mitogenic influence on MCF-7 cells in culture, irrespective of the nature of 
substratum though lower doses may be more effective on EHS.
EGF treated MDA cells had an opposite effect of doses when grown on EPIS 
as compared to plastic. On EPIS, a low concentration of EGF was inhibitory. 
Gradual increase of EGF dosage however led to an increase in growth which 
reached a maximum of 17%. Maximum stimulation was observed on plastic at 
low concentrations whereas no significant effect, as compared to the control, 
was observed at higher EGF concentrations.
It had previously been observed that EGF at low or very high concentration 
had only minor effects on the growth of MDA-MB-231 cells on plastic. 
Murayama & Mishima (1995) have also confirmed the inhibitory action of 
high concentration of EGF on breast cancer, oesophageal and gastric cancer 
cells. Long & Rose (1996) have shown no effect of EGF on MDA-MB-231
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cell growth using the same range of concentrations as were used in our 
experiments. Further Veber Nelal also showed that under standard culture 
conditions MDA cells, which possess large amounts of EGFR on the cell 
surface, do not respond to EGF (Verber et al., 1994; Jarrard et al., 1994) 
Carruba et al., (1994) showed that EGF did not influence the growth of 
prostate epithelial carcinoma cell line PC3.
The growth response of MCF-7 to low concentrations of EGF was stimulatory 
both on EHS and plastic with the maximum stimulation being 1.6 fold on EHS 
(0.63 ng/ml) and 2 fold on plastic (at 1.89 ng/ml). This observation is keeping 
with (Cappelleti et a l, 1993) who reported a 1.6-1.8 fold increase in growth of 
MCF-7 cells on plastic although at an EGF concentration that was 5 times 
higher than that used here. Surprisingly exposure of MCF-7 cells to gradually 
higher doses of EGF (i.e. from 1.89 to 63 ng/ml, in three increments) led to a 
linear decrease in growth on plastic but had the opposite effect on EHS. In this 
experiment, there was no significant difference in the maximum stimulation in 
growth of MCF-7 cells by EGF whether they were grown on EHS or plastic.
Transforming growth factor P (TGFP) is a potent growth inhibitor for normal 
epithelial cells. Both ER positive and negative cells contain TGFP receptors 
and are growth inhibited by both TGFpl and TGFP 2 (Dickson et al., 1990). 
The escape of malignant transformed cells from regulation by TGFP may be 
an important stage in tumour development. The inhibitory effect of TGpp on 
the growth of MDA cell line, has been shown previously by other groups 
(Desruisseau et al., 1996). However, the effect of TGFp on cells grown on 
matrigel has not been studied. MDA cells grown on EHS displayed the classic 
inverse bell-shaped curve in response to treatment of TGFp after 24, 48, and 
72 hours. Maximum decrease was seen at 0.01 ng/ml at all three time points 
while higher concentrations did not appear to have much inhibitory effect on
Growth Response of Breast Cancer Celts to Steroid Hormones and Anti- 
Oestrogens
Steroid hormones play an important role in the control of growth and 
development of normal mammary gland and breast eancer progression. 
Therefore, the growth response of hormone receptor positive MCF-7 cell line 
to estradiol, progesterone and an anti-oestrogen tamoxifen was evaluated on 
both plastic and EHS. It is known that oestrogen stimulates the growth of 
oestrogen receptor positive breast cancer cells like MCF-7 and ZR75 
(Zajchowski et a l ,  1993) (Dickson et al., 1989). However, these early
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growth on EHS. On plastic, these cells underwent growth inhibition at high 
concentrations but no effect was observed at lower concentrations.
Unexpectedly, MCF-7 cells on the other hand, showed a dose-dependent 
inerease in growth on EHS over 24 hours which was much more pronounced g
with cells grown on plastic. The fact that TGFp stimulates growth of MCF-7 
cells is really surprising given the plethora of literature which indicates 
without exception that this molecule has an inhibitory role in cell proliferation 
(Ying & Zhang, 1996; Welch et al., 1990; Dickson et al., 1990). However, the 
TGFp preparations used were the same as those which growth inhibition in I
MDA cells and the sub-clone of MCF-7 used has given expected results in 
other conditions. Some recent studies have shown a cell-density and serum 
dependent sensitivity to TGFp in MATLyLu (Morton & Barrack, 1995). The 
authors have shown that at high density and in the presence of serum (0.5%), 
cell growth was insensitive to TGFP while in the absence of serum and low 
density, growth was inhibited in response to TGFp. The escape of inhibitory 
action of MCF-7 cells in réponse to TGFp may therefore be due to the 
presence of serum in the medium.
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observations were achieved on plastic only. In the current studies the effect of 
estradiol (E2) was observed on both kinds of substrata. The growth rate on the 
two surfaces were comparable. Oestrogen, as expected, showed stimulation in 
the proliferation of MCF-7 cells both on plastic and EHS. The dose response 
curve was similar on both the surfaces. On plastic, significant stimulation of 
about 1.6 fold was observed with 10"^M concentration, while the same dose 
showed about 1.25 fold stimulation on EHS indication of nearly 3 fold 
difference in response. Others e.g. (Cappelleti et al., 1993) have found an 
increase in proliferation of MCF-7 cells on plastic. Similarly, (Masamura et 
a i,  1995) have shown that wild type MCF-7 cells respond maximally to 10"  ^
M E2  ^ while Cappelleti et al. (1993) have observed a 1.5-fold increase in 
proliferation with 10"8 M E2- Progesterone also increased the growth rate of 
MCF-7 cells on both substrata. 10“^^  M progesterone gave maximum 
stimulation of about 1.7 and 1.3 fold after 48 hours on plastic and EHS, 
respectively.
TAM is known .to display both agonistic and antagonistic effects 
(Katzenellenbogen et al., 1995) and exert its agonistic effect through the 
oestrogen receptor (ER). Bliss has shown that the agonistic effect of TAM 
may be due to the ability of this anti-oestrogen to dimerize the oestrogen 
receptor necessary for gene transcription (Bliss et al., 1996). In our 
experiments, TAM showed a dose dependent stimulatory effect on MCF-7 
cells on both plastic and EHS. 10"  ^ and 10"  ^ M TAM gave the maximum 
growth between 1.7-1.65 fold on plastic and EHS, respectively. These results 
are corroborated by (Cabot et a l, 1995) and (Dickson et al., 1990) who have 
described an increase in proliferation with TAM. ( Gr o n d ah 1 - H an sen et a i ,  
1988) also have shown no inhibition of growth by anti-oestrogens. TAM has 
no growth effect on the MDA-MB-231 cells (data not shown).
■ 3 |
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3.1.8 Summary
In this chapter we have examined the effects of various growth factors and 
hormones on the two cell lines, MDA and MCF-7, plated on both EHS and 
plastic. The aforegoing results unequivocally demonstrate that the growth of 
cells in response to certain growth factors or hormones vary depending on the 
substratum. For instance, as discussed above, when MDA and MCF-7 cells 
were treated with EGF and TGFa, on either plastic or EHS, the pattern of 
proliferation was different. MCF-7 cells were more responsive to lower doses 
of growth factors on EHS. TGF(3 showed significant differences in the growth 
pattern, depending on the concentrations used, between the two substrata.
In contrast to growth factors, steroid hormones used in this study, had 
comparable effects on both plastic and EHS. It is clear therefore, from this and 
other examples, that the growth of a given cell line can either be enhanced or 
inhibited depending upon the surface on which it is grown. These results 
suggest that in addition to hormones and growth factors the surface is also a 
co-determinant of a cell line's potential for growth.
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3.2 PLASMINOGEN ACTIVATORS
3.2.1 Determination of uPA, PAI-1 and uPAR niRNA levels in MDA and 
MCF-7 cells exposed to various hormones and growth factors
In order to monitor the respective amounts of the uPA, PAl-1 and uPAR 
niRNA from MDA and MCF-7, cells treated with TG Fa or TGF(3, and EGF 
were then processed using reverse transcriptase polymerase chain reaction 
(RT-PCR) (Tables 2 & 3). Since it is technically very difficult to use this 
technique quantitatively, it has been used in this study as a qualitative 
yardstick for the presence or absence of a certain mRNA species. Total RNA 
was isolated from each of the cell lines which had been treated with various 
doses of hormones and growth factors and subsequently converted into cDNA. 
Primers specific for each of the three genes, as well as that for [3-actin, which 
was used as a positive control, were used in a PCR reaction and the products 
analysed on an agarose gel. It should be noted that the identity of all four PCR 
products was established by cloning and analysis of the recombinant clones by 
DNA sequencing (data not shown).
The MDA cell line has been well characterised by several groups and it has 
been shown to be highly invasive in vitro (Long & Rose, 1996). This is most 
likely due to the fact that it expresses all the components essential for 
invasiveness. RT-PCR analysis of total RNA obtained from untreated MDA 
cells showed that, in contrast to the MCF-7 cells, it contained some uPAR and 
larger amounts of uPA and PAI-1 mRNAs. Exposure of MDA cells to 1 ng/ml 
of EGF, TGFa or (3, had no net effect on the levels of uPA and PAl-1 mRNA 
relative to the control. Treatments with growth factors, however, increased the 
uPAR transcript as compared to the control (Fig. 27B).
In spite of numerous attempts no uPA, PAI and uPAR mRNA could be 
detected in the untreated MCF-7 cell line (Fig. 28A). The possibility that the
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three mRNAs were not found because of RNA degradation can be eliminated 
given that the mRNA for p-actin, which was used as a positive control, was 
detected successfully using this protocol. As a further control, PCR primers 
for p-actin failed to produce a band of the expected size for amplified genomic 
DNA when the purified RNA alone was used in a PCR reaction, suggesting 
that the purified RNA had not been contaminated with genomic DNA.
Upon exposure of MCF-7 cells to 1 ng/ml of TGFp, no uPA was found but 
PAI-1 and uPAR mRNA were found after 48 hours of incubation (Fig.28B). In 
EGF 1 ng/ml treated cells, no uPA mRNA could be found, as had been 
observed with the other growth factor. A considerable amounts of uPAR and 
PAI-1 was observed at 48 hours after EGF addition.
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Figure 27 The effect of growth factors on uPA, PAI-1 and nPAR 
transcripts in MDA-MB-231 cells at different time periods
MDA cells were treated with growth factors TGFa (1 ng/ml), EGF (10 ng/ml)
and TGFp (1 ng/ml) and were incubated for 48h. After exposure to these 
growth factors, RNA was extracted as described in the methods section 2.11. 
It was followed by RT-PCR using the primers specific for uPA, PAI-1 and
uPAR with the expected 460, 452 and 455 bps, respectively. P-actin was 560 
bps The PCR reaction employed 1 minute at 95 '^C, 1 minute at 50 ^C, and 1.5 
minute at 72 °C for 30 cycles. The products were electrophoresed on 1.5 % 
agarose gel and visualised with ethidium bromide under UV light. The results 
are representative of three different experiments using RNA from different 
extractions.
Figure A: Control Cells
Time period Lane numbers
24h 1,2, 3, 4
48h 5, 6, 7, 8
72h 9 ,10 ,11 ,12
Marker M
P-actin 4, 8, 12
Figure B: Treated Cells (48h)
Treatment Lane numbers
TGFp 1 ,2 ,3
EGF 5, 6, 7
TGFa 9,10,11
P-actin 4, 8, 12
The lanes in figures (A and B) represent transcripts in the following order:
uPA 1 ,5 ,9
PAl-1 2 ,6 ,1 0
uPAR 3,7 ,11
P-actin 4, 8, 12
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T a b le  2  T h e  e f f e c t  o f  g r o w t h  f a c t o r s  o n  m R N A  in  MDA-MB-231 c e lls
The effect of growth factors on mRNA in MDA-MB-231 cells are presented in 
+/- symbols. This table shows the qualitative determination of the message in 
MDA cells in response to growth factors (ng/ml), TGFp, EGF, TGFa, as 
compared to control. Results are the mean of three independent experiments.
Key to symbols: + =present, -t-+ = abundant
Doses uPA PAI-1 uPAR p-actin
48h 48h 48h 48h
control +-1- 4—f- 4- 4-
TGFp 1 ng/ml 4—h 4—H 4-4- 4-
EGF 10 ng/ml 4-4- -f-f 4-4- 4-
TG Fa 1 ng/ml 4-4- 4-4- + + 4-
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Figure 28 The effect of growth factors on uPA, PAI-1 and uPAR 
transcripts in MCF-7 cells at different time periods
MCF-7 cells were treated with growth factors EGF (lOng/ml) and TGFp (1 
ng/ml) and were incubated for48h. After exposure to these growth factors, 
RNA was extracted as described in the methods section 2.11. It was followed 
by RT-PCR using the primers specific for uPA, PAI-1 and uPAR with the 
expected 460, 452 and 455 bps, respectively. P-actin was 560 bps The PCR 
reaction employed 1 minute at 95 ^C, 1 minute at 50 °C, and 1.5 minute at 72 
^C for 30 cycles. The products were electrophoresed on 1.5 % agarose gel and 
visualised with ethidium bromide under UV light. The results are 
representative of three different experiments using RNA from different 
extractions.
Figure A: Control Cells
Time period Lane numbers
24h 1 ,2 ,3 ,4
48h 5, 6, 7, 8
72h 9, 10, 11, 12
Marker M
P-actin 4 ,8
Figure B: Treated Cells (48h)
Treatment Lane numbers
TGFp 1,2 ,3
EGF 5, 6, 7
P-actin 4 ,8
The lanes in figures (A and B) represent transcripts in the following order;
uPA 1 ,5 ,9
PAI-1 2 ,6 ,1 0
uPAR 3,7 ,11
p-actin 4, 8, 12
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Table 3 The effect of growth factors on mRNA in MCF-7 cells are presented 
in +/- symbols. This table shows the qualitative determination of the message 
in MCF-7 cells in response to growth factors (ng/ml), TGFp, EGF as 
compared to control. Results are the mean of three independent experiments.
Key to symbols: + =present, ++ = abundant
Doses uPA PAI-1 uPAR P-actin
48h 48h 48h 48h
control - - - +
TGPP 1 ng/ml - + +H” +
EGF 10 ng/ml - + ++ +
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3.3 Secreted and Cel! Associated Plasminogen A ctivator 
Levels
3.3.1 The effect of growth factors on secretion of uPA antigen by the 
MDA-MB-231 cell line
Transforming Growth Factor a  (TGFa)
After treating the cells with 1 ng/ml and 0.1 ng/ml TGFa on EHS and plastic, 
the amount of secreted uPA was measured in the conditioned medium (CM). 
On EFIS, uPA secretion was not altered by incubation of cells with high or low 
amounts of TGFa during all time points (Figs 29A, 30A).
On plastic, an initial increase of about 60-70% observed in uPA levels with 
both 0.1-1 ng/ml TGFa, (Fig 29B) subsequently reduced to control values or 
showed slight inhibition in uPA levels after 72 hours (Fig 30B).
Epidermal Growth Factor (EGF)
EGF is known to induce the expression of uPA in a culture system on plastic. 
To compare this with uPA secretion on EHS, MDA cells were exposed to 10 
ng/ml and 1 ng/ml of EGF. On EHS, uPA secretion remained lower than the 
control values, after treating the cells with high or low doses of EGF (Figs 
29A, 30A).
On plastic, EGF 1 ng/ml significantly increased uPA secretion up to 104% 
above control after 48 hours (Fig 29B). The same dose after 72 hours 
decreased the uPA levels. EGF treatment for longer time did not increase the 
amounts of uPA, instead uPA levels were reduced by 30% with 1 ng/ml EGF, 
as compared to control values (Fig 30B).
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Taken together the results suggest that the effects of TG Fa and EGF on 
secretion of uPA into the conditioned medium were similar on EHS and 
plastic; in that both did not effect the antigen amounts on EHS.and increased 
uPA levels after 48 hours on plastic. The nature of the substratum showed a 
small transient effect on the secreted uPA levels.
Transforming Growth Factor p (TGFP)
MDA cells were treated with TGpp at 1 ng/ml and 0.1 ng/ml. On EHS, a 
dramatic time and concentration dependent effect was observed when the cells 
were treated with this growth factor for 48 and 72 hours. TGFp I ng/ml 
significantly increased uPA levels by 330% after 48 hours and about 250% 
after 72 hours. (Figs 29A, 30A). The lower concentration of TGFp 0.1 ng/ml 
also increased uPA levels by about 105% after 48 and 72 hours (Figs 29A, 
30A).
On plastic, when incubated with 1 ng/ml or 0.1 ng/ml for 48 hours, uPA levels 
increased but still only above control values 58% and 86%, respectively (Fig. 
29B). TGFp did not increase the levels when the cells were treated for 72 
hours. The amounts of proteins secreted are shown in the tables 4 and 5.
Taken collectively the results suggest that, whereas on EHS TGFp increased 
uPA levels after 48 hours by a very large amount. Further incubation of 72 
hours decreased the levels significantly. On plastic, TGFP potentiates a small 
increase in uPA levels secreted into CM after 48 hours.
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Figure 29 The effect of growth factors on uPA secretion 
in MDA cells, on both EHS (A) and plastic (B).
T G F a(l and 0.1 ng/ml), TGFB (1 and 0.1 ng/ml) and EGF (10 and 
1 ng/ml) were used for 48h. uPA levels in the CM, in all experiments 
were assayed in duplicate using 4-span ELISA (see section 2.7.2). 
The average of three independent determinations ± SD is presented.
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Figure 30 The effect of growth factors on uPA secretion in 
MDA cells, on both EHS (A) and plastic (B), (%2 h')
TGFa (1 and 0.1 ng/ml), TGFB (1 and 0.1 ng/ml) and EGF (10 and I 
ng/ml) were used for 72h. uPA levels in the CM, in all experiments 
were assayed in duplicate using 4-span ELISA (see section 2.7.2). The 
average of three independent determinations ± SD is presented.
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Table 4 Secreted uPA protein in MDA-MB-231 cells on EHS.
The amounts of uPA protein was measured in the conditioned medium (CM), 
on EHS in MDA-MB-231 cell line. Values (ng/ml) represents the mean of 
three independent experiments and each experiment was carried out in 
duplicate.
Time Control
CM
TGFa 
1 ng/ml
EGF 
1 ng/ml
TGFB 
1 ng/ml
48h 10.4 8 9.1 45^
72h 16.6 14.4 12^ 58A
Table 5 Secreted uPA protein in MDA-MB-231 cells on plastic.
The amounts of uPA protein was measured in the conditioned medium (CM), 
on plastic in MDA cell line. Values (ng/ml) represent the mean of three 
independent experiments and each experiment was carried out in duplicate.
Time Control
CM
TGFa 
1 ng/ml
EGF 
1 ng/ml
TGFB 
1 ng/ml
48h 14 10 9.3 23.1
72h 11.5 11.4 18.1 2A8
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3.3,2 The effect of growth factors on cell associated iiPA antigen in
MDA-MB-231 cell line in cell extracts
uPA is active when bound to its receptor, uPAR on a cell membrane. To find 
the effects of growth factors on cell associated uPA levels, cells, after 
removing medium, were washed with PBS and treated with 1% Triton X-100. 
Cell extracts were prepared as described in method section 2.7.1. Cell 
supernatants (SN) were then measured for the amounts of uPA antigen in the 
presence of different concentrations of growth factors at different time points.
TGFa
On EHS, uPA levels remained unchanged after 48 hours when cells were 
exposed to both doses of TGFa (1 and 0.1 ng/ml) as compared to the control 
values (Fig 31 A)) whereas about 70% stimulation was observed with 0.1 
ng/ml after 72 hours (Fig 32A). The higher concentration of TGFa did not 
effect uPA levels at any time point. On plastic, uPA levels remained 
unchanged after 48 hours with TG Fa whereas a small increase, about 26% 
was observed with TGFa 1 ng/ml (Fig 3 IB).
Overall, MDA cells treated with 1 ng/ml or 0.1 ng/ml of TG Fa showed little 
change of uPA levels in cell supernatants at either concentration of growth 
factor.
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EGF
EGF, like TGFa, also stimulated uPA levels after longer incubation hours but 
to a greater extent. On EHS, a concentration and time dependent increase was 
observed after 48 and 72 hours. EGF 1 ng/ml and 10 ng/ml showed a gradual 
increase in uPA levels by 39% and 44% after 48 hours (Fig. 31 A). The 
increase (123%) was observed in the presence of 1 ng/ml EGF after 72 hours 
(Fig 32A).
On plastic, MDA cells in the presence of EGF 10 ng/ml and 1 ng/ml increased 
uPA levels in cell extracts to 85% and 140% after 72 hours, respectively (Fig 
32B). uPA levels remained below the control values in the presence of the 
same concentrations after 48 hours.
Conclusions
The general effect of EGF, on the levels of uPA antigen, was stimulatory on 
both the surfaces. However, different time periods were observed for the 
mediation of induction of uPA. Although an early uPA induction was 
observed on EHS, a longer time was required by EGF to induce the cell 
associated uPA on plastic.
It is interesting to note that on EHS lower doses of both TG Fa (0.1 ng/ml) 
EGF (1 ng/ml) inhibited cellular proliferation, but at the same time increased 
the amount of uPA.
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TGFp
TGFp increased both secreted and cell associated uPA levels quite 
significantly. On EHS, cell associated uPA showed time and concentration 
dependent stimulation. MDA cells in the presence of 1 ng/ml TGFp showed 
significant stimulation by 151% after 48 hours (Fig 31 A). This increase 
remained the same after 72 hours (Fig 32A). On the other hand, treatment of 
cells with 0.1 ng/ml TGFP showed a little increase in uPA levels by 36% after 
48 hours.
On plastic, MDA cells when incubated with 1 ng/ml and 0.1 ng/ml TGFP 
showed significant increase in uPA levels with the greater stimulation at the 
lower concentration. 0.1 ng/ml TGpp increased uPA levels by 90% after 48 
hours (Fig 3 IB). The antigen levels were subsequently increased much 
significantly to 360% after 72 hours incubation (Fig 32B).
Conclusions
The aforementioned results suggest that TGFp modulates uPA levels in cell 
extracts according to the nature of the substratum. On EHS, the low dose 
could only marginally increase uPA antigen but the high dose gave large 
increase in cell associated uPA levels. On plastic, the lower dose was quite 
enough to stimulate uPA levels very significantly.
This observation shows that lower concentrations of TGFp remained either 
inert or slightly inhibited the growth on plastic, whereas lower doses of TGpp 
increased uPA levels significantly. This may be due to the fact that TGFp may 
follow a different pathway to stimulate uPA levels than proliferation.
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Figure 31 The effect of growth factors on uPA in cell 
cytosol (SN) in MDA cells, on both EHS (A) and plastic 
(B). (^S Ufs)
TGFa (1 and 0.1 ng/ml), TGFB (1 and 0.1 ng/ml) and EGF (10 and 1 
ng/ml) were used for 48h. uPA levels in the SN, in all experiments 
were assayed in duplicate using 4-span ELISA (see section 2.7.2). The 
average of thr ee independent determinations + SD is presented.
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Figure 32 The effect of growth factors on uPA in cell cytosol (SN) in MDA cells, on both EHS (A) and plastic
(B). ( 1 2  t )
TGFa (1 and 0.1 ng/ml), TGFB (1 and 0.1 ng/ml) and EGF (10 and 1 
ng/ml) were used for 72h. uPA levels in the SN, in all experiments were 
assayed in duplicate using 4-span ELISA (see section 2.7.2). The 
average of three independent determinations ± SD is presented.
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Table 6 uPA protein in cell cytosol in MDA cells on EHS.
The amounts of uPA protein was measured in the cell cytosol (SN), on EHS in 
MDA-MB-231 cell line. Values (ng/mg protein) represents the mean of three 
independent experiments and each experiment was carried out in duplicate.
Time Control
SN
TGFa 
1 ng/ml
EGF 
1 ng/ml
TGFB 
1 ng/ml
48h 13 14.4 18.1 327
72h 21.7 40.4 48^ 54.4
Table 7 uPA protein in cell cytosol in MDA cells on plastic.
The amounts of uFA protein was measured in the cell cytosol (SN), on plastic 
in MDA-MB-231 cell line. Values (ng/mg protein) represents the mean of 
three independent experiments and each experiment was carried out in 
duplicate.
Time Control
SN
TGFa 
1 ng/ml
EGF 
1 ng/ml
TGFB 
1 ng/ml
48h 2T3 15.4 18 21.1
72h 14.4 16.9 3A6 3&8
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3.3.3 The effect of growth factors on secretion of PAI-1 antigen in MDA-
MB-231 cell line
uPA may be regulated by many inhibitors, but the most established inhibitor is 
the plasminogen activator inhibitor type-1 (PAT-1 ) (see introduction section 
1.13.1). Therefore, it was also important to measure this inhibitor in response 
to various growth factors.
Transforming growth factor a  (TGFa)
MDA cells grown on EHS revealed that both doses of TG Fa ( 1 and 0.1 ng/ml) 
showed no significant alteration of secreted PAI-1 levels at any time points 
(Figs 33A, 34A). When the same experiment was carried out on plastic, PAI- 
1 levels were stimulated by about 30% after 48 hours and 67% after 72 hours 
with 0.1 ng/ml TGFa (Figs 33B, 34B).
TGFa did not alter the secreted PAI-1 levels on EHS but did increase the 
levels on plastic.
Epidermal growth factor (EGF)
PAI-1 levels were also measured in the MDA cells in response to 10 ng/ml 
and 1 ng/ml EGF. On EHS, cells exposed to EGF, showed no stimulation of 
secreted PAI-1 after 48 hours, (Fig 33A) and the levels actually dropped after 
72 hours with the 1 ng/m l. On plastic, the high dose of EGF 10 ng/ml slightly 
increased PAI-1 levels by 18% after 48 hours (Fig 33B). No significant effect 
was observed at further time point.
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The results suggest that EGF, like TGFa, did not have significant effect on 
secreted PAI-1 levels, on both EHS and plastic.
Transforming growth factor P (TGFp)
Experiments were designed to determine whether ceils cultured on plastic or 
EHS altered the sensitivity. MDA cells were exposed to 1 ng/ml and 0.1 ng/ml 
TGFp. On EHS, the high dose of TGFP showed a dramatic increase in PAI-1 
levels by 379% (Fig 33A) after 48 hours. Susequently the levels were reduced 
to 105% after 72 hours (Fig 34A). Lower amounts of TGFp also significantly 
increased the secretion of PALI levels, although to lesser extent by 123% after 
48 hours. On plastic, TGFp 1 ng/ml showed an increase in PAI-1 levels by 
147% (Fig 34B) and 123% with TGFP 0.1 ng/ml, after 48 hours. This was 
followed by a subsequent reduction in PAI-1 levels after 72 hours.
The foregoing results showed that the secretion of PAI-1 levels into the 
conditioned medium in response to TGFP was concentration and time 
dependent on both plastic and EHS. On EHS, the high dose stimulated the 
secretion much more significantly than the lower dose. The extent of secretion 
was higher on EHS than on plastic. The secretion of PALI levels was reduced 
with longer incubation time.
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Figure 33 The effect of growth factors on PAI~1 secretion in 
conditioned medium (CM) in MDA cells, on both EHS (A) 
and plastic (B). (j^B k)
TGFa (1 and 0.1 ng/ml), TGFP (1 and 0.1 ng/ml) and EGF (10 and i 
ng/ml) were used for 48h. PAI-1 levels in the CM, in all experiments were 
assayed in duplicate using 4-span ELISA (see section 2.7.2). The average 
of three independent determinations ± SD is presented.
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Figure 34 The effect of growth factors on PAI-1 secretion in 
conditioned medium (CM) in MDA cells, on both EHS (A) and 
plastic (B). ( j2 .  !v)
TGFa (1 and 0.1 ng/ml), TGFB (1 and 0.1 ng/ml) and EGF (10 and 1 
ng/ml) were used for 72h. PAI-1 levels in the CM, in all experiments were 
assayed in duplicate using 4-span ELISA (see section 2.7.2). The average of 
three independent determinations ± SD is presented.
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Table 8 Secreted PAI-1 in MDA cells on EHS.
The amounts of PAI-1 protein measured in the conditioned medium (CM), on 
EHS in MDA-MB-231 cell line. Values (ng/ml) represents the mean of three 
independent experiments and each experiment was carried out in duplicate.
Time Control
CM
TGFa 
1 ng/ml
EGF 
1 ng/ml
TGFB 
I ng/ml
48h 135.4 9&9 95^ 64T6
72h 29T8 216.5 145.7 604.9
Table 9 Secreted PAI-1 in MDA cells on plastic.
The amounts of PAI-1 protein measured in the conditioned medium (CM), on 
plastic in MDA-MB-231 cell line. Values (ng/ml) represents the mean of three 
independent experiments and each experiment was carried out in duplicate.
Time Control
CM
TGFa 
1 ng/ml
EGF 
I ng/ml
TGFB 
1 ng/ml
48h 363 385 236 602
72h 399 424 558 459
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3.3.4 The effect of growth factors on ceil associated PAI-1 antigen in
MDA-MB-231 cell line in cell extracts
PAI-1 has been shown to bind to the uPA/uPAR complex which is then 
internalised and degraded. Therefore, PAI-1 complexed to membrane bound 
uPA was measured in ceil extracts in response to various growth factors.
T G F a
MDA cells when exposed to 1 ng/ml and 0.1 ng/ml showed a time dependent 
increase of cell associated PAI-1 antigen. On EHS, though a slight increase of 
10% was observed after 48 hours in the presence of 0.1 ng/ml. The same dose 
significantly stimulated PAI-1 levels by 91% after 72 hours (Fig 36A).
On plastic, however the effect of TGFa was inhibitory over the time period. 
Both, TGFa 0.1 and 1.0 ng/ml slightly inhibited the growth after 48h. At 72h. 
TGFa reduced PAI-1 levels by about 40-50% (Fig 36B).
The overall effect of TG Fa on PAI-1 levels was very different on both the 
substrata i.e. stimulatory on EHS and inhibitory on plastic. This stimulation 
was time dependent which increased with time.
EGF
On EHS, EGF showed increased PAI-1 levels by 46% and 41% when the cells 
were treated with 10 ng/ml and 1 ng/ml after 48 hours (Fig 35A) and by 132% 
in the presence of 0.1 ng/ml EGF after 72 hours (compared with stimulation of 
91% by 0.1 ng/ml TGFa).
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The effect of EGF, like TGFa, was also inhibitory on plastic. Incubation with 
either 10 or 1 ng/ml reduced PAI-1 levels by about 10%. Further incubation 
over a time period of 72 hours, reduced the PAI-1 levels by about 30-50% (Fig 
36B).
Conclusions
The overall effects of TGFa and EGF showed how selection of substratum is 
critical to establish the physiological role of these growth factors In vitro.
TGFP
The effects of TGFp on PAI-1 levels in the cell extracts were as dramatic as 
they were in conditioned medium. On EHS, TGFp 1 ng/ml, was more 
effective in increasing PAI-1 by 180% after 48 hours (Fig 35A) in contrast to 
plastic. This level was more or less maintained after 72 hours in the presence 
of the same dose. TGFp at 0.1 ng/ml slightly increased PAI-1 levels by 38% 
after 48 hours.
On plastic, MDA cells showed a dramatic increase of about 260% in PAl-1 
levels with a low dose of 0.1 ng/ml after 48 hours (Fig 35B), whereas only 
34% increase was observed after 72 hours (Fig 36B). At higher concentration 
of TGFP 1 ng/ml, antigen levels after 48 hours were only 20% above control 
which was further reduced after 72 hours.
P la sm in o g e n  activ a to r  resu lts 166
Conclusions
Considering the overall effect of TGFp on PAI-1 levels in cell extracts of 
MDA cell line, the results suggest that much greater PAI-1 levels were 
observed on plastic with TGpp 0.1 ng/ml as compared to EHS. General effect 
of TGFP observed on both the substrata, was the induction of PAI-1 levels, 
though different concentrations were required for the inductions.
Iou
a
P la sm in o g e n  a c liv a to r  resu lts  167
3 0 0
2 0 0
00
bd
-f-
i
A: EHS
1
Z7
control T a I T a . l  TP 1 Tp. l  EGFIO EGF 1
(3OU
"o
Ph
'S
a
4 0 0 - /
3 0 0
2 0 0 -
1 0 0
-f-
...21
1 r
control T a l  T a . l
i
B: Plastic
X,
ZI
xp 1 x p . l  EGFIO EGF 1
Figure 35 The effects of growth factors on PAI-1 in cell ^cytosol (SN) in MDA cells, on both EHS (A) and plastic k)
TGFa (1 and 0.1 ng/ml), TGFB (1 and 0.1 ng/ml) and EGF (10 and 1 
ng/ml) were used for 48h. PAI-1 levels in the SN, in all experiments were 
assayed in duplicate using 4-span ELISA (see section 2.7.2). The average of 
three independent determinations ± SD is presented.
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Figure 36 The effect of growth factors on PAI-1 in cell .
cytosol (SN) in MDA cells, on both EHS (A) and plastic (B). (t2.k)
XGFa (1 and 0.1 ng/ml), XGFB (1 and 0.1 ng/ml) and EGF (10 and 1 
ng/ml) were used for 72h. PAI-1 levels in the SN, in all experiments were 
assayed in duplicate using 4-span ELISA (see section 2.7.2). Xhe average of 
three independent determinations ± SD is presented.
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Table 10 PAI-1 Protein in SN in MDA cells on EHS.
The amounts of PAI-1 protein measured in the cell cytosol (SN), on EHS in 
MDA-MB-231 cell line. Values (ng/mg protein) represents the mean of three 
independent experiments and each experiment was carried out in duplicate.
Time Control
SN
TGFa 
1 ng/ml
EGF 
1 ng/ml
TGFB 
1 ng/ml
48h 51 50.4 72.1 13T7
72h 86.7 90.7 201.6 227^
Table 11 PAI-1 Protein in SN in MDA cells on plastic.
The amounts of PAI-1 protein measured in the cell cytosol (SN), on plastic in 
MDA-MB-231 cell line. Values (ng/mg protein) represents the mean of three 
independent experiments and each experiment was carried out in duplicate.
Time Control TGFa EGF TGFB
SN 1 ng/ml 1 ng/ml 1 ng/ml
48h 265 182 249.1 319
72h 583 213 29E6 380
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3.3.5 Dose response curve of TGFp on uPA levels
Effect of different doses of TGFP on secretion of uPA into the culture 
medium and on the cell associated uPA levels
It has been observed in the previous experiments that the MDA-MB-231 cell 
line when exposed to 1 ng/ml and 0.1 ng/ml TGFp showed an enormous 
increase in the levels of uPA antigen both on plastic and EHS but with 
different dose dependence. An experiment was performed to determine the 
dose response to TGFP over a range of doses, 0.01, 0.1, 0.3 and 1 ng/ml.
Dose response of TGFp on secreted uPA levels in conditioned medium:
A time course experiment was performed with varying amounts of TGpp 0.01 
to 1 ng/ml. MDA cells when incubated with these doses showed a 
concentration dependent increase in uPA levels. The most significant increase 
of over 300% was observed in the presence of 1 ng/ml TGFP after 48 hours. 
Lower doses gave the expected smaller stimulation (Fig 37A). uPA levels 
significantly dropped after 72 hours.
Dose response of TGFP on uPA levels in the cell extracts:
Cell lysates were prepared as described in method (2.7.1) and uPA levels were 
measured in the presence of different doses of TGFp 0.01-1 ng/ml for 48 and 
72 hours. It was observed that uPA amounts varied with TGFp concentrations 
and also with length of time. As the concentration increased from 0.01-1 
ng/ml, uPA levels increased to about 100% above control, after 48 hours. 
After further incubation the level of stimulation was reduced although the 
antigen levels retained a dose response curve (Fig 37B). Taken together the 
results suggest that TGFP maintained uPA levels in the conditioned medium 
and cell extracts in a concentration dependent manner.
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Figure 37 Dose response of TGFP on the amounts of 
uPA in MDA cells in conditioned medium (A) and cell 
cytosol (B)
uPA protein in response to different doses of TGFB (ng/ml) 
were assayed for different time points, by ELISA in duplicates. 
The average of thiee independent detenninations + is presented.
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3.3.6 Dose response curve of TGFp on PAI-1 levels
TGFp increased PAI-1 levels, even more than uPA levels, in MDA-MB-231 
cell line in the presence of 1 ng/ml and 0.1 ng/ml. Therefore cells were 
exposed to different concentrations (0.1, 0.1, 0.3 and 1.0 ng/ml) of TGpp to 
determine dose response at different time points.
Dose response of TGFp on secreted PAI-1 levels in conditioned medium;
MDA cells were incubated with different doses of TGFp ranged from 0.01-1 
ng/ml. As the concentration of TGFP increased PAI-1 levels increased 
correspondingly. The most remarkable stimulation 350% was observed in the 
presence of 1 ng/ml TGFp (Fig 38A). The lowest concentration 0.01 ng/ml 
also showed increased PAI-1 levels by 50%. The levels of stimulation reduced 
significantly after 72 hours.
Dose response of TGFp on PAI-1 levels in cell extracts:
TGFp increased PAI-1 levels in the cell extracts of MDA cells when exposed 
to 0.01-1 ng/ml TGFp amounts. Maximum increased levels of PAI-1 (125%) 
were observed with 1 ng/ml after 48 hour (Fig 38B). The levels of PAI-1 fell 
after 72 hours, though not significantly.
These results suggest that exposure of cells to increasing concentrations of 
TGFp causes a linear increase in the relative amounts of uPA and PAI-1 (i.e., 
the higher the concentraton of TBpp, the higher the levels of uPA and PAI-1) 
The extent of stimulation was similar for both uPA and PAI-1.
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3.3.7 The effect of Growth factors and hormones on PAI-1 antigen 
secretion into conditioned medium by the MCF-7 cell line
TGFa
A time course experiment was performed with MCF-7 cells in the presence of 
1 ng/ml and 0.1 ng/ml TGFa. Both concentrations of TGFa increased PAI-1 
levels after 72 hours (Fig 39A).
EGF
A time and concentration dependent increase was observed in the presence of 
10 ng/ml and 1 ng/ml EGF. Both doses increased PAI-1 levels after 48 hours 
which were substantially increased (17 fold) after 72 hours (Fig 39A).
TGFp
MCF-7 cells when treated with TGFP at 1 ng/ml and 0.1 ng/ml, showed a 
remarkable increase over a time period 48 and 72 hours. Maximum 
stimulation of about 19 fold was observed in the presence of I ng/ml TGFP 
after 72 hours (Fig 39A). The effect of 0.1 ng/ml TGFp could only increase 
the PAI-1 levels to about 5 fold.
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Oestradiol
MCF-7 cell line is oestrogen receptor positive and therefore various steroid 
hormones were used to check their effects on the PAI-1 secretion into the 
medium. Cells were incubated with iO"^M and 10"'^M  E2. Neither 
concentrations of E2 stimulated any PAI-1 into the medium after 48 hours. 
High concentrations of estradiol (lO'^M) did increase the antigen levels by 
about 3 times as compared to control values, after 72 hours (Fig 39B). The 
lower concentration remained ineffective.
Progesterone
MCF-7 cells when exposed to 10"^M and 10“'^M showed an increase of PAI- 
1 levels The hormone only slightly increased PAI-1 antigen after 48 hours 
with 10"^M. This increase remained high after 72 hours with 10"^^M (Fig 
39By
Tamoxifen
Tamoxifen is an anti-oestrogen and is used as a first line endocine therapy for 
breast cancer patients. To find its effect on the secretion of PAI-1 levels into 
the conditioned medium, the drug was incubated at a concentration of 10"^M 
and lO'^^M. Both doses increased the antigen levels in a concentration and 
time dependent manner (Fig39B).
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Figure 39 Effect of growth factors (ng/ml) (A) and steroid hormones (Molar conc.) (B) on PAI-1 levels in conditioned medium (CM) by MCF-7 cells.
Total PAI-1 in the CM of MCF-7 cells was determined by ELISA. The samples were collected for 48 and 72 hours. The results (mean±SD) are for three separate experiments.
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3.3.8 The effect of growth factors and hormones on PAI-1 antigen levels
in cell cytosols of MCF-7 cells
TGFa
This molecule has been known to have a mitogenic affect on various cell lines. 
When used at a concentration of I, 10 and 100 ng/ml it stimulated cell growth. 
The results of its effects on PAI-1 levels in the MCF-7 cell line are depicted in 
Fig 40A. It should be noted that a time and concentration dependent increase 
was observed when MCF-7 cells were incubated with TG Fa (1 and 0.1 
ng/ml). Maximum increase of 7.5 fold was observed after 72 hours.
EGF
EGF 10 and 1 ng/ml concentrations were used in the study to determine its 
effects on PAI-1 levels in MCF-7 cell cytosols. The higher dose of EGF 
increased PAI-1 levels by about 4 fold which remained high 5 fold, after 72h 
(Fig 40A). Lower dose remained ineffective.
TGFp
As with other growth factors, TGFp also increased the PAI-1 levels. The 
higher dose 1 ng/ml increased PAI-1 levels by about 4 folds after 48h whereas 
TGFp 0.1 ng/ml increased PAI-1 levels by about 17.5 folds (Fig 40B).
Steroid Hormones
The effects of lower concentrations of hormones E2, Pg remained ineffective 
over a time period of 48-72h. The only significant increases of 4.5 and 3.5 
fold, respectively, were observed with E2 (lO'^M) and TAM (lO'^^M) after 
72h, respectively (Fig 40B)
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Figure 40 Effect of growth factors (ng/ml) (A) and steroid 
hormones (Molar conc.) (B) on PAI-1 levels in cell 
cytosol (SN) by MCF-7 cells.
Total PAI-1 in the SN of MCF-7 cells was determined by ELISA. The 
samples were collected for 48 and 72 hours. The results (mean±SD) are 
for three separate experiments.
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3.3,9 Analysis of uPA and PAI-1 Levels in the MDA and MCF-7 Cell 
Lines by W estern Blotting
In order to determine the presence of uPA and PAI-1 and to find its apparent 
molecular weight, a Western blotting was carried out. Extracts from both the 
normal and hormone/growth factor treated MDA and MCF-7 cell lines were 
prepared, eiectrophoresed on a 10% SDS-PAGE, electroblotted onto a 
membrane and subsequently probed with the mouse anti-uPA (Fig 41) and 
PAI-1 mAb (Fig 42). Surprisingly but consistent with the ELISA results, no 
detectable uPA was found in the control and treated MCF-7 cells. However, 
PAI-1 protein was detected in both MCF-7 and MDA cells, both in control and 
TGFp treated cells (Fig 42). In the control MDA cells, uPA was detected as a 
single band of about 55 kDa. The amount of this protein increased about 3- 
fold in the cell cytosol when the cells were exposed to TGFP ( 1 and 0.1 ng/ml) 
and EGF 1 ng/ml (compare lanes 2, 3 and 4 to lane 1). The same cells with 
TGFp showed uPA antigen in the conditioned medium also (compare lane 6 
and 7 and 8 to control lane 5) However, TGFp treated MCF-7 cells showed no 
uPA (lane 10) as compared to control cells (lane 9) (Fig 41 A). To ensure that 
equal amount of protein was loaded in all the lanes a separate gel containing 
the same amount of protein as was used in the gel which was electroblotted 
was run and subsequently stained with silver. This showed that the relative 
increase or decrease in uPA levels is real, since all lanes contained 
approximately equal amounts of the samples (Fig 4 IB).
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Figure 41 Immunological identification of uPA protein in MDA-MB-231 
and MCF-7 cells
Control and growth factor treated MDA and MCF-7 cells were collected after 
48h. The cell extract prepared was resuspended in Laemmli buffer. The 
samples were then separated by 10% (w/v) SDS-PAGE and transferred to 
Hybond C membrane. ECL detection of the protein was performed with uPA 
mAb (1/50 dilution) as described in materials and methods (section 2.6). 
Silver staining was performed on the same samples run separately on 10% 
SDS-PAGE to show equal loading (Fig B). Both CM and SN were analysed 
for MDA cell line. Only CM was tested for MCF-7 cells.
Blot A: The lane numbers correspond to the following in MDA cells
Control TGFP 1 ng/ml TGFp 0.1 ng/ml EGF 1 ng/ml
1,5 2 ,6  3 ,7 4 ,8
MCF-7 lane numbers
Lane 9 is control and lane 10 is TGFp 1 ng/ml.
uPA
CM CM
u p  - 5 8 k D
3 4 5 6 7 8  9 10
l«o
B
1 2 3 4 5 6 7 8 9  10
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Figure 42 Immunological identification of PAI-1 in MDA-MB-231 and
MCF-7 cells
Control and growth factor treated MDA and MCF-7 cells were collected after 
48h. The cell extract prepared was resuspended in Laemmli buffer. The 
samples were then separated by 10% (w/v) SDS-PAGE and transferred to 
Hybond C membrane. ECL detection of the protein was performed with anti- 
PAI-1 mAb (1/200 dilution) as described in materials and methods (section 
2.6). All the samples were treated with TGFp 1 ng/ml.
Blot A; The lane numbers correspond to the following in MDA cells.
Lane 1, marker; lane 2 and 7, control; lane 3 and 6, CM; lane 4 and 5, SN.
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3.3.10 Regulation of uPA Enzyme Activity
Effect of growth factors on the activity of uPA in conditioned medium 
(CM) and cell cytosols (SN) of MDA-MB-231 cell line on both EHS and 
plastic
uPA directed invasion and metastasis depend on the presence of active uPA in 
the system although uPA is initially secreted as an inactive form. uPA activity 
in response to various growth factors was analysed by using a chromogenic 
substrate specific for uPA as described in the method (2.8). A time course 
experiment was carried with different amounts of growth factors on both EHS 
and plastic.
TGFa
MDA cells were treated with TGFa 1 ng/ml and 0.1 ng/ml, as in ELISA, to 
find its effeet on the activity of uPA over a length of 48 and 72 hours. On EHS 
TG Fa showed no increase in uPA activity in conditioned medium (CM) (Fig 
43A) whereas in the cell extract (SN) uPA activity increased significantly by 
about 40% after 72 hours, with TGFa 1 ng/ml (Fig 44A). On plastic, TGFa 
showed no effect on the uPA activity levels either in CM (Fig 43B) or SN 
(Fig 44B).
EGF
The effect of EGF on uPA activity on both EHS and plastic was observed. 
When uPA activity was analyzed in the CM of MDA cells, an increased 
activity levels of 10% were obtained with EGF 10 ng/ml after 72hours (Fig 
43A). In the cell extracts also initially EGF 10 ng/ml showed increased uPA 
activity after 48 hours (35%) which was subsequently increased by about 50% 
(Fig 44A).
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On plastic, initially EGF showed no effect on the uPA activity levels either in 
CM or SN. After 72 hours incubation a higher dose (lOng/ml) showed a 
marginal increase of 10% in CM and about 50% in SN. EGF 1 ng/ml also 
stimulated uPA activity after 72 hours by 65% (Fig 44B).
TGFP
The dramatic increase in the uPA activity was obtained with TGFp I ng/ml 
and 0.1 ng/ml in a time dependent manner. On EHS, TGpp both doses 
inhibited the activity levels by about 50% in CM. When CM on plastic was 
analyzed in the presence of 1 ng/ml TGFp, a huge amount of active uPA was 
observed. This stimulation was 280% as compared to the control values (Fig 
43B)) after 48 hours. This increase was further enhanced to 320% during the 
course of 72 hours. TGpp 0.1 ng/ml initially showed a significant increase of 
uPA activity by 135% after 48 hours(Fig 43B). This increase in the active 
uPA remained the same after 72 hours.
In cell extracts the levels of active uPA on EHS, were higher as compared to 
the levels in the CM. TGFp 1 and 0.1 ng/ml showed an increase of (45-55%) 
in uPA activity on EHS. Whereas, on plastic a remarkable increase in uPA 
activity by 280% was observed at both time points in the presence of TGFP 
(45-55%) 1 ng/ml (Fig 44B). TGFp at 0.1 ng/ml also showed stimulation, 
though to a lesser extent, showing an increase of 150% after 48 hours which 
was further enhanced to 180% after 72 hours (Fig 44B).
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Figure 43 uPA enzyme activity in conditioned medium (CM) 
on EHS (A) and plastic (B) in MDA cells in réponse to 
different doses of growth factors at different time points.
Effects of TGFB (1 and 0.1 ng/ml),TGFa ( I and 0.1 ng/ml) and EGF (10 
and 1 ng/ml) on the levels of uPA in CM is shown as percentage of control. 
Activity was measured by using S-2224 in duplicates in all the samples. The 
results (mean + SD) are for tlmee seperate experiments.
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Figure 44 uPA enzyme activity in cell cytosols (SN) on EHS 
(A) and plastic (B) in MDA cells in réponse to different doses 
of growth factors at different time points.
Effects of TGFB (1 and 0.1 ng/ml),TGFa (1 and 0.1 ng/ml) and EGF (10 
and 1 ng/ml) on the levels of uPA in SN is shown as percentage of control. 
Activity was measured by using S-2224 in duplicates in all the samples. The 
results (mean + SD) are for three seperate experiments.
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3.3.11 Discussion
Effect of Growth Factors on the Expression of Plasminogen Activators 
and Plasminogen Activator Inhibitor in Human Breast Cancer Cells
The rate of protease and inhibitor secretion by MCF-7 and MDA-MB-231 cell 
lines, under various treatments and at different time points were investigated. 
The levels of plasminogen activators and their inhibitors were initially 
determined by western blotting and then later on quantified by enzyme-linked- 
immunosorbent assays (ELISAs).
Using the techniques described herein, although ample uPA was found in the 
MDA cells, surprisingly no uPA could be detected in the MCF-7 cells. In 
contrast, PAI-1 was found in both cell lines.
Effect of TGFa and EGF on uPA and PAI-1 protein levels
When cells were grown on EHS, TGFa initially decreased the levels of both 
secreted and cell associated uPA and PAI-1. However, after 3 days both uPA 
and PAI-1 levels were increased in cell extracts with lower dose of TG Fa i.e. 
0.1 ng/ml.
The effect of TGFa on plastic was different to that on EHS, in that TGFa 
initially increased the secreted forms of both uPA and PAI-1 levels in CM 
while the cell associated levels of uPA and PAI-1 levels were inhibited in cell 
extracts.
The effect of EGF on the secretion of uPA and PAI-1 followed the same 
pattern as TGFa. EGF also had no detectable effect on uPA and PAI-1 levels 
in CM on EHS, but both uPA and PAI-1 levels were increased by about 40- 
46% after 48 hours, on EHS. It was interesting to note that unlike TGFa, after
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72 hours uPA and PAI-1 levels increased by nearly 130% in the cell extract, 
with EGF 1 ng/ml. On plastic however the general trend of increase in uPA 
and PAI-1 levels was only 30-40% in the presence of various doses of EGF.
In MDA cells higher concentrations of EGF and TGFa stimulated the growth 
of rate whereas the same growth factors did not alter the plasminogen activator 
and inhibitor levels significantly. It may be that EGF and TGFa follows 
different a different pathway to influence proliferation and/or plasminogen 
activaor levels.
In MCF-7 cells, TGFa and EGF increased the PAI-1 levels in a concentration 
and time dependent manner. Higher concentrations increased PAI-1 levels in 
CM whereas in cell extracts the same dose was not much more effective as 
compared with the lower dose. Maximum stimulation (7.5 fold) was achieved 
with TG Fa 0.1 ng/ml. Like TGFa, EGF also increased both secreted and cell 
associated PAI-1 levels and the extent of stimulation was more in CM about 8 
fold with highest dose 10 ng/ml. However the absolute levels remained very 
low in this cell line.
In MCF-7 cells, increased growth rate and also increased PAI-1 secretion was 
observed in the presence of higher doses of TGFa and EGF
Effect of TGF(31 on uPA and PAI-1 Protein Levels
The levels of uPA in MDA cells were significantly elevated in response to 
transforming growth factor (3 (TGF(3) on EHS and plastic, in both the 
conditioned medium (CM) and in cell cytosol (SN). The increased levels of 
uPA and PAI-1 in response to TGF(3 were time and dose dependent. The doses 
required for the stimulation on both the surfaces were different. For instance, 
on EHS high dose 1.0 ng/ml TGF(3 increased the uPA levels to maximum
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whereas on plastic, the lower dose was more effective in increasing the antigen 
levels. The amount of stimulation observed also varied in CM and SN on the 
same surface. On EHS, TGFp at 1 ng/ml gave maximum stimulation of uPA 
by 330% in CM which decreased with time, whereas the increase in cell 
extracts was only 150-160% in response to the same dose. The effect of TGFP 
on cells grown on plastic was dose dependent. Lower doses of TGFp, i.e. 0.1 
ng/ml, did not have any effect on uPA levels in the CM after 72 hours but 
increased the amount of uPA by 360% in cell extracts after 72 hours. There is 
no obvious explanation for this contrast. The only reason may be that EHS is 
more a physiological substratum than plastic and therefore the cell interactions 
with extracellular matrix modulates the functions of the ceils, thereby 
requiring higher doses for the maximum stimulation. However, it is interesting 
to note the remarkable contrasting differences in the secreted and cytosolic 
amounts of uPA in cells grown on plastic and EHS in response to TGFp.
This stimulatory effect of TGFp on PAI-1 levels was even more pronounced 
on both EHS and plastic. TGFp at 1 ng/ml increased PAl-1 levels after 24 
hours by 415% and about 300% in the CM on both EHS and plastic as 
compared to the untreated cells, respectively. After 48 and 72 hours the 
amount of PAI-1, however, gradually decreased substantially on both 
substrata. At ten-fold lower concentration TGpp, increased PAI-1 levels in the 
CM by 136% after 24 hours on EHS. On plastic the increase in PAI-1 levels 
was initially 226% after 24 hours but later dropped off after 48 and 72 hours.
In the cytosol, 1 ng/ml increased PAI-1 by 186% on EHS, while on plastic the 
increase was 198% after 24 hours. On both substrata a decrease in the amount 
of PAI-1 was noted although this decrease was more substantial on plastic. At 
lower doses (0.1 ng/ml) TGFp increased PAI-1 by a modest 38% on EHS
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while it dramatically increased PAI-1 levels by 414% on plastic after 24 hours. 
After 48 hours, the PAI-1 levels decreased substantially.
The overall effect of TGpp was stimulatory on uPA and PAI-1 levels, both on 
EI-IS and plastic. The effect was more dramatic on PAI-1 levels in the CM of 
EHS. The same effect was maintained in SN on plastic. The relative amounts 
in both these cases were similar.
In MCF-7 cells, modest amounts of PAI-1 already present were substantially 
increased by TGFP in a dose and time dependent manner. Though TGFp 
mediates its effect by a different receptor than EGF and TGFa, it showed the 
same pattern of PAI-1 stimulation in MCF-7 cells, in that the lower doses 
increased PAI-1 levels in SN whereas a higher concentration was more 
effective in stimulating PAI-1 levels in CM. The extent of stimulation was 
greater in CM (17.5 fold) than SN (12 fold). The absolute amounts of PAI-1, 
however remained very low. The growth rate was however, stimulated with all 
doses.
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3.4 IlNlfASlBOrf
In vitro tumour cell invasion was assessed by the microinvasion Boy den 
chamber invasion assay as described in methods section 2.9.2.
3.4.1 Assessment of Invasive Capacity of the Control Versus Treated 
MCF-7 and MDA Cell-Iines
Since metastasis is the principal life threatening event in the process of 
carcinogenesis, it is important to understand the effect(s) that certain hormones 
or growth factors have in bringing about certain biochemical changes in a 
group of cells which enhance their invasive ability. The next series of 
experiments were, therefore, designed to address this question.
Untreated, as well as oestrogen, EGF, TGF-a and P treated MDA and MCF-7 
cells were used in an invasion assay and the invasion was measured by 
confocal microscopic analysis as well as by the MTT assay.
Consistent with the aggressive nature of MDA cells, they were found to be 
more intrinsically invasive than MCF-7 cells (Hachiya et a!., 1995). In the 
initial phase of the study, different experiments were performed in order to 
optimise the conditions for invasion as well as to compare different methods 
available for its measurement. Different amounts of matrigel/well were tested. 
80 jig matrigel/well was found to be the optimal amount to discriminate the 
invasive potential of both the cell lines.
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Fetal calf serum (FCS ) and invasion
The effect of fetal calf serum (FCS) on the invasive ability of MDA and MCF- )j
7 cells was studied. This experiment demonstrated that in the presence of FCS, 
invasiveness of both cell lines was inhibited, compared to those which had 
never been exposed to FCS. The effect of FCS on the invasion was measured 
by both confocal microscopy (Fig 45) and the MTT assay (Fig 46). It was 
found that the two methods showed approximately the same level of inhibition 
in their invasive potential (11% for the MDA cells which had been exposed to 
2.5% FCS for 72 hours). A gradual increase in the amount of FCS (0, 2.5. 5.0 
and 10%) resulted in a gradual decrease in the invasive capacity of both cell 
lines after 72 hours as measured by the MTT assay (Fig 46).
Interestingly MCF-7 cells after incubation with 2.5% FCS showed a 34% 
decrease in invasive capacity whereas in the MDA cell line a drop of only 
11% was observed. This suggests that the MCF-7 cells are much more 
sensitive to serum and this may reflect the fact that they are better 
differentiated cells. At higher concentrations of FCS, the relative decrease in 
the percent inhibition for the two cell lines became less marked, 41% and 46% 
decrease in inhibition for MCF-7 cell line (Fig 46A), to 21% and 34% for 
MDA cells (Fig 46B), in the presence of 5 and 10% FCS, respectively.
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Figure 45 Comparison of invasion across a niatrigel, in 
control MDA-MB-231 cells in the presence or absence of 
serum as determined by confocal microscopy.
Transwell filters were coated with 80|ig matrigel/well and 5 x 10  ^cells 
were plated per well. After 72h, the invasion of matrigel by cells, was 
determined by confocal microscope as described in methods (2,9.4). 
The effect of FCS on the in vitro invasion was studied. The results 
(mean ± SD) are from three separate determinations.
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Figure 46 Percent inhibition in in vitro invasion of 
MCF-7 and MDA-MB-23 cell in response to FCS.
Transwell filters were coated with 80pg matrigel/well and 5 x 10  ^
cells were plated per well. After 72h, the invasion of MCF-7 (A) 
and MDA (B) cells across a matrigel was measured by MTT as 
described in methods (2.9.3). Different amounts of fetal calf 
serum (FCS) (2.5-10%) were used. Each sample was measured in 
duplicates and the mean of three different experiments ± SD is 
presented.
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Effects of matrigel use as a chem oattractant on invasion
In vitro invasion is affected by many factors. After determining the 
concentration of matrigel and concentration of FCS, the next study was 
medium with/without matrigel (as a chemoattractant) (Fig 47). It had been 
observed that the presence of a chemoattractant (100|iig/ml matrigel and 
2)Lig/ml plasminogen) placed in the lower compartment of the chamber, only 
increased the percentage of invasion by about 2% as compared to the wells 
where no matrigel was added in the lower chambers (Fig 47). This shows that 
chemoattractant in the lower compartment of the chamber only slightly 
influence the invasive ability of the cells.
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Figure 47 Effect of chemoattractant on the 
percentage of invasion
The invasive potential of both MCF-7 and MDA cells were determined.
5 xlO^ cells were plated in the wells. The medium in the lower chamber
was supplemented with matrigel (lOOpg/ml) as a chemoattractant. The 
values are expressed as a mean ± SD for triplicate experiments
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Effect of plasminogen on invasion
Effect of plasminogen on invasion with or without PCS is shown in (Fig 48). 
Plasminogen is the direct substrate of uPA. Therefore, its effect on invasion 
was determined by mixing plasminogen with matrigel. Plasminogen increased 
the invasiveness of MDA cells by only 6%. In the previous experiments it was 
shown that PCS inhibited the invasion of these cells. So, to find if PCS inhibits 
the increased invasion by plasminogen, PCS was added to the medium. It was 
interesting to see again that PCS could even reduce the plasminogen mediated 
increase in invasion (Fig 48).
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Figure 48 Effects of plasminogen on th e  invasion 
of MDA ceiis
The invasive potential of MDA cells were determined. 5
xlO^ cells were plated in the wells. The matrigel in the insert was 
supplemented with plasminogen (2ug/ml) and the medium used was with 
or without PCS. The values are expressed as a mean ± SD for triplicate 
experiments.
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3.4.2 Effect o f  G r o w t h  Factors on Invasion
E v a lu a t io n  o f  in v a s io n  b y  c o n f o c a l  la s e r  m ic r o s c o p e
After optimising all the necessary conditions for invasion, the effects of 
growth factors on invasion was determined. Both MDA-MB-231 and MCF-7 
cells were cultured in a growth medium containing EGF (10 ng/ml), TGFa (1 
ng/ml) or TGpp (1 ng/ml), on matrigel coated filters. Control cells were 
cultured only in the presence of culture medium. The percentage of invasion is 
expressed as the number of cells that migrate above a minimum distance from 
the original layer, in comparison with the number of cells invading under 
control conditions. Percentage of invasion was measured under the confocal 
laser microscope after fixing the cells on matrigel as described in methods 
section 2.9.4.
It was observed that after five days of incubation, EGF increased the invasive 
ability of the MDA cell line by 10%. Exposure of cells to TGFa did not result 
in any significant change in their invasive ability as compared to the control. 
Incubation of cells with TGpp, which has been shown to be an inducer of uPA 
gene expression, increased invasiveness by about 30%. (Fig 49).
Evaluation of invasion using MITT
MDA cells were cultured in the same concentration of EGF, TGFp and TGFa 
for 5 days. Invasion was defined as the proportion of cells that crossed the 
matrigel and filter in each compartment as determined by MTT assay. It was 
observed that EGF induced invasion by 10% whereas TGpp increased the 
invasion by about 40%. TGFa, as observed in confocal experiment, remained 
ineffective in increasing the invasive properties of cell (Fig 49).
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Taken together these data suggest that both methods, confocal and MTT, 
showed comparable results in that TGFp stimulated invasion by 30% as 
assessed by confocal microscopy, and 40% as assessed by MTT assay. TGFp 
showed maximum invasion as compared to EGF or TGFa.
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Figure 49 Comparison of the percentage of invasion between 
confocal and MTT in MDA cells in response to growth factors.
5x10^ cells were left for 5 days on the bottom of the filter for confocal 
microscopy and inside the insert on top of the matrigel for MTT assay as
described in methods section 2.9.3. TGFB 1 ng/ml, EGF 10 ng/ml, TGFa 
1 ng/ml were used in the study. The results (mean ± SD) are the average of 
three separate experiments. Each experiment was performed in duplicate.
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Table 12 Growth factor modulation of invasion of MDA-MB-231 ceils 
into matrigel evaluated by confocal microscopy and MTT.
MDA cells (5x 10^) were plated in the Boy den chamber microinvasion assay. 
Different growth factors (TGFp, TGFa, EGF) were used in the study. The 
percentage of invasion was compared by both confocal microscopy and MTT.
Results (mean) are from three independent experiments.
Doses % of invasion confocal % of invasion MTT
control 67.4 31
TGFP 5 ng/ml 87 42.5
EGF 10 ng/ml 72 34
TGFa 1 ng/ml 65 30
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Time course invasion
In the next experiment the effect of growth factors and hormones on the 
invasive ability of both MDA and MCF-7 cells was observed over 48 and 72 
hours in order to study the kinetics of invasive capacity of cells. To this end, 
both cell lines were treated with the EGF (10 ng/ml), TGpp (1 ng/ml), TGFa 
(10 ng/ml) or tamoxifen (lO'^M); since the MDA cell line is oestrogen 
insensitive, only MCF-7 cells were exposed to oestrogen (10"^ M) and 
progesterone (10‘^M) (Fig 50A). Because both methods, confocal and MTT 
were comparable as shown in section 3.9.2 therefore invasion was evaluated 
by using MTT alone.
Figure 50A show that MCF-7 cells treated with oestrogen were found to be 
60% more invasive after 72 hours as compared to the non-oestrogen treated 
cells. Initially progesterone slightly inhibited the invasiveness after 48 hours 
which reached to the level of control after 72h. Tamoxifen inhibited invasion 
by 25% after 48 hours but the inhibition was much more pronounced, about 
40% after 72 hours. TGFp had a stimulatory effect on invasion with an 
increase of 27% and 75% after 48 and 72 hours, respectively.
When the same experiment was done in the presence of a monoclonal anti- 
uPA antibody invasive capacity was not completely reduced to control levels 
implying that TGFp stimulated invasion cannot be ascribed entirely to 
increased uPA secretion. Treatment of cells with EGF did not appear to have 
any effect after 48 hours. After 72 hours, however, it increased the invasive 
capacity of the MCF-7 cells by 55%. Initially TGFa inhibited invasion by 
about 35%. This inhibition overcame after 72h (30% stimulation in invasion 
was observed).
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For the MDA cell line TGFp stimulated invasiveness by 22% after 48 hours 
and 40% after 72 hours. The anti-uPA antibody when used together with 
TGpp reduced the invasive ability of cells to control levels.(Fig 50). EGF 
stimulated invasion by about 20% after 72h. TGFa and tamoxifen both failed 
to influence invasion by MDA cells.
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Figure 50 Time course effects of growth factors on the 
invasion of MCF-7 (A) and MDA (B) cells.
Effects of growth factors TGF(3 1 ng/ml, TGFa 1 ng/ml, EGF 10 ng/ml were used 
for both MCF-7 and MDA cells in the Boy den chamber invasion for 48 and 72 
hours. uPA antibody (1 in 200) dilution was used to check the uPA dependent 
invasion. Also in MCF-7 cells steroid hormones were used to determine its effects 
on the invasion under the same experimental conditions.
The results (mean ± SD) represents the average of three separate determinations.
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3.4.3 Discussion
Growth factors, steroid hormones and invasion
It has been known for sometime that the invasive potential of a given cell line 
is related to the amount of active uPA it synthesizes and secretes. It is also 
clear that when bound to its receptor, uPAR, uPA catalyzes the conversion of 
plasminogen to piasmin which in turn activates the proteases required for the 
breakdown of the extracellular matrix. As discussed previously (section 
1.13.1), an important molecule which is responsible for inhibiting the action of 
uPA is its inhibitor PAI-1. When bound to uPA, PAl-1 masks its catalytic site 
and renders uPA inactive. When this is the case then the cell does not have 
much invasive ability. Yet, paradoxically, high levels of PAl-1 within the 
tumour are associated with poor prognosis. In this study, uPA and its 
associated molecules were measured both by ELISA and in the case of uPA, 
enzyme activity.
Further experiments were designed to determine the effect of growth factors 
and steroid hormones on the invasive ability of MCF-7 and MDA-MB-231 
cells. It is known that In vitro invasion is affected by many factor e.g. number 
of cells per well, the amount of matrigel used in the inserts of Boy den 
chambers, the amount of fetal calf serum and plasminogen (the only substrate 
for uPA) the length of time and the filter size. Therefore, it was necessary to 
optimise the conditions for the cell lines that were used in this study. In doing 
so, we found that 80|ig matrigel per well was a good concentration to 
demonstrate the relative invasive potential between the cell lines. Furthermore, 
it was observed that FCS inhibits invasion of both cell lines used but had a 
much more dramatic effect on MCF-7 cells at lower concentrations. This may 
reflect the relative agressiveness and differentiation of the two cell lines. 
MCF-7 cells showed inhibition (34%) in the presence of 2.5% FCS, while a 
drop of only 11% was observed in MDA cells.
:
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It is widely accepted that plasminogen increases the invasiveness of cells. 
However, in this study addition of plasminogen (2ug/ml) had little effect 
implying that our EHS preparations already contained adequate plasminogen. 
Furthermore, it was interesting to note that when plasminogen was added in 
the presence of FCS, it did not increase the invasive ability of the cells. In 
addition to the above mentioned factors, we tried to compare the two available 
methods for the determination of invasion, confocal laser microscopy and 
MTT. The results showed that both the methods were comparable, as can be 
seen in Fig. 49 although confocal microscopy normaly gave a higher value 
than MTT. This may be because confocal microscopy is less invasive than 
MTT and therefore the percentage of manual error is minimum. The effect of 
growth factors after 5 days in culture, were evaluated by both confocal and 
MTT. TGFp showed maximum stimulation of invasion as compared to EGF 
and TGFa. TGFp 1 ng/ml stimulated invasion of MDA cells by about 40% as 
assessed by MTT as compared to about 30% as determined by confocal 
microscope.
Since the results were comparable in reflecting TGFp effect on urokinase 
components, the subsequent time course experiments with growth factors were 
determined by MTT only. These experiments showed a different pattern of 
invasion for MCF-7 and MDA cells. Invasion in MDA cells only slightly 
increased with time while MCF-7 cells showed a significant increase in 
invasion with time. In MDA cells, TGFp 1 ng/ml increased invasion after 48 
and 72 hours by about 25 and 30%, respectively, although the same dose 
increased invasion in MCF-7 cells, with time. The maximum stimulation 
observed in MCF-7 cells, however was greater (75% after 72h) than MDA 
cells. EGF lOng/ml also increased invasion in MCF-7 by 60% after 72h. The 
effect of EGF and TGFa were barely significant in MDA ceils. Importantly, 
TAM inhibited invasion in MCF-7 cells significantly by about 32% after 72 
hours. This implies a full anti-oestrogenic effect of TAM on invasion not the
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usual weak agonist effect. TAM did not effect the levels of invasion in MDA 
cells. To determine if the invasion was uPA dependent, uPA antibody was 
used. It was interesting to note that uPA antibody 1/500 dilution reduced 
activity of MDA cells to control levels implying that TGpp-induced invasion 
was due to uPA but that the endogenous level of invasion was due to some 
other mechanisms.
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Figure 51 A photograph of invading cells across a matrigel as seen under 
the confocal microscope.
This Fig illustrates the use of confocal microscopy in the assessment of 
invasive potential. MDA cells were plated into the boyden chamber under 
control conditions and then confocal microscopy was used to visualise cells at 
the surface and at 10, 20 , 30 and 40 jam into the gel as shown in figure. Cells 
were counted at each depth and relative migration assessed under different 
conditions of stimulations.
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3.5 Immunofluorescence
Having used ELISA to quantitate the respective amounts of uPA and PAI-1 in 
MCF-7 and MDA cel lines, we wanted to determine the localization of these 
proteins in both MDA and MCF-7 cells. For this, anti-uPA and anti-PAl-1 
antibodies were used in immunofluorescence studies to visualise the two 
antigens and their patterns of distribution. The uPA and PAI-1 antibodies as 
described in the Materials and Methods (section 2.10) were used at a dilution 
of 1:200. Negative controls had only normal goat serum at the same dilution. 
The number of stained cells were counted under the immunofluorescence 
microscope and the photographs were taken to show the distribution of both 
the PAl-1 and uPA in untreated and TGFP treated MDA cells (Figs 52 and 
53). The pattern of distribution could not be clearly distinguished. However, 
the micrographs clearly show an increase in staining in the treated cells (Figs 
53 and 55) confirming the ELISA data. On the other hand, MCF-7 cells 
showed no staining for uPA but did show some PAl-1 antigen. The level of 
distribution was not much different both in control and TGFp treated cells 
(data not shown), again confirming the ELISA data.
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Figure 52 PAI-1 staining in control MDA cells.
The cells were incubated with anti-PAI-1 antibody for 2 hours after fixation as 
described in methods (section 2.10) The cells showed diffused staining 
throughout.
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Figure 53 PAI-1 staining in TGFP treated MDA cells.
The cells were pretreated with TGFp (1 ng/ml) for 48 hours, and then 
incubated with anti-PAI-1 antibody for 2 hours after fixation as described in 
methods (section 2.10) The cells showed diffused staining.
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Figure 54 uPA staining in control MDA cells
The cells were incubated with anti-uPA antibody for 2 hours after fixation as 
described in methods (section 2.10) The cells showed diffused staining.
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Figure 55 uPA staining in TGFP treated MDA cells
The cells were pretreated with TGFp (1 ng/ml) for 48 hours and then 
incubated with anti-uPA antibody for 2 hours after fixation as described in 
methods (section 2.10) The cells showed diffused staining.
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3.6 Effect of Different Surfaces on the Shape and Morphology of the 
MDA and MCF-7 Cells
Since the nature of the substratum has been shown to effect the morphology of 
the plated cells, we compared the shapes of both MCF-7 and MDA cells after 
plating them on plastic and EHS. When MCF-7 cells are plated on plastic (Fig 
56), they are bigger in diameter than on EHS where they form aggregates. 
This aggregations starts 5-6 hours after plating the cells on EHS (Fig. 57). 
With time they grow and fold the matrigel on themselves and form a pseudo- 
mammosphere structure (Fig. 58). Upon changing the medium or after 96 
hours the cells detach themselves from the matrigel and begin to grow on 
plastic.
With MDA cells (Fig. 59), they are smaller in size than MCF-7 cells and are 
more epidermoid in shape. They start making "communication lines" or 
pseudopodia like structures within 4-6 hours of their plating on EHS (Fig. 60). 
On EHS, these pseudopodia like structures that appear from one cell to 
another were more defined after 48 hours and appeared like a network under a 
microscope (Fig. 61).
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Figure 56 Morphology of MCF-7 ceils on plastic.
5 X 10^  cells were cultured in 6-well plates. The cells were left overnight and 
the photographs were taken.
Morphology results
Figure 57 Morphology of MCF-7 cells on EHS.
5 X 10  ^cells were cultures in 6 - well plates precoated with matrigel. The 
photographs were taken within 4-6 hours. Magnification used was x4 x 1.5.
Morphology results
Figure 58 Morphology of MCF-7 cells on EHS.
5 X 1 0 ^  cells were cultures in 6-well plates precoated with matrigel. The 
photographs were taken after 48h. The magnification used was 4 xl.5.
Morphology results
Figure 59 Morphology of MDA cells on plastic.
5 X 10^  cells were cultures in 6 - well plates tissue culture plates. The cells were 
left overnight and photographs were taken.
Morphology results A\8
Figure 60 Morphology of MDA cells on EHS.
5 x 1 0 ^  cells were cultures in 6-well plates precoated with matrigel. The 
photographs were taken after 4-6 hours. Magnification used was 4 x 1.5.
/  A  a.'-. '-3  ^ ^  '
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Figure 61 Morphology of MDA cells on EHS.
5 X 10  ^cells were cultures in 6-well plates precoated with matrigel. The 
photographs were taken after 48 hours. The magnification used was 4 x 1.5.
CHAPTER 4 
DISCUSSION
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DISCUSSION
Many biological processes involve a precise and co-ordinated network of 
cellular proliferation and differentiation. The development and progression of 
cancer is believed to involve altered events in the regulation of these 
fundamental processes. In cancer the balance of cells entering S-phase to those 
going into apoptosis changes. Breast cancer, like other tumours of epithelial 
origin including ovary, endometrium and prostate, belongs to a group of 
cancers that may be hormone dependent. These tumours, however, contain 
both hormone dependent and independent cells.
Steroid hormones, peptide hormones and growth factors play a critical role in 
the control of normal growth and development of the breast and also play a 
pivotal role in breast cancer progression. Previously, a plethora of reports has 
shown the role of these effectors of cell growth on plastic only. Clearly, the 
results of these studies should be taken with caution since growing cells on 
plastic is far from the real in vivo scenario. It is known that growth factors 
influence the growth characteristics of cells also by affecting the structure of 
the extracellular matrix and may therefore disturb or enhance the interactions 
of the cells with their growth substratum (Laiho & Oja, 1989). In the light of 
this, it was important to compare the behaviour of cells on plastic and EHS 
(Engelbreth Holm Swarm, a tumour basement membrane) in parallel, when 
treated with different growth factors and hormones. The present study was 
conducted in order to specifically address three questions of fundamental 
biological importance: (a) what effect, if any, do the various hormones have 
on the growth properties of breast cancer cells when grown on different 
substrata (i.e. EHS and plastic)? (b) are there changes in the expression of 
uPA, uPAR and PAI-1 gene products when cells are exposed to steroids and
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growth hormones? and (c) is there is a correlation between the amount of uPA, 
uPAR and PAI-I with invasive ability of a cell line? (In other words, can 
certain hormones or growth factors alter the invasive potential of breast cancer 
cells?).
Proliferation Studies
Breast epithelium is directly under hormonal control and these hormones play 
an important role in regulating proliferation and protein synthesis of target 
cells. Oestrogen hormones also control the regulation of locally acting growth 
factors (Dickson et al., 1990), thus steroid hormones, including oestrogen, 
progesterone and the anti-oestrogen, tamoxifen, were used in this study. The 
effect of growth factors was also analysed on the two human breast cancer cell 
lines. MCF-7 (hormone responsive) and MDA-MB-231 (hormone 
independent).
Proliferation results presented in this thesis showed that EGF and TGFa 
increased the growth rate of MCF-7 cells on both plastic and EHS. Stimulation 
of growth on either substratum was relatively small but cells grown on EHS 
showed growth stimulation at lower concentrations of TGFa than those grown 
on plastic. It may be the result of interactions of cells with the extracellular 
matrix (EHS) which may modify or alter the receptor levels in a three 
dimentional growth thereby making the cells more responsive to lower doses 
of growth factors. This response may vary from cell line to cell line and may 
alter according to different conditions. This can be seen in MDA cells on EHS 
where lower doses of EGF and TG Fa decreased the growth. The actual 
mechanism of action of these growth factors on EHS is complex and remains 
to be further elucidated. By contrast, the growth of MDA cells on plastic was
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stimulated by EGF at the lower concentrations though only a maximum of 
15% increase above control was observed. It should be noted that (Murayama f
& Mishima, 1995) have shown that whereas lower concentrations of EGF 
support cell proliferation, higher concentrations cause growth inhibition. i
Similarly, studies of (Imai et a i, 1982) (Dong et a i, 1991) on human breast 
cancer cells, corroborate the EGF results presented in this study on plastic, 
where higher concentrations are inhibitory. TGFa increased MDA cell growth 
at higher concentrations on either substratum.
TGFa, like EGF, exerts its effect via the EGF receptor (EGFR). In spite of 
this, the MDA cell line responded differently to the two growth factors. It 
should be noted, however, that the percentage of increase in growth of MDA 
cells, as compared to MCF-7 cells, was small, about 20% (Fig 9 and 10), as 
compared to MCF-7 cells (about 60%). In other words, it appears that the 
exogenously added growth factors had little or no effect on MDA 
proliferation. This lack of response might be due to the large amounts of EGF 
or TGFa that is produced endogenously by the cells which masks the effect of |
the exogenously added growth factors. Cappelleti et al. (1993) have estimated 7
the amount of EGFR to be 3 fmol/mg of total protein in MDA cells as 
compared to 60 fmol/mg in MCF-7. It is likely that the differences in EGFR 
levels shown by various groups may be due to different experimental 
conditions. The literature also suggests that co-expression of the receptor and 
the growth factor leads to the cytoplasmic activation of the receptor without 
involvement of the cell surface membrane. This may create an autocrine loop 
between the endogenous growth factors and their receptors leaving only a few 
receptors accessible to exogenously added EGF to stimulate growth (Long &
Rose, 1996; Verber et al., 1994).
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effect on MDA cells in this study. All these different observations show the 
complexity of TGF[3 and also that different cell lines and different 
experimental conditions can alter results for the same cell line and same drug 
used under different laboratory conditions. The status becomes even more 
complex when cells interact with EHS components and also in the presence of 
growth factors. Because both growth factors and EFIS components (collagen, 
fibronectin, laminin etc.) affect and alter each other's functions, e.g. TGFp 
regulates the ECM remodelling and functions such as immunosuppresion may 
help in tumour progression.
MCF-7 cells showed a similar growth pattern towards oestrogen, 
progesterone or anti-oestrogen, tamoxifen on either plastic or EHS. 
Concentrations required for proliferation were similar but the extent of growth 
between the two substrata were consistently different. The extent of 
stimulation was 2 to 3 times more on plastic than EHS. However, the extent of 
stimulation of MDA cells in response to growth factors remained similar. 
Albini and associates showed an increased growth of MCF-7 cells on 
reconstituted basement membrane (ECM/EHS) and or laminin (component of 
ECM) but they have not compared the same on plastic (Albini et al., 1986).
It can be concluded from the proliferation studies that EHS has no significant 
effect on the growth of MCF-7 cells in response to both hormones and growth 
factors. Whereas, MDA-MB-231 cells showed a significant difference on both 
the substrata in response to growth factors, especially TGFp. The restricted 
growth on EHS may be because the cells are relatively differentiated when in 
association with extracellular matrix.
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Plasminogen Activators
It is known that the inoculation of matrigel together with human tumour cells 
MDA-MB-435 (Bao et al., 1994) MDA-MB-231 or MCF-7 cells (Noel et al., 
1993) into nude mice has increased the formation and growth of the tumour 
but the exact mechanism is unknown. They showed differences in growth 
rates, MCF-7 being slower in tumour formation than MDA, in spite of the 
same conditions. No work has been done so far to find the effect on 
inoculation of TGpp and other growth factor treated cells and matrigel. As 
matrigel effected the growth and and tumour formation ability of the cells in 
vivo, it should influence the invasive behaviour of MCF-7 and MDA cells in 
vitro also.
It is clear from this as well as other studies that hormones and growth factors 
effect not only the biosynthesis and subsequent secretion of a number of 
different proteins, but also the proliferative and invasive potential of both ER+ 
and ER" cells (Tedone et a l, 1996) . Although it is still unclear how hormones 
and growth factors alter the invasive properties of tumour cells it is widely 
accepted that the process of invasion impinges upon the activities of the 
various components of the plasminogen activator system.
In this study the relative amounts of urokinase (uPA), its inhibitor PAI-1 and 
uPAR were quantitated in two well characterised breast cancer eell lines in 
order to understand how their levels are effected in response to various 
hormones and growth factors on different substrata and whether there exists a 
linear correlation between the levels of these three molecules to the invasive 
potential of a cell line.
uPA, PAI-1 and uPAR transcripts and protein expression were measured in 
MDA and MCF-7 cells. Although uPA was detected in the MDA cell line in
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large quantities, no uPA could be detected in the MCF-7 cells in spite of 
numerous attempts throughout the course of this study. This is surprising 
given that other groups have documented the presence of uPA in the MCF-7 
cell line. It should be noted that the same antibody which detected uPA in 
MDA cells failed to find its antigen in the MCF-7 cells. Moreover, no uPA 
niRNA could be detected using RT-PCR analysis carried out on total RNA 
isolated from untreated MCF-7 cells. The same set of PCR primers however 
successfully detected large amounts of the uPA mRNA in the MDA cell lines. 
Remarkably, neither uPA mRNA nor its protein product were detected even 
after 72 hours of treatment with growth factors in MCF-7 cells. The situation 
is specially conflicting since in this study control MCF-7 cells retain their 
ability to invade, although with much less efficiency than MDA cell line. Does 
this mean that proteins other than uPA are able to activate plasmin or the 
proteases which directly breakdown the BM?
In the MDA cells, ELISA showed large amounts of uPA. More importantly 
activity assays revealed an active uPA and it is not surprising therefore, that 
this cell line is much more aggressive in the invasion assay than MCF-7 cells. 
Although the levels of uPA are thought to dictate whether a cell line is 
invasive, the amount of PAI-1 is also an important co-determinant of the 
invasive capacity of a cell line. It has been shown that it is the relative 
amounts of uPA and PAI-1 which determine whether a cell line would be 
invasive or not.
The MDA-MB-231 and MCF-7 cells have been shown to produce and secrete 
mainly uPA or tPA and PAI-1. The synthesis of uPA, its inhibitor, PAI-1 and 
receptor, uPAR is known to be controlled by a variety of hormones, growth 
factors and cytokines (Andreasen et al., 1990; Dano et a i, 1985; Saksela, 
1985). Growth factors especially TGFp have been implicated in invasion and 
metastasis in some malignant cells. However, the importance mf EGF and
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TGFa in the process of invasion remains to be elucidated. TGFp is involved in 
the metastatic cascade in some cells, including MCF-7 and MDA-MB-231 
(Thompson et al., 1990) and TGFp mRNA levels have also been found to be 
elevated in malignant human breast tumour biopsy specimens. The work 
describe here shows that TGpp induces an increase in cell-associated uPA 
expression, but has little effect on uPA secretion. These results are in line with 
those of Arnoletti et al. (1995) and Keski-Oja et al. (1988) who demonstrated 
that TGFpl induced an increase in cell-associated uPA expression and uPAR 
biosynthesis in the A549 cell line. Lund et a i (1987) have shown that TGFP 
strongly decreases the PA production in W l-38 human lung fibroblasts. In 
contrast, Hachiya et al. (1995) have reported that exogenous TGFpl 
suppresses both PA production and in vitro invasiveness of MDA-MB-231 
cells. In MCF-7 cell line, however, they found that TGFp increased PA and 
also In vitro invasiveness. In contrast, our results show an induction in the cell 
associated uPA levels by 2-4 fold in MDA-MB-231 cells, whereas levels of 
uPA in the CM were either decreased or slightly affected by TGpp in MDA- 
MB-231 cells and therefore demonstrates the importance of assessing 
extracellular plasminogen activator levels as well as cell associated factors.
Our results showed that TGFp also induced a remarkable elevation of cell 
secreted PAI-1 (250-300%) as compared to (100-150%) increase in the cell 
secreted PAI-1 (in the CM of MDA-MB-231 cells). Arnoletti et al. (1995) 
have also shown increased cell secreted PAI-1 levels in CM of breast cancer 
cells in response to thrombospondin, an adhesive glycoprotein known to be 
involved in the mechanism of tumour progression and TG Fpl. TGFP also 
increased the amounts of PAI-1 and uPA secreted from cultured adult skin 
fibroblasts Lund et al. (1987; Desruisseau et al. (996) further confirmed that 
TGFp increases the levels of secreted PAI-1 by about 700% in a dose 
dependent manner in human prostatic cancer cell line PC3.
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In some studies decreased uPA levels and increased PAI-1 levels are translated 
into decreased plasmin activity, measured by chromogenic assay, and 
ultimately decreased invasion. However this work shows that elevated levels 
of up A and PAI-1 in breast cancer cells results in increased proteolytic 
activity. The levels of uPA and PAI-1 both were up-regulated in MDA-MB- 
231 cell line whereas in MCF-7 cells, a significant PAI-1 increase was 
observed. The increase in uPA is associated with malignancy, while the role of 
PAI-1 is still conflicting. Duffy et a l, (1998) has proposed that the levels of 
the two proteins, uPA and PAI-1, are inversely correlated with patient 
prognosis. Others have argued that high levels of PAI-1 leads to decreased 
invasion by inhibiting uPA proteolytic activity. Several authors including 
(Pappot & Brunner, 1995) have demonstrated that high levels of PAI-1 
propagate tumour progression by increasing the motility of the cells, which is 
a pre-requisite of tumour invasion. The results in this thesis are in agreement 
with the latter hypothesis.
This simultaneous up-regulation of uPA and PAl-1 in association with 
increased invasion confirms the hypothesis that both uPA and PAI-1 are 
strong and independent prognostie factors in breast cancer patients (Duffy et 
al., 1990; Janicke et al., 1993; Schmitt et a i, 1990; Schmitt et a i, 1994; 
Grondahl-Hansen et a i, 1993; Janicke et a i, 1991; Bouc he t et a i, 1994; Blasi. 
1993; Brunner et al., 1994; etc). Both the enzyme and its inhibitor are thought 
to be required for cell migration, adhesion and invasion. uPA is localised at 
the cell surface and at the invasive foci whilst PAI-1 is distinctly localised in 
the ECM. Receptor bound uPA remains available to PAI-1. Internalisation and 
degradation of the uPA-PAI-1 complexes enables cells to migrate through the 
recycled receptor, uPAR. Increased levels of PAI-1 restricts invasion (Mignatti 
& Rif kin, 1993). Thus PAI-1 has a role in new tumour stroma formation and 
also protects cancer tissue against proteolytic degradation. This is obviously 
important in the formation of distant metastasis. Grondahl-Hansen et al.
It is important to note that the anti-uPA Ab abolished TGFp-Induced invasion 
but not the level of invasion by control cells. This suggests that TGFP-induced 
invasion is directly due to secreted uPA but the basal level is due to other 
proteases.
It is also important to draw attention to the fact that tamoxifen, usually 
considered as a weak agonist did increase proliferation, but inhibited invasion 
by MCF-7 cells. This observation strongly supports the anti-invasive ability of 
tamoxifen and underline its use as an effective anticancer drug in breast cancer 
patients.
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(1993) and Janicke et a i (1993) have shown that high levels of PAI-1 are 
present in distant metastasis. PAI-1 synthesis by breast cancer cells is 
influenced by activation of the protein kinase C and protein kinase A pathways 
(Knudsen et a i, 1993).
Cell associated uPA can be considered partially equivalent to receptor bound 
uPA and therefore can be used as an index of cell surface proteolytic activity. 
When cells were cultured with TGpp, it promoted cell expression of uPA and 
thus mediated tumour cell invasiveness by increasing proteolytically active 
areas of the cell surface. Welch et a i  (1990) also showed that TGpp can 
stimulate invasion and metastatic potential for mammary adenocarcinoma 
cells.
The inhibition of proliferation by TGFp in MDA-MB-231 cell line and 
stimulation of uPA/PAI-1 system indicate that proliferation and plasminogen 
activator system are regulated by two distinct mechanisms independent of 
each other. This has been suggested by Lambrecht and colleagues during their 
study on the regulation of proliferation and uPA/PAl-1 system in breast cancer 
cell lines, MCF-7 and MDA-MB-231 (Lambrecht et a i, 1998).
S u m m ary  231
SUMMARY
MDA is more invasive than MCF-7. This is reflected in uPA and PAI-1 
contents. The effects of various exogenous factors in the levels of these critical 
components of the invason system were suprisingly variable. TGFa and EGF 
showed no exciting effects on the uPA and PAI-1 levels. Interestingly, TGFp 
showed huge effects on the plasminogen activator and inhibitor levels, 
proliferation. This study has shown that the in vitro invasive potential of 
human breast cancer cell line MDA-MB-231, across a reconstituted basement 
membrane (matrigel) correlated with the synthesis of both uPA and PAI-1 
which were effected by growth factors EGF, TGFa and TGFp. Matrigel, an 
important component of invasion assay has been used as a substratum, in the 
present study, to determine its effects on the growth potential and plasminogen 
activator secretion from epithelial cells
This study has clearly demonstrated that the nature of the substratum is critical 
for physiological experiments. Comparitive study on EFIS and plastic of the 
two breast cancer cell lines, MDA-MB-231 and MCF-7, showed that the level 
of stimulation in growth and secretion of secreted and cell associated 
plasminogen activators, uPA and its inhibitor PAI-1 responded differently to 
growth factors and steroid hormones, on EFIS and plastic.
Low concentrations of TGFa and EGF demonstrated an increase in the cell 
associated uPA and PAI-1 levels on EHS and inhibition on plastic, under same 
experimental conditions. Similarly, the activity of cell associated uPA in 
response to TG Fa slightly increased on EHS and remained unaltered on 
plastic. Growth studies showed that cells on EHS responded to high doses and 
thus stimulated the rate of proliferation while low doses slightly inhibited the 
growth. On plastic, however, higher doses were inhibitory.
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Invasion assays also showed that EGF and TG Fa did not increase 
invasiveness of MDA cells. As the MDA cells were intrinsically highly 
invasive, it is perhaps not surprising that exogenous factors had little effect in 
increasing invasive activity. This correlated to the fact that uPA levels and 
uPA activity only slightly changed in response to these growth factors, and 
therefore played no role in the process of invasion. However, the anti-uPA 
antibody used in the invasion studies did not completely inhibit the in vitro 
invasion of cells. Thus it showed that uPA may not be the only enzyme 
necessary for invasion. Other metalloproteases may be involved in the process.
The effects of TGpp on PA production and in vitro invasiveness was 
examined. The studies showed that TGFp stimulated both uPA, PAl-1 
production on both EHS and plastic by about 350%, The level of secreted 
proteins were high on EHS than on plastic. On the other hand, the production 
of cell associated proteins were higher on plastic than on EHS.The effects 
were clearly dose dependent on both EHS and plastic. Higher doses stimulated 
uPA and PAI-1 expression on EHS but on plastic much lower doses were 
needed to achieve the same level of stimulation. As a potent growth inhibitor, 
TGpp inhibited the growth of MDA cells on EHS at a low coneentration but 
on plastic a much higher dose is needed to inhibit cellular proliferation. All 
these observations point to the fact that the mechanisms of regulations of 
growth are different from those of invasion.
It was surprising to see that MCF-7 cells showed invasion with EGF, E2 and 
much enhanced with TGpp, although no detectable uPA could be observed 
both at the transcriptional or translational levels. The uPA antibody used also 
did not inhibit the invasion completely but did decrease it slightly. This shows
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that the invasion may not only be uPA dependent but other proteases may be 
similarly able to drive this process.
It is clear from these studies that changes in the growth and invasive potential 
of a cell line are not only dependent on the type and concentration of a given 
growth factor or a steroid, but are also dependent on the nature of the 
substratum and the nature of the cells themselves.
Future w o rk  2 3 4
Future Work
The work reported herein shows the effects of different growth factors and 
hormones on the proliferation and invasive potential of two breast cancer 
derived cell lines, MDA and MCF-7. Although, the biochemical features of 
the MDA-MB-231 cells are consistent with those that have been reported 
previously, the MCF-7 cells appear to be completely distinct from the 
conventional MCF-7 cell-line. It is important to further charcaterise this cell 
line in order to understand and define its salient features which make it 
different from other MCF-7 cells. For instance, the TGFp stimulation of 
growth of this sub-clone of MCF-7 cells was unexpected and while MCF-7 
cells have been shown by others to express uPA, neither the mRNA nor the 
uPA protein could be detected in the MCF-7 cell-line reported here. Since the 
same anti-uPA antibody could successfully detect uPA in MDA cells, it is 
unlikley that failure to detect uPA in MCF-7 cells on several occasions was 
due to technical reasons. It is interesting to note however, that in spite of the 
absence of uPA, MCF cells scored positively, albeit to a much lesser extent 
than the MDA cells, in invasion assays. This observation, together with the 
fact that anti-uPA antibody brought invasion to the levels of control but 
control continued to invade that was independent of uPA is indicative of the 
fact that proteins other than uPA are also capable of triggerring a cascade of 
events that lead to metastasis. Identifying such factor(s) in the future is of 
obvious importance since they have the potential to be used as targets for 
therapeutic intervention.
It has also become clear from this work that the proliferative behaviour of cells 
in response to various growth factors and hormones is affected by the nature 
of the substratum. Although EHS, which is a mixture of various proteins, was
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used for these studies it would be interesting to identify specific proteins 
whose presence or absence affects the growth of cells. It would also be 
interesting to mix the stromal fibroblasts from normal or tumour cells in 
matrigel and find their effects on the functional modification of these cell lines 
in term of invasion rates.
In order to monitor cellular invasion a new strategy that is more sensitive than 
that used here needs to be adopted. Such a novel and cost-effective method 
employing the use of eggs from chickens was in fact reported recently and 
appears to be very promising. It would be useful in future to rely on such 
methods in order to make the data more quantitative.
Tamoxifen inhibited invasion in the ER-f MCF-7 cell line, whereas it showed 
an agonistic effect on the growth of the same cells. Therefore, it will be 
interesting to find the mechanisms of this differential behaviour of tamoxifen 
in the regulation of growth and invasion.
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